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Abstract 
 
This cumulative PhD thesis covers the first total synthesis of valerenic acid, the development of a 
new methodology to provide 2,4-dienols and the first total synthesis of lycoflexine. 
 
The sesquiterpene valerenic acid belongs to the class of valerenanes and was recently subject of 
several pharmacological studies. Despite its interesting biological profile, no total synthesis had been 
completed before 2009. Both successful and unsuccessful approaches developed during this PhD 
thesis are discussed in detail. Eventually a very robust and concise total synthesis based on a novel 
one-pot sequence, a hydroxy directed Diels-Alder reaction and a regio- and stereoselective Crabtree 
hydrogenation has been established. This approach has provided the basis for derivatization and 
structure-activity relationship (SAR) studies. In these tests a series of easily accessible valerenic 
amides has displayed greater activity than the natural product itself. 
 
During the optimization of the total synthesis of valerenic acid a very efficient one-pot protocol for 
the synthesis of 2,4-dienols has been developed. These compounds are important building blocks in 
synthetic organic chemistry. The second part of this cumulative thesis will describe the underlying 
concept of this methodology and its application in the synthesis of various substrates. 
 
Finally the last part of this thesis summarizes the first total synthesis of lycoflexine. The structure of 
this Lycopodium alkaloid consists of an unprecedented tetracyclic skeleton, with four stereogenic 
centers. During this PhD thesis a very general approach towards Lycopodium alkaloids has been 
developed that culminates in the first total synthesis of lycoflexine and the unpublished shortest 
syntheses of fawcettimine and fawcettidine. A series of complex as well as straight forward one-pot 
and tandem reactions has been incorporated including a tandem catalyzed ene-yne-ene RCM and 
regioselective hydrogenation as keystep. 
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Kurzfassung 
 
Diese kumulative Dissertation beschäftigt sich mit der ersten Totalsynthese von Valerensäure, der 
Entwicklung einer neuartigen Methodologie zur Herstellung von 2,4-Dienolen und der ersten 
Totalsynthese von Lycoflexine. 
 
Das Sesquiterpen Valerensäure gehört zur Substanzklasse der Valerenane und wurde erst kürzlich in 
mehreren pharmakologischen Studien eingehend untersucht. Trotz des interessanten biologischen 
Profils war vor Beginn dieser Dissertation keine Totalsynthese bekannt. Sowohl erfolgreiche als auch 
missglückte Strategien, die im Laufe dieser Arbeit entwickelten wurden, werden ausführlich 
besprochen. Optimierung führte schlussendlich zu einer sehr robusten und kurzen Totalsynthese, die 
im Wesentlichen auf einer neuartigen One-Pot-Reaktion, einer Diels-Alder-Reaktion und einer regio- 
und stereoselektiven Crabtree Hydrierung basiert. Mit dieser neuentwickelten Syntheseroute war es 
möglich eine Reihe einfach zugänglicher Verbindungen in SAR-Studien zu testen. Im Zuge dieser Tests 
wurden verschiedene Valerensäureamide synthetisiert, die über eine größere Aktivität verfügen als 
Valerensäure selbst. 
 
Während der Optimierung der Synthese von Valerensäure wurde eine sehr effiziente One-Pot-
Reaktion entwickelt, die die einfache Herstellung von 2,4-Dienolen ermöglicht. Der zweite Teil dieser 
Dissertation beschäftigt sich sowohl mit den Grundlagen dieser neuartigen Methode, als auch mit 
der Synthese mehrerer Vertreter dieser wichtigen Substanzklasse. 
 
Der abschließende Teil dieser Dissertation setzt sich mit der ersten Totalsynthese von Lycoflexine 
auseinander. Die Struktur dieses Lycopodium Alkaloids besteht aus einem bemerkenswerten 
Kohlenstoffskelett, dass sich aus vier Ringen mit vier Stereozentren aufbaut. Während dieser Arbeit 
wurde eine sehr allgemeine Synthesestrategie entwickelt, mit der es nicht nur möglich war die erste 
Totalsynthese von Lycoflexine zu bewerkstelligen, sondern auch die noch nicht veröffentlichten 
kürzesten Totalsynthesen von Fawcettimine und Fawcettidine abzuschließen. Die Synthese basiert 
auf einer Reihe von komplexen One-Pot- und Tandem-Reaktionen, wobei die tandem-katalysierte  
en-in-en Ringschlussmetathese und anschließende Hydrierung besonders hervorzuheben sind. 
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1 General Introduction and Overview 
  
This cumulative PhD thesis covers the first total synthesis of valerenic acid (chapter 2), the 
development of a new methodology to provide 2,4-dienols (chapter 3) and the first total synthesis of 
lycoflexine (chapter 4). 
 
 
Scheme 1: The three subtopics of this PhD thesis. 
 
The sesquiterpene valerenic acid (1) belongs to the class of valerenanes and was recently subject of 
several pharmacological studies.1,2,3 Despite its interesting biological profile, no total synthesis was 
completed before 2009. The first synthesis of this interesting substance is described in two 
publications.4,5 Whereas the first describes the early efforts that have finally led to completion of the 
synthesis, the second summarizes both successful and unsuccessful approaches in more detail. 
Eventually a very robust and concise total synthesis based on a novel one-pot sequence, a hydroxy-
directed Diels-Alder reaction and a regio- and stereoselective Crabtree hydrogenation has been 
established. This approach has provided the basis for derivatization and structure-activity 
relationship (SAR) studies. In these tests a series of easily accessible valerenic amides has displayed 
greater activity than the natural product itself. The results of in vitro and in vivo tests can be found in 
the third publication.6 
 
During the optimization of the total synthesis of valerenic acid a very efficient one-pot protocol for 
the synthesis of 2,4-dienols 3 has been developed. These compounds are important building blocks in 
synthetic organic chemistry. The fourth publication of this cumulative thesis will describe the 
underlying concept of this methodology and its application in the syntheses of various substrates.7 
 
Finally the last part of this thesis summarizes the first total synthesis of lycoflexine (4). The structure 
of this Lycopodium alkaloid consists of an unprecedented tetracyclic skeleton, with four stereogenic 
centers. During this PhD thesis a very general approach towards Lycopodium alkaloids has been 
5 
 
developed that culminates in the first total synthesis of lycoflexine (published in the fifth publication 
of this thesis)8 and the unpublished and so far shortest syntheses of fawcettimine and fawcettidine. A 
series of complex as well as straight forward one-pot reactions has been incorporated including a 
tandem catalyzed ene-yne-ene RCM and regioselective hydrogenation as keystep. 
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2 Total Synthesis of Valerenic Acid 
2.1 About Terpenes 
2.1.1 Classification of Terpenes 
 
Terpenes represent an extremely large class of natural products with diverse structural and biological 
properties.9 Depending on the corresponding biosynthesis, complex processes like cationic 
cyclizations, rearrangements and oxidation of comparatively simple isoprenoid precursors provide an 
impressive variety of natural products including more than 30.000 organic compounds. According to 
the so called “isoprene rule” the most common classification of terpenes refers to the number of 
isoprene units (C5), that are needed to build up the carbon skeleton of the corresponding natural 
product (see Scheme 2).10 
 
 
Scheme 2: Carbon skeletons of terpenes. 
 
2.1.2 General Biosynthesis of Terpenes 
 
The general precursors in the biosynthesis of terpenes are γ,γ-dimethylallylpyrophosphate (DMAPP, 
8) and isopentenylpyrophosphate (IPP, 9). Both compounds are interconvertible and are either 
obtained by the acetate-mevalonate pathway starting with acetyl-coenzyme A (5) or by the Rohmer 
pathway starting with pyruvate (6) and glyceraldehyde-3-phosphate (7).11,12 
7 
 
 
Scheme 3: General Biosynthesis of Terpenes. 
 
As outlined in Scheme 3, coupling of electrophilic DMAPP with nucleophilic IPP leads to 
geranylpyrophosphate (10), which is the general precursor for monoterpenes (C10). Consecutive 
coupling with a second IPP unit provides the chain-elongated farnesylpyrophosphate (11), which is 
the biosynthetic precursor for sesquiterpenes (C15) like valerenic acid (1) (For a more detailed 
discussion of the biosynthesis of valerenic acid, see chapter 2.3.1). Geranylgeranylpyrophosphat is 
obtained in a similar fashion, whereas homologous pyrophosphates with more than four isoprene 
units are derived by coupling of two already chain-elongated terpene precursors. 
 
2.2 About Valerenanes 
 
Valerenanes are a comparative small subgroup of bicyclic sesquiterpenes with interesting biological 
profiles and structural features (see Scheme 4).9 
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Scheme 4: Group of valerenanes. 
 
Because all members of this group were isolated from the rhizome and roots of valerian (lat.: 
valeriana officinalis), this class of terpenes was called valerenanes. Structurally all compounds have 
an identical indanyl core as carbon skeleton, but differ in their oxidation state. Whereas valerenic 
acid (1), valerenal (13) and valerenol (14) have no substituent at C2 of the valerenane skeleton (12), 
valerenolic acid (15) as well as acetylvalerenolic acid (16) possess an additional hydroxy group in this 
position. However, the most remarkable feature about the valerenanes is their uncommon 
configuration of both onring substituents of the six-membered ring. Although a hypothetic 
diequatorial configuration would be thermodynamically much more stable, the three stereogenic 
centers C1, C6 and C9 of the valerenane skeleton fix the substituents at C6 and C9 in an axial position 
(For illustration the three dimensional structure of valerenic acid is depicted in Scheme 5). 
 
 
Scheme 5: 3D model of valerenic acid (1). 
 
Interestingly, only valerenanes with this diaxial configuration have been isolated so far, whereas the 
corresponding epimers with the thermodynamically more stable diequatorial configuration remain 
unknown. 
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2.3 About Valerenic Acid 
 
Due to its interesting biological activity (see also chapter 2.3.2) valerenic acid (1) is probably the most 
prominent member of the family of valerenanes. Valerenic acid was isolated by Stoll and Seebeck for 
the first time in 1957.13 Shortly thereafter Büchi et al. proposed the correct isoprenoid structure, 
although both the relative and the absolute stereochemistry of all stereocenters and the 
configuration of the double bond of the side chain still remained unclear.14 Eventually Birnbaum et al. 
confirmed the already proposed diaxial configuration of valerenanes by crystal structure analysis.15 In 
the very same publications also the biosynthesis of valerenic acid was discussed, which led to the 
proposal of two different mechanisms. 
 
2.3.1 Biosynthesis of Valerenic Acid 
 
As key intermediate of the first proposal Büchi and coworkers suggested guaianolide 20. A plausible 
mechanism towards this compound starts with farnesylpyrophosphate (11) derived germacrene A 
(17) (see Scheme 6).14 
 
 
Scheme 6: Biosynthesis of valerenic acid proposed by Büchi et al. 
 
In an acid catalyzed cyclization of germacrene A (17) the bicylic carbenium ion 18 is delivered, which 
rapidly forms guaiane 19. After subsequent oxidation, Brønsted acid induced opening of the resulting 
lactone probably leads to the formation of allylic carbenium ion 21. According to Büchi’s proposal 
this species finally undergoes rearrangement with subsequent ring contraction to form the six-
membered ring of valerenic acid (1). 
 
A few years later Bates and Paknikar rationalized that it is more likely that valerenol (14) and 
valerenal (13) are found as precursors in the biosynthesis of valerenic acid.16 All three compounds 
10 
 
could be isolated from the very same extract and it was reasoned that oxidation starting from 
valerenol would be more plausible than reduction of valerenic acid. Based on this suggestion an 
alternative biosynthesis was devised, which is depicted in Scheme 7. 
 
 
Scheme 7: Biosynthesis of valerenic acid proposed by Bates and Paknikar. 
 
In contrast to the biosynthesis proposed by Büchi and coworkers, Bates and Paknikar related 
valerenic acid to terpene 22. The first steps are very similar to the proposal of Büchi and lead to the 
acid catalyzed formation of α-gurjunene (24). After epoxidation of the double bond the resulting 
epoxide 25 is protonated, which leads to fragmentation of the cyclopropane ring to form 
intermediate 26. Simultaneous dehydration of the tertiary alcohol and nucleophilic attack of water 
induces rearrangement and ring contraction to provide valerenol (14). After oxidation finally 
valerenic acid (1) is formed. 
 
2.3.2 Biological Background 
 
Already in ancient Greece and Rome valerian and extracts of valerian have been used to cure 
insomnia and sickness.17 Nowadays valerian extracts are still popular medicinal products and sold at 
most pharmacies because of calming and soporific effects. Beginning in the late 20th century several 
scientific workgroups became interested in the mode of action of valerenic extracts. Interestingly, 
several constituents of valerian exhibit an affinity to GABAA receptors similar to benzodiazepines.
18 
Because benzodiazepines are among the most important pharmaceuticals, studies to clarify the 
interaction of constituents of valerian and the GABA neurotransmitter receptor system have been 
intensified. Very recently the group of Hering at the University of Vienna identified valerenic acid (1) 
to be an allosteric modulator of GABAA receptor subtypes.
1 
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GABA (γ-aminobutyric acid) is one of the most important inhibitory neurotransmitters of the CNS.19 
According to their structural and functional properties GABA receptors are divided into two major 
subgroups: The class of ionotropic receptors (ligand-gated ion channels) includes GABAA and GABAA-ρ 
(often also called GABAC) receptors, whereas GABAB receptors belong to the class of metabotropic 
receptors (only indirectly linked with ion channels through G proteins). 
 
As is depicted in Scheme 8 the GABAA receptor is a complex structure build up by five different 
subunits, which surround the central pore of the ion channel. 
 
 
Scheme 8: The GABAA receptor. The binding sites of GABA and benzodiazepines (BZs) are also displayed.
19
 
 
In the human brain seven different subunit families (α, β, γ, δ, ε, θ and π) are typically encountered. 
Combination of different subunits provides various receptor subtypes with different properties. In 
most cases two α-units, two β-units and a γ-unit assemble the pentameric ion channel. Whereas a 
general modulator activates receptors independent of the corresponding subunits, a specific 
modulator, like valerenic acid, stimulates only receptors with particular subunits. Interaction of GABA 
with the receptor leads to opening of the pore and causes influx of chloride ions into the neuron. If a 
modulator is also present the conformation of the receptor is alterated and the interaction of GABA 
and the active site is intensified. This leads to a prolonged opening of the pore and as result the 
membrane potential of the neuron is further lowered (hyperpolarization). The overall effect is an 
attenuation of central nervous activity, because it is more difficult to stimulate the neuron the lower 
the membrane potential. 
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2.4 Contributions by Other Groups 
 
Although valerenic acid has been known for more than 50 years, no total synthesis of this molecule 
was completed until 2009. In 1967 an interesting but unsuccessful attempt towards valerenic acid 
was published by Joseph and Rao, which will be discussed in the following (see chapter 2.4.1).20 
Including other valerenanes two racemic syntheses of valerenol (14) and valerenal (13) by the groups 
of Bohlmann and Baudouy have been published in the early 1980s (see chapter 2.4.2 and 2.4.3).21,22 
Finally, the synthetic strategy developed during this PhD thesis has lead to the first total synthesis of 
valerenic acid.4 Shortly thereafter the group of Prof. Altmann published the second total synthesis of 
the title compound (see chapter 2.4.4).23 
 
2.4.1 Approach towards Valerenic Acid by Joseph and Rao 
 
Ten years after its first isolation Joseph and Rao were the first to attempt the synthesis of valerenic 
acid.20 Noteworthy, at this time both absolute and relative stereo configuration were still unknown, 
so eventually the devised strategy led to the synthesis of an epimer of valerenic acid (see Scheme 9). 
 
 
Scheme 9: Total Synthesis of epi-Valerenic acid ethyl ester 37. 
 
The sequence started with the Diels-Alder reaction of trans-ocimene 27 and maleic anhydride 28 to 
provide racemic substrate 29. Simple heating of the neat Diels-Alder product caused a beautiful 
cascade reaction starting with an Alder-Ene reaction and subsequent fragmentation of intermediate 
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30 to furnish compound 31.24 In the next step the redundant isopropenylidene group was cleaved by 
means of a retro-aldol reaction. After esterification the authors had planned to introduce the final 
stereogenic center of valerenic acid via hydrogenation of the double bond. Unfortunately, the open-
book effect of the substrate led to the formation of the wrong diastereomer and epimer 33 was 
obtained exclusively. However, because the configuration of valerenic acid was not established at 
that time the authors continued their investigations. In the next step treatment with methyl 
magnesium iodide and reduction provided diol 34. After oxidation of the secondary alcohol and 
subsequent Wittig-olefination of the corresponding aldehyde the resulting compound 36 was 
dehydrated to yield epi-valerenic acid ethyl ester (37) in moderate yield. Although not mentioned in 
the publication, comparison of synthetic and authentic material (obtained by esterification of natural 
valerenic acid) most likely led to revelation of the unnatural configuration and the final saponification 
was not carried out. 
 
In summary the strategy developed by Joseph and Rao incorporated several interesting 
transformations, but unfortunately it is not suitable for the synthesis of valerenic acid. Noteworthy, 
even if hydrogenation of compound 32 had led to the right configuration at C9 of the valerenane 
skeleton, the hypothetical endgame of this sequence would still have been extremely difficult (see 
Scheme 10). 
 
 
Scheme 10: Considerations about the hypothetically endgame devised by Joseph and Rao. 
 
Bicyclic alcohol 38 would exist in two different chair conformations. Whereas in conformation 38b 
only one single substituent is in an axial position, the second conformer 38a has three axial 
substituents. Therefore conformation 38b would be thermodynamically much more stable and 
14 
 
should clearly predominate. However, to generate the desired product 39 chair conformation 38a 
would be needed. As result the formation of the undesired product 40 should clearly predominate. 
 
2.4.2 Total Synthesis of (+/-) Valerenol and (+/-) Valerenal by Bohlmann 
 
The first total synthesis of racemic valerenol 14 and valerenal 13 by Bohlmann and Lonitz in 1980 is 
outlined in Scheme 11.21 
 
 
Scheme 11: Total Synthesis of racemic Valerenol and Valerenal. 
 
The first step was the literature known preparation of diallylic alcohol 42 starting from ethyl acetate 
and an excess vinyl magnesium bromide. Alcohol 42 was then converted into the β-keto ester 44, 
which underwent a Lewis acid catalyzed Claisen rearrangement into intermediate 45. Under the 
applied conditions this substrate decarboxylated to yield keto compound 46. After 1,2-addition of 
alkyne 47 the resulting alkoxide was treated with TMSCl to furnish silylether 48. The silyl-protecting 
group was essential to block one site of the triple bond. Consequently the IMDA (intramolecular 
Diels-Alder) reaction was highly selective and only compound 49 was obtained. Birch reduction of the 
Diels-Alder product provided a three to one diastereomeric mixture of the desired ester 50 and its 
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epimer 51. Hydrogenation and reduction of this mixture proceeded without incident, but the 
subsequent oxidation of the corresponding primary alcohol was problematic. According to intensive 
studies aldehyde 52 was unfortunately labile under both acidic and basic conditions and tended to 
epimerize (see also Scheme 12). Consequently after column chromatography a one to four ratio of 
the desired aldehyde and its epimer was obtained. This problem could partly be solved by avoiding 
purification (in this case a two to one ratio was obtained). However, epimerization was also observed 
during the subsequent Wittig olefination, so the ratio of both diastereomeric esters 39 further 
decreased to three to two. Nonetheless, these compounds were stable and could be separated. To 
complete the synthesis of racemic valerenal and valerenol, ester 39 was reduced to provide valerenol 
14, which was easily oxidized to yield valerenal 13. 
 
The sequence devised by the group of Bohlmann provided a general synthetic access to the class of 
valerenanes, so in principle also the synthesis of valerenic acid could be accomplished using this 
strategy. Although not enantioselective the applied strategy was straight forward and provided the 
bicyclic core in few steps. Nevertheless, the preparation of acid and base labile aldehyde 52 as one of 
the key intermediates seemed to be problematic, so epimeric mixtures could not be avoided even 
without isolation of this compound. A rationalization for its lability was provided by the authors (see 
Scheme 12). 
 
 
Scheme 12: Isomeric forms of aldehyde 52. 
 
Starting with enolization of aldehyde 52 several different isomers are accessible. As all isomers were 
in equilibrium, the most stable form was enriched. From a thermodynamic point of view the isomer 
with the desired diaxial configuration 52 is the least probably formed, whereas epimer 53 with a 
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diequatorial configuration is the most stable isomer. As result already a trace of acid or base led to 
enrichment of epimer 53. 
 
2.4.3 Total Synthesis of (+/-) Valerenal by Baudouy 
 
In 1983, three years after the first racemic synthesis of valerenal (13), Baudouy and Sartoretti 
finished their approach towards the same target (see Scheme 13).22 
 
 
Scheme 13: Total synthesis of valerenal by the group of Baudouy. 
 
The sequence devised by the group of Baudouy started with literature known racemic methyl 
cyclohexanone 60, which could be prepared from commercially available cyclohexenone 59 by simple 
cuprate addition. Enolization of 60 and addition of ethyl formate provided β-keto compound 61, 
which was stereoselectively reduced and TBS protected. After formation of the trisylhydrazone 63, a 
mixed cuprate was prepared by Shapiro reaction and subsequent addition of copper species 64. 
Nucleophilic substitution of tosylate 65 by this compound provided allene 66. In the keystep of the 
synthesis a thallium mediated cyclization of this substrate furnished a one to one mixture of the two 
diastereomers 67 and 68. Unfortunately, attempted epimerization of this mixture into the desired 
isomer 67 was not possible, but led to the complete formation of the undesired epimer 68 instead. 
Without separation of both isomers this mixture was deoxygenated in a three step procedure 
including reduction of the keton, acetylation and Birch reduction. After deprotection of TBS ether 69 
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oxidation yielded acid and base labile aldehyde 52, which had already been known from the 
synthesis by Bohlmann and coworkers. Instead of a Wittig olefination a Peterson olefination with 
subsequent isomerization of the conjugated double bond with pyridinium hydrochloride finally 
provided valerenal (13). Noteworthy, because of the lability of the precursors the ratio decreased 
over the last steps, so eventually only a 44 to 56 ratio of valerenal and its epimer was obtained. 
 
Like the synthesis of valerenal by Bohlmann also the synthesis of Baudouy and Sartoretti provides a 
general access to valerenanes. The number of steps and the overall yield are reasonable and, despite 
its toxicity, the novel thallium mediated cyclization highlighted the usefulness of such 
transformations. Contrary, again labile intermediates had to be used to provide the natural product. 
As result once more epimeric mixtures were obtained. 
 
2.4.4 Total Synthesis of Valerenic Acid by Altmann 
 
A few months after the completion of the first total synthesis of valerenic acid by our group, also the 
group of Altmann published a different approach towards this natural product (see Scheme 14).23 
 
 
Scheme 14: Second total synthesis of valerenic acid by Altmann and coworkers. 
 
The synthesis began with the literature known formation of enantiopure methylcyclohexenone 73 
from readily available (+)-pulegone (72) in six steps. After 1,4-addition of cuprate 74 the in situ 
formed enolether was TMS protected to yield compound 75. Because the cuprate addition 
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predominantly led to the undesired diastereomer, Wacker oxidation was used to form the 
α,β-unsaturated keto compound 76. After deprotection of acetal 76, stereoselective reduction of the 
double bond furnished diketo compound 79 with the desired configuration at C1. In the next steps 
the five-membered ring was closed by an aldol condensation and an exo-methylene group was 
installed by Wittig olefination, which was converted into an alcohol by hydroboration. To avoid 
epimerization, the subsequent Dess-Martin-periodinane oxidation was performed at very low 
temperature to yield aldehyde 52, which has already been used by Bohlmann and Baudouy for their 
syntheses of valerenol and valerenal. Without purification of the aldehyde, Wittig olefination under 
microwave conditions gave the desired valerenic acid ethyl ester as single product with reasonable 
yield. After 16 steps finally saponification of the ester provided valerenic acid. 
 
The synthetic strategy developed by Altman and coworkers once again rests upon the use of labile 
compounds, but oxidation with a mild oxidizing agent at very low temperature and the microwave 
assisted Wittig olefination provided effective tools to limit epimerization to a minimum. 
 
2.5 First Total Synthesis of Valerenic Acid 
2.5.1 Introduction 
 
During this PhD thesis a completely different synthetic strategy was developed, which eventually led 
to publication of the first total synthesis of valerenic acid (see Scheme 15). 
 
 
Scheme 15: Retrosynthetic considerations to avoid instable intermediates. 
 
Instead of Wittig olefination of labile aldehyde 52, installation of the endocyclic double bond was 
chosen as one of the last steps. To fix the crucial diaxial configuration of the two onring substituents 
trans-annulated bicyclic alcohol 82 was identified as key intermediate, which could be derived by 
Wittig olefination of lactol 83. Based on the well-founded assumption that lactol 83 does not tend to 
epimerize, Wittig olefination of this substrate should proceed selectively and provide the desired 
epimer exclusively. 
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A more detailed retrosynthetic analysis and further details concerning the initially devised synthesis 
starting with commercially available (R)-glycidol can be found in the following communication. 
 
2.5.2 Total Synthesis of Valerenic Acid, a Potent GABAA Receptor Modulator 
 
Ramharter, J.; Mulzer J. Org. Lett. 2009, 11, 1151 
 
The supporting information of this publication is omitted to avoid redundancy. For experimental and 
analytical data of all compounds see the supporting information of the full paper in chapter 5.1. 
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ABSTRACT
The first total synthesis of the sesquiterpenoid valerenic acid, a constituent of Valeriana officinalis, is described. The compound is a potent
modulator of the GABAA receptor and may thus be useful in the treatment of various dysfunctions of the central nervous system. The synthesis
is enantio-, diastereo-, and regiocontrolled and utilizes an enyne-RCM, a metal-coordinated Diels-Alder reaction, a hydroxy-directed Crabtree
hydrogenation, and a Negishi methylation as key steps.
γ-Aminobutyric acid (GABA) is the principal inhibitory
neurotransmitter in the mammalian brain and mediates its
action by interaction with GABA type A (GABAA) receptors
representing a ligand-gated chloride channel, second mes-
senger linked GABAB receptors that are coupled to Ca2+-
and K+-channels via G-proteins and GABAC receptors.1
There is clear evidence for specific expression of certain
GABAA receptor subtypes (with different subunit composi-
tions) in different regions in the central nervous system
(CNS).2 The subunit composition determines the GABA-
sensitivity and the pharmacological properties of the GABAA
receptor.3 Searching for molecules selective for a certain
GABAA receptor subtype is, therefore, a promising approach
to develop new therapeutics.
Valerenic acid (1), isolated from the roots of Valeriana
officinalis,4 has recently been shown to selectively modulate
GABAA receptor subtypes.5 These data suggest that 1 is a
subunit-specific allosteric modulator of GABAA receptors and
as a drug, might be applicable against a variety of CNS
dysfunctions, such as panic disorders, hyperactivity, poor
motor coordination, learning deficits, spontaneous epileptic
seizures, and abnormal facial development. Therefore, as
more extensive and elaborate structural variations are envis-
aged, an efficient total synthesis of 1 appeared of importance.
This intention seemed all the more worthwhile to us as,
despite some fruitless efforts in the past,6 no total synthesis
of 1 has been reported so far.
(1) (a) Barnard, E. A.; Skolnick, P.; Olsen, R. W.; Mohler, H.; Sieghart,
W.; Biggio, G.; Braestrup, C.; Bateson, A. N.; Langer, S. Z. Pharmacol.
ReV 1998, 50, 291–313. (b) Bormann, J. Trends Pharmacol. Sci. 2000, 21,
16–19.
(2) (a) Korpi, E. R.; Grunder, G.; Luddens, H. Prog. Neurobiol. 2002,
67, 113–159. (b) Pirker, S.; Schwarzer, C.; Wieselthaler, A.; Sieghart, W.;
Sperk, G. Neuroscience 2000, 101, 815–850.
(3) (a) Hevers, W.; Luddens, H. Mol. Neurobiol. 1998, 18, 35–86. (b)
Sieghart, W.; Sperk, G. Curr. Top. Med. Chem. 2002, 2, 795–816. (c)
Boileau, A. J.; Li, T.; Benkwitz, C.; Czajkowski, C.; Pearce, R. A.
Neuropharmacology 2003, 44, 10031012.
(4) Stoll, A.; Seebeck, E. Justus Liebigs Ann. Chem. 1957, 603, 158–
168.
(5) Khom, S.; Baburin, I.; Timin, E. N.; Hohaus, A.; Sieghart, W.;
Hering, S. Mol. Pharmacol. 2002, 69, 640–649.
(6) (a) Joseph, K. T.; Krishna, R. G. S. Tetrahedron 1967, 23, 3215–
3220. (b) Bohlmann, F.; Lonitz, M. Chem. Ber. 1980, 113, 2410–2423. (c)
Baudouy, R.; Sartoretti, J.; Choplin, F. Tetrahedron 1983, 39, 3293–3305.
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Structurally, 1 is a sesquiterpene featuring an indanyl core
with three stereogenic centers and two double bonds (Figure
1). A particular challenge in a total synthesis lies in the
diaxial arrangement7 of two onring substituents, which had
to be installed without subsequent epimerization.6b
From the retrosynthetic perspective (Scheme 1), an obvious
route to 1 might start from a pulegone-derived cyclohexanone
such as 2 and attach the cyclopentene ring via alkylation to
3 and olefination/ring closing metathesis (RCM) to 4.
However, enolate additions to 2 are known8 to favor the
trans-diastereomer, which would generate 4 with the wrong
configuration at the ring juncture. Therefore, we decided to
prepare the bicyclic core from an acyclic precursor 7 via an
enyne-RCM9-IMDA (IMDA ) intramolecular Diels-Alder
addition) sequence via 6 to generate lactone 5. The relative
configuration at C-7/7a should be created via hydroxy-
directed catalytic hydrogenation. As the ultimate steps of our
synthesis we considered a Negishi-coupling to introduce the
methyl substituent at C-3, whereas the exocyclic enoate
appendage at C-4 should be formed by an E-selective Wittig
olefination. This plan had two main unknowns: (a) the
stereochemical outcome of the IMDA reaction generating 5
and (b) the possibility to achieve the correct relative
configuration at C-7/7a with respect to C-4.
The IMDA reaction of ester-linked trienes such as 8 is
known to proceed exclusively via the so-called trans () exo)
transition state 9a (Scheme 2).10,11 Because of great distortion
and steric hindrance the electronically normally preferred cis
() endo) transition state 9b is clearly disfavored and, thus,
product 10 should be formed. On the other hand, this
outcome would be contra-thermodynamic, as 10, according
to STO 3-21G calculations, is 13.2 kcal·mol-1 higher in
energy than product 11.
Our synthesis (Scheme 3) started with readily available
racemic 3-OTBS-oct-1-en-6-yne (7),12 which smoothly un-
derwent RCM to cyclopentene 12 with Grubbs’ first genera-
tion catalyst, if the reaction was carried out under an ethylene
atmosphere (Mori’s conditions).13 Several other conditions
such as using an argon atmosphere instead of ethylene or
PtCl2 as catalyst led to no conversion or decomposition. In
situ deprotection and acylation furnished acrylic ester 8 as
the envisaged IMDA substrate. However, all attempts to
achieve cycloaddition under thermal conditions just led to
decomposition. After this failure we switched to a metal-
coordinated Diels-Alder reaction14 of alcohol 6 and methyl
acrylate with MgBr2 as the template. This reaction furnished
lactone 11 stereoselectively.15 The transition state (13) of
this Diels-Alder reaction now resembles the electronically
favored endo-arrangement 9b and furnishes lactone 11 as
the thermodynamically more stable product, so that all
disadvantages of the covalently tethered acrylate are now
reversed.
The synthesis was continued (Scheme 4) by installing the
side chain at C-4 via reduction to the lactol 14 (not isolated)
(7) Cf. the crystal structure of valerenolic acid: Birnbaum, G. L.; Findlay,
J. A.; Krepinsky, J. L. J. Org. Chem. 1978, 43, 272–276.
(8) Touriya, Z.; Santelli-Rouvier, C.; Santelli, M. J. Org. Chem. 1993,
58, 2686–2693.
(9) Diver, S. T.; Giessert, A. J. Chem. ReV. 2004, 104, 1317–1382.
(10) Strekowski, L.; Kong, S.; Battiste, M. A. J. Org. Chem. 1988, 53,
901–904.
(11) Cayzer, T. N.; Paddon-Row, M. N.; Moran, D.; Payne, A. D.;
Sherburn, M. S.; Turner, P. J. Org. Chem. 2005, 70, 5561–5570.
(12) Adrio, J.; Rodrı´guez Rivero, M.; Carretero, J. C. Angew. Chem.,
Int. Ed. 2000, 39, 2906–2909.
(13) Kinoshita, A.; Sakakibara, N.; Mori, M. J. Am. Chem. Soc. 1997,
119, 12388–12389.
(14) Barriault, L.; Thomas, J. O. D.; Clement, R. J. Org. Chem. 2003,
68, 2317–2323.
(15) The relative configuration of 11 was secured via 2D NMR
techniques (see the Supporting Information).
Figure 1. Structural features of valerenic acid (1).
Scheme 1. Retrosynthetic Analysis of 1
Scheme 2. Stereochemical Implications of the IMDA Reaction
of 8
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and Wittig reaction to form enoate 15. The free OH group
was now used as an anchoring group for Crabtree’s catalyst,16
which delivered dihydrogen in a syn fashion to generate
hydrindane 16 stereo- and chemoselectively. Oxidation to
ketone 17 was followed by deprotonation to the thermody-
namically more stable enolate, formation of vinyl triflate 18
(not isolated), and Negishi coupling17 with dimethyl zinc.
From this sequence the tetrasubstituted olefin 19 was
obtained with >90% regioselectivity. Base-catalyzed ester
hydrolysis led to rac-1. After that, the synthesis was repeated
with enantiomerically pure (S)-718 to provide the natural
enantiomer (-)-1. All analytical data of rac-1 and (-)-1 were
in full agreement with those of an authentic sample (see the
Supporting Information).
In conclusion we have achieved a concise stereo- and
regiocontrolled synthesis of valerenic acid (1) in racemic (8
steps from 7, 26% overall yield) and optically pure form
(13 steps from (R)-glycidol, 8% overall yield). Remarkably,
the initial stereochemical information introduced with the
carbinol center in compound 7 is used in a relay-manner to
control the stereogenic centers in the target molecule. After
that it is discarded in favor of an endocyclic double bond.
The route is flexible and should be applicable to a variety
of derivatives, suitable for SAR investigations.
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(16) Crabtree, R. H.; Davis, M. W. J. Org. Chem. 1986, 51, 2655–
2661.
(17) (a) Marshall, J. A.; Zou, D. Tetrahedron Lett. 2000, 41, 1347–
1350. (b) Review: Negishi, E.; Hu, Q.; Huang, Z.; Qian, M.; Wang, G.
Aldrichim. Acta 2005, 38, 71–92.
(18) (S)-7 was prepared via a stereo-unambiguous route from (R)-
glycidol in five steps and 32% overall yield (see the Supporting Information).
Scheme 3. Preparation of Lactone 11a
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Scheme 4. Completion of the Synthesisa
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2.6 Second Generation Approach 
2.6.1 Introduction 
 
To provide suitable amounts of valerenic acid 1 and its derivatives for SAR (structure-activity 
relationship) studies a short, flexible and scalable synthesis was required. While highly enantio- and 
diastereoselective the first generation synthesis starting from (R)-glycidol (84) suffered from three 
major disadvantages. First of all preparation of the Diels-Alder substrate 85 was rather lengthy. 
Although only of moderate complexity, its preparation took seven steps with an overall yield of 27 % 
(see Scheme 16). 
 
 
Scheme 16: Analysis of the first generation synthesis of valerenic acid. 
 
Secondly a rather pricy metathesis catalyst (Grubbs’ first generation catalyst) was needed in an early 
stage of the synthesis and last but not least the starting material was derived from the chiral pool 
and quite expensive. As consequence only mg-quantities of valerenic acid were obtained from the 
first generation synthesis. 
 
To optimize the devised synthesis several different approaches towards compound 85 have been 
developed, which are summarized together with all unsuccessful attempts concerning the total 
synthesis of valerenic acid in the following full paper. 
 
2.6.2 From Planning to Optimization: Total Synthesis of Valerenic Acid 
 
Ramharter, J.; Mulzer, J. Eur. J. Org. Chem. submitted (21.12.2011) 
 
The supporting information of this full paper includes 1H-NMR and 13C-NMR spectra of all discussed 
compounds. These spectra are depicted in chapter 5.1. 
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A detailed study of the total synthesis of valerenic acid, a well 
known GABAA receptor subtype modulator, is described. Both 
successful as well as unsuccessful attempts towards the title 
compound are presented including four different strategies to 
synthesize one of the key intermediates of this synthesis. The first 
two strategies are based on epoxides provided from the chiral pool, 
whereas the last two approaches rest on stereocontrolled 
modifications of 2-cyclopentenone. The streamlined synthesis 
implements a novel one-pot reaction, which combines the addition  
of a Grignard species with an acid catalyzed isomerization of the 
intermediate allylic alcohol. Further highlights are a stereo- and 
regioselective hydroxy-directed Diels-Alder reaction, a hydroxy-
directed hydrogenation and a final Negishi coupling. After 
optimization of our synthesis also the preparation of several 
easily available derivatives is discussed. Amides obtained by 
functionalization of the carboxyl group are more than twice as 
active as valerenic acid. 
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Introduction 
Valerenic acid (1) was isolated in 1957 by Stoll and Seebeck 
from the rhizome and roots of valerian (valeriana officinalis) and 
by now is probably the most prominent member of valerenanes.1 
Already known in ancient Greece valerian has been one of the 
oldest medicinal herbs in folk medicine and has been applied 
against various afflictions like insomnia, anxiety or pain.2 Due to 
these interesting pharmacological effects valerian has attracted 
extensive studies to identify the bioactive target. It is now 
understood that several constituents of valerian interact with the 
GABA neurotransmitter receptor system and recently, valerenic 
acid (1) has been shown to act as subunit-specific allosteric 
modulator of GABAA subtype receptors.
3  Because of this 
selectivity and its overall activity, 1 is envisaged as a potential 
candidate in drug discovery and development. 
Structurally 1 features an indanyl core with three stereogenic 
centers and two double bonds. As a sesquiterpene, it belongs to the 
class of guaianes, a group of more than five hundred natural 
products biogenetically derived from farnesyl pyrophosphate (2) by 
bond connections between C-1/C-10 and C-2/C-6 (Scheme 1). 4 
After formation of the guaiane core 4, isomerization and oxidation 
lead to guaianolide 5, which undergoes a Wagner-Meerwein type 
ring contraction to 1.5 Most interestingly, both onring substituents 
of the six-membered ring are now fixed in an axial position. This 
unusual conformation has already been confirmed by X-ray 
crystallography in 1978.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Biosynthesis of Valerenic Acid (1). 
The challenging architecture and the promising pharmacological 
profile prompted us, and shortly thereafter the group of Altmann to 
devise a concise and flexible total synthesis of 1, which was 
extended to suitable derivatives and SAR studies thereof.7 In this 
report we also disclose a considerably simplified and streamlined 
route and discuss the preparation of several derivatives, which are 
more active than the natural product itself.8,9 
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Results and Discussion 
Many of the already known approaches towards valerenanes are 
based on intermediates which are moderately stable and prone to 
epimerization of the diaxial onring substituents, and/or include low 
yielding steps to install the substituents stereoselectively.10 The key 
concept of our synthesis rests upon the construction of a trans-
fused indane core for the following reason. A trans-annulated five-
membered ring locks one of two chair conformations of the 
cyclohexane ring and thus allows us to fix both substituents in an 
axial position (see Scheme 2). 
 
 
 
 
 
 
Scheme 2. Transannulated Indanyl Core as Key Concept. 
As depicted in Scheme 3 our retrosynthetic analysis leads back 
to a Diels-Alder reaction of diene 9 with acrylic ester to generate 
the indane structure 8 stereoselectively. Further key steps are a 
Wittig reaction to introduce the side chain and a stereocontrolled 
hydrogenation to place the methyl group in the desired axial 
position. 
 
 
 
 
 
 
 
 
Scheme 3. Retrosynthetic Analysis. 
Racemic approach: At the beginning of our project we needed 
a simple strategy to get enough material of hydroxydiene 9 to 
verify our retrosynthetic considerations. As depicted in Scheme 4 
we devised a six step sequence starting with vinyloxirane (rac-10). 
Although 10 is available in both racemic and optically active forms 
only racemic material rac-10 was used. In the first step oxirane 
rac-10 was opened with 3-(trimethylsilyl)propargyllithium to 
furnish a separable mixture of the desired allylic alcohol rac-11 and 
the undesired primary alcohol rac-12 in a 2:1-ratio with a 
combined yield of 94%. Noteworthy, all attempts to use 
3-(trimethylsilyl)propargylmagnesium bromide instead of the 
lithium compound only led to an increased amount of the undesired 
alcohol rac-12, whereas the use of the unsubstituted 
propargyllithium or 3-methylpropargyllithium predominantly 
afforded the corresponding allenes. The allylic alcohol of 
compound rac-11 was protected as the TBS-ether, then the 
TMS-group was removed selectively and alkyne rac-13 was 
methylated to provide enyne rac-14 for the envisaged enyne-RCM 
reaction. Initially we planned to use platinum dichloride as catalyst 
for a skeletal rearrangement according to a protocol by Murai et 
al. 11  However, even though the cyclization of very similar 
substrates is known, all attempts failed and only led to isolation of 
the starting material, if an argon atmosphere was used, or to 
complete decomposition, if a carbon monoxide atmosphere was 
used instead. We rationalized that compared to other substrates the 
missing Thorpe-Ingold effect prevents the noble metal catalyzed 
rearrangement of our precursor. Therefore we switched to a 
Grubbs’ I catalyzed enyne-RCM. Under an ethylene atmosphere 
(Mori’s conditions) the reaction proceeded smoothly to furnish 
cyclopentene rac-15 with excellent yield.12 After deprotection of 
the alcohol the desired key intermediate rac-9 for the envisaged 
Diels-Alder reaction was obtained in six steps from vinyloxirane 
(rac-10). 
 
 
 
 
 
 
 
 
 
 
Scheme 4. Racemic Approach. a) TMSC≡CCH2Li, Et2O/THF = 5/1, -25 °C, 
65% of rac-11 and 29% of rac-12; b) TBSCl, imidazole, DMF, rt; c) K2CO3, 
MeOH/THF = 1/1, rt, 80% over two steps; d) n-BuLi, MeI, THF, -78 °C, 
89%; e) ethylene atmosphere, Grubbs’ I cat., rt, 86%; f) TBAF, THF, rt, 
94%. 
Glycidol approach: To obtain key compound 9 in optically pure 
form, we decided to avoid the expensive enantioenriched 
vinyloxirane (10). Therefore, our first enantioselective approach 
was based on (R)-glycidol (16), which can be used without 
protecting group in the first step (see Scheme 5). Regioselective 
opening of the epoxide with unsubstituted propargylmagnesium 
bromide led to diol 17, whose primary alcohol was selectively 
tosylated with catalytic amounts of dibutyltin oxide in the next 
step.13 Treatment of tosylate 18 with an excess of the basic Corey-
Chaykovsky reagent afforded epoxide 19, which was immediately 
opened by an additional equivalent of dimethylsulfonium 
methylide to furnish the slightly volatile allylic alcohol 20. 14 
Without purification the crude alcohol was protected as the TBS-
ether 13 in enantiopure form. The last three steps were the same as 
in the racemic series and provided the optically active key 
intermediate 9 in seven steps from (R)-glycidol. 
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Scheme 5. Glycidol Approach. a) HC≡CCH2MgBr, Et2O, -78 °C, 97%; b) 
TsCl, NEt3, cat. Bu2SnO, DCM, rt, 80%; c) Me3SI, n-BuLi then 19, THF,-
20 °C; d) TBSOTf, NEt3, DCM, 0 °C, 58% over two steps; e) n-BuLi, MeI, 
THF, -78 °C, 89%; f) ethylene atmosphere, Grubbs’ I cat., rt, 86%; g) 
TBAF, THF, rt, 94%. 
Oxidative rearrangement approach: The third approach 
towards compound 9 was developed to shorten our synthesis, and 
avoid costly starting materials and metathesis catalysts. As 
depicted in Scheme 6, this approach started with inexpensive 
cyclopentenone 21. 
 
 
 
 
 
 
 
 
 
Scheme 6. Oxidative Rearrangement Approach. a) isopropenyllithium, 
Et2O, -78 °C; b) PDC, DCM, rt, 49% over two steps; c) DIBALH, DCM, -
78 °C, 95%; d) vinyl acetate, Amano lipase PS, MTBE, rt, 45% of 9 with 
ee ≥ 95% and 46% of 24; e) silica gel, THF, H2O, rt, 95%. 
Noteworthy, the 1,2-addition of an appropriate isopropenyl 
nucleophile proved more difficult than we had envisaged, because 
in most cases the yield was low and competitive 1,4-addition was 
observed. After screening different conditions, diethyl ether as 
solvent and isopropenyllithium as nucleophile was found to 
provide allylic alcohol 22 in satisfying yield. However, this 
compound turned out to be very sensitive to acids and therefore 
only of moderate stability, as well as slightly volatile. Therefore, 
without further purification, an oxidative rearrangement with PDC 
was performed to furnish dienone 23 in reasonable yield.15 The 
reduction to the alcohol proceeded smoothly, and chiral resolution 
with Amano lipase PS and vinyl acetate gave enantiomerically 
enriched hydroxy diene 9 along with acetate 24.16  Interestingly 
chromatographic separation of both compounds had to be 
performed on aluminium oxide because the acetate was hydrolyzed 
on silica gel. This observation proved useful in the end, as simple 
treatment of the acetate with aqueous silica gel in THF reconverted 
it into the racemic hydroxy diene, which can be recycled in another 
chiral resolution. 
One-pot reaction approach: The final and by far shortest 
method to provide sufficient amounts of 9 incorporates a novel 
one-pot reaction, which has been recently devised by our group 
(see Scheme 7).8 
 
 
 
 
Scheme 7. One-Pot Reaction Approach. a) i) isopropenyllithium, Et2O, -
78 °C; then ii) TFA, H2O, 0 °C, 81% (72% on gram scale). 
The idea is based on the above mentioned acid lability of the 
allylic alcohol 22. We rationalized, that this compound should be 
able to undergo an acid induced [1,3]-isomerization, which would 
lead to the formation of the thermodynamically more stable 
product.17 To confirm this hypothesis the initially formed tertiary 
alkoxide 25 was protonated with aqueous acid to form the alcohol, 
which isomerizes to the more stable secondary hydroxy diene rac-9. 
If an inorganic acid such as sulphuric acid or hydrochloric acid was 
added, low yields were obtained, indicating that decomposition and 
side reactions seemed to be competitive with the [1,3]-
isomerization. However, when acetic acid or trifluoroacetic acid 
was used, the yield considerably increased. Whereas isomerization 
induced by acetic acid took much longer and led to considerable 
amounts of 1-acetoxy-3-isopropenylcyclopent-2-ene (26) as a 
byproduct, treatment of 25 with trifluoroacetic acid resulted in the 
selective formation of 2,4-dienol rac-9. Finally with this scalable 
and high yielding one-pot reaction we were able to synthesize gram 
quantities of the racemic hydroxy diene rac-9 in a single step. 
Combined with the chiral resolution, 9 is now accessible in just 
two steps. 
To test the usefulness of this one-pot reaction we successfully 
expanded the scope of this reaction.8 Fortunately the same 
principle could be applied on several other cycloalkenones as well, 
although depending on the substrates, slight alterations of the used 
conditions sometimes were necessary (see Table 1). As is depicted 
in table 1, the reaction is not restricted to the use of 
isopropenyllithium and smooth conversion is also observed with 
vinylmagnesium bromide (entries 1-5). Also substrates with larger 
ring size undergo selective isomerization (entries 2 and 3), as well 
as substituted cycloalkenones (entries 4 and 5). Noteworthy, the 
conversion of substrate 32 was much more acid-sensitive than of 
other substrates (entry 4). Therefore, the corresponding 
intermediate was treated with aqueous acetic acid instead of 
trifluoroacetic acid to provide the expected alcohol as sole product. 
Interestingly, in the isomerization of this substrate no other 
products were obtained. Finally, clean and selective isomerization 
was also observed for phenylmagnesium bromide (entry 6). 
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Table 1. Selected Examples of the Conversion of different Substrates.[a] 
entry substrate nucleophile conditions product yield 
1 
  
TFA,   
0 °C 
 
  78%  
(73%)[b] 
2  
 
TFA,   
0 °C 
 
79% 
3 
  
TFA,   
25 °C 
 
80% 
 
4 
  
AcOH,   
0 °C 
 
99% 
 
5 
  
TFA,   
0 °C 
 
79% 
 
6 
  
TFA,   
25 °C 
 
94% 
 
[a] i) 0.1 M in Et2O at 0 °C, 2.0 equiv nucleophile; ii) 0 °C or rt, H2O, 
2.5 equiv acid. 
[b] Conducted on gram scale. 
Hydroxy-directed Diels-Alder reaction: With both racemic as 
well as optically pure substrates in our hands, we proceeded with 
the remaining steps of our planned synthesis (see Scheme 8). Ester 
38 was prepared by treatment of alcohol 9 with acryloyl chloride to 
get the precursor of the envisaged IMDA reaction. However, all 
attempts failed as either no conversion at all or decomposition was 
observed. According to literature precedence the IMDA reaction of 
compounds such as ester 38 should exclusively lead to the exo 
product 8b.18 The electronically preferred endo transition state 39a 
is highly strained and should be disfavoured relative to the exo 
transition state 39b. However, closer inspection and calculation of 
the predicted exo product 8b reveal that such a compound would be 
extremely distorted, which makes its formation unlikely. In 
conclusion it seems that the endo product 8a is not accessible 
because of kinetic reasons, whereas the exo product is not formed 
because of thermodynamic instability.  
To solve this problem a hydroxy-directed Diels-Alder (HDDA) 
reaction was chosen, because in this case the esterification occurs 
after the Diels-Alder reaction.19 Therefore the endo transition state 
39c lacks the distortion described above. The hydroxy function 
serves as anchoring group for the metal and allows enantio- and 
regioselective cyclization (see Table 2). Whereas all attempts to 
use phenyl magnesium bromide either with or without a scavanger 
alcohol to generate the alkoxide led to no conversion or complete 
decomposition (entries 1 and 2), deprotonation with triethylamine 
in the presence of magnesium dibromide etherate and addition of 
the dienophile according to a protocol of Barriault and coworkers 
provided lactone 8a with 45% yield (entry 3).20 Gratifyingly, the 
use of Huenig’s base instead of triethylamine increased the yield to 
81% (entry 4). Unfortunately, all attempts to deprotect racemic 
diene rac-15 with boron trifluoride and to use the in situ formed 
boronate failed, probably because of the instability of rac-15 under 
the conditions applied. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 8. Attempted IMDA. a) pyridine, acryloyl chloride, dichloro-
methane, 0 °C, 32%. 
Table 2. Optimization of the HDDA. 
 
 
 
 
 
entry R conditions yield 
1 H PhMgBr, toluene, rt to 50 °C    0%[a] 
2 H 0.5 eq PhMgBr, C5H11OH, toluene, rt    0%
[b] 
3 H MgBr2∙Et2O, NEt3, rt    45% 
4 H MgBr2∙Et2O, DIPEA, rt    81% 
5 TBS BF3∙Et2O, DCM or CH3CN, -15 °C    0%
[a] 
[a] Decomposition. 
[b] No conversion of 9 observed. 
Unsuccessful attempts: To introduce the trans-ring fusion in 
the hydroindane core and hence the two missing stereogenic 
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centers of valerenic acid, lactone 8a was reduced to diol 40, in 
which both hydroxy groups may serve as anchoring groups for a 
substrate directable hydrogenation (see Scheme 9). Indeed, 
Crabtree’s catalyst furnished diol 41 stereoselectively with 
excellent yield. 21  After oxidation to ketoaldehyde 42 a Wittig 
olefination was used for introducing the enoate sidechain. However, 
although the desired compound 6a was also obtained, the major 
product of this reaction was 6b, resulting from epimerization of 6a 
to its cis-fused diastereomer. Unfortunately, the consequences of 
this epimerization are crucial, because in 6b both onring 
substituents are in equatorial positions of the six-membered ring. 
Therefore all attempts to convert 6b into the desired enol triflate 43 
failed, because this would place both substituents in axial positions. 
Only the formation of the less substituted enol triflate was 
observed. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 9. Envisaged Endgame. a) LiAlH4, Et2O, 0 °C to rt, 90%; b) cat. 
Ir(cod)(py)PCy3, H2, DCM, rt, 91%; c) IBX, DMSO, rt, 80%; d) 
Ph3P=CMeCO2Et, DCM, rfx, 14% of 6a and 65% of 6b. 
Completion of the synthesis: To prevent the detrimental 
epimerization lactone 8a was reduced to lactol 44 instead (see 
Scheme 10). Gratifyingly, subsequent Wittig olefination led to the 
chain elongated product 7 without epimerization. Again the 
secondary alcohol was used to direct the chemo- and 
stereoselective Crabtree hydrogenation, which produced compound 
45 with satisfying yield. Mild oxidation allowed us to isolate 6a as 
sole product, 22  which was converted regioselectively into the 
tetrasubstituted enol triflate 43. Negishi cross coupling with 
dimethylzinc furnished ethyl valerenate (46).23 Small amounts of 
the undesired regioisomer were removed by column 
chromatography on silica gel (conditioned with silver nitrate) or by 
HPLC. Finally saponification furnished (-)-valerenic acid (1) with 
an overall yield of 13% (25% if compound 24 is fully recycled) 
over 10 steps (7 isolated intermediates) starting from commercially 
available cyclopentenone 21. 
Synthesis of derivatives: After completion and optimization of 
our synthesis we turned our attention to the preparation of suitable 
derivatives. Recently Rudolph and Altmann have demonstrated 
that functionalization of the carboxyl group has drastic 
consequences on the activity of valerenic acid.24,25 Therefore we 
identified synthetic valerenic amides as potential targets. In an 
effort to learn more about the structure-activity relationship (SAR) 
of these compounds and their interaction with the GABAA receptor 
six simple amides with different substituents are chosen for a first 
series of derivatives. (see Table 3) 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 10. Final Steps towards Valerenic Acid (1). a) DIBALH, DCM, -
78 °C; b) Ph3P=CMeCO2Et, benzene, rfx, 83% over two steps; c) cat. 
Ir(cod)(py)PCy3, H2, DCM, rt, 72%; d) IBX, DMSO, rt, 93%; e) Tf2O, 
pyridine, DCM, rt; f) cat. Pd(PPh3)4, Me2Zn, THF, rt, 78% over two steps; 
g) LiOH, THF, H2O, MeOH, rt, 99%. 
Table 3. Preparation of Derivatives. 
 
 
 
 
 
entry R-H product yield 
1 NH3 47 96% 
2 NH2Me 48 95% 
3 NH2Et 49 94% 
4 NHEt2 50 94% 
5 piperidine 51 91% 
6 morpholine 52 90% 
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Although activation of valerenic acid with chloroformates or 
other coupling reagents and treatment with ammonia furnishes the 
desired unsubstituted amide 47, unfortunately yields decrease when 
bulkier amines are used as nucleophiles. After testing several 
procedures eventually the use of Ghosez’ reagent to form valerenic 
acid chloride under very mild conditions and subsequent addition 
of the corresponding amine provides the best yields. 26  In 
cooperation with the Department of Pharmacology and Toxicology, 
University of Vienna these substrates were both tested in vitro and 
in vivo.9 To our delight all substances are highly active GABAA 
receptor modulators. Depending on the degree of substitution the 
activity of compound 47 to 52 decreases with growing substituents. 
As consequence the best results are obtained for unsubstituted 
valerenic amide 47, which is more than twice as active as valerenic 
acid (1). To get a better understanding of this class of substances 
also a second series of derivatives with modified valerenane core 
has been synthesized. A more detailed discussion of these highly 
active and easily available substrates will be published in due 
course. 
Conclusions 
In conclusion we have developed a concise, protecting group 
free and highly stereoselective total synthesis of valerenic acid. 
Altogether four different approaches to provide key intermediate 9 
are described, leading to gradual improvements. Both successful 
strategies as well as unsuccessful attempts are discussed to outline 
the difficulty to synthesize compounds with thermodynamically 
instable axial substituents and prevent irreversible epimerization. 
The final route incorporates a novel one-pot reaction, which allows 
the formation of key intermediate 9 in gram quantities. Further 
extension of this reaction underlines the scope and applicability of 
this reaction. The number of steps has been reduced from fifteen to 
ten steps, which makes this route suitable for the synthesis of a 
variety of derivatives and provides the basis for extensive SAR 
studies. In a first effort a series of derivatives has been prepared. 
Interestingly, easily available valerenic amides display a higher 
activity than valerenic acid both in vitro and in vivo. 
Experimental Section 
All reactions were carried out in oven-dried glassware under an argon 
atmosphere unless stated otherwise. Anhydrous CH2Cl2 was distilled under 
Argon from P2O5, diethyl ether, methanol and benzene from sodium, 
DMSO, triethylamine, and diisopropylethylamine from CaH2 and 
anhydrous THF, DMF and MTBE were purchased from Aldrich. All other 
solvents were HPLC grade. Commercially available reagents were used 
without further purification besides stated otherwise. Reactions were 
magnetically stirred and monitored by thin layer chromatography. Flash 
column chromatography was performed with silica gel (0.04-0.063 mm, 
240-400 mesh) under pressure besides stated otherwise. Yields refer to 
chromatographically and spectroscopically pure compounds unless stated 
otherwise. NMR-spectra were either recorded on 400 MHz or 600 MHz (1H 
NMR) or 100 MHz or 150 MHz (13C NMR) spectrometers. Besides stated 
otherwise all NMR spectra were measured in CDCl3 solutions. The 
chemical shifts δ are reported relative to the residual solvent peaks. All 1H 
and 13C shifts are given in ppm (s = singulet; d = doublet; t = triplet; q = 
quadruplet; m = multiplet; bs = broad signal). If possible, assignments of 
proton resonances were confirmed by correlated spectroscopy. Optical 
rotations were measured at 20 °C. IR spectra were recorded of samples 
prepared as films on silicium plates. MS spectra were measured with a 
resolution of 10000. 
7-(Trimethylsilyl)hept-1-en-6-yn-3-ol (rac-11): 1-(Trimethylsilyl)prop-
1-yne (98%, 0.94 mL, 6.221 mmol, 2.0 eq) dissolved in anhydrous diethyl 
ether (30 mL) and anhydrous THF (6 mL) was cooled to -25 °C before 
1.6 M n-BuLi (3.9 mL, 6.240 mmol, 2.0 eq) was added dropwise. After 15 
minutes the solution was warmed to 0 °C and stirred for another 60 minutes. 
Then the resulting mixture was recooled to -25 °C and treated with racemic 
vinyloxirane (0.25 mL, 3.103 mmol, 1.0 eq). Stirring over night the solution 
was slowly warmed to room temperature. After quenching with saturated 
aqueous NH4Cl, the aqueous phase was extracted with diethyl ether (4x), 
dried over Na2SO4 and concentrated in vacuo. Purification by column 
chromatography (pentane/diethyl ether 20/1 to 10/1) provided 370 mg of 
slightly impure alcohol rac-11 as clear, slightly yellow oil with 65% yield. 
Analytical data is in agreement with the data reported in the literature.27 1H-
NMR (400MHz, CDCl3, ppm): 5.87 (ddd, J=17.2 Hz, J=10.5 Hz, J=6.0 Hz, 
1H), 5.27 (dt, J=17.2 Hz, J=1.4 Hz, 1H), 5.14 (dt, J=10.4 Hz, J=1.3 Hz, 1H), 
4.27 (m, 1H), 2.35 (m, 2H), 1.84-1.70 (m, 3H), 0.15 (s, 9H).  13C-NMR 
(100MHz, CDCl3, ppm): 140.5, 115.2, 106.9. 85.6, 72.3, 35.6, 16.3, 0.2. IR 
(film, cm-1): 3345, 2958, 2927, 2175, 1426, 1249, 1122, 1043, 989, 923, 
841, 760. HRMS (ESI, m/z): calcd for C10H18NaOSi+: 205.1019; found: 
205.1026. 
tert-Butyl(hept-1-en-6-yn-3-yloxy)dimethylsilane (rac-13) (racemic 
approach): A solution of alcohol rac-11 (931 mg, 5.106 mmol, 1.0 eq) in 
anhydrous dimethylformamide (20 mL) was cooled to 0 °C and imidazole 
(869 mg, 12.76 mmol, 2.5 eq) and tert-butyldimethylsilyl chloride (927 mg, 
6.150 mmol, 1.20 eq) were added. The solution was warmed to room 
temperature and stirred over night. The solution was quenched by the 
addition of water and the aqueous phase was extracted with diethyl ether 
(3x). The combined organic phases were washed with brine, dried over 
Na2SO4 and concentrated in vacuo. The crude yellow oil was dissolved in 
methanol (35 mL) and THF (35 mL) and K2CO3 (1065 mg, 7.706 mmol, 
1.5 eq) was added. The resulting mixture was stirred over night, cooled to 
0 °C and finally quenched by the addition of diluted aqueous NH4Cl. The 
aqueous phase was extracted with diethyl ether/pentane 1/1 (3x) and the 
combined organic extracts were washed with brine, dried with Na2SO4 and 
the solvent evaporated. Column chromatography (hexane/ethyl acetate 
100/1) furnishes 918 mg of the TBS-protected alcohol rac-13 with 80% 
yield over two steps. 1H-NMR (400 MHz CDCl3, ppm): 5.78 (ddd, J=17.1 
Hz, J=10.4 Hz, J=6.1 Hz, 1H), 5.21-5.03 (m, 2H), 4.23 (dd, J=12.2 Hz, 
J=6.2 Hz, 1H), 2.32-2.16 (m, 2H), 1.94 (t, J=2.7 Hz, 1H), 1.76-1.62 (m, 2H), 
0.90 (s, 9H), 0.07 (s, 3H), 0.04 (s, 3H); 13C-NMR (100MHz, CDCl3, ppm): 
141.1, 114.5, 84.6, 72.4, 68.5, 36.8, 26.0, 18.4, 14.5, -4.2, -4.7; IR (film, 
cm-1): 3314, 2929, 2857, 1939, 1645, 1472, 1362, 1251, 1091, 1027, 987, 
923, 837, 776, 633; HRMS (ESI, m/z): calcd for [M-C4H9]
+, C9H15OSi: 
167.0892; found: 167.0894. 
(S)-Hex-5-yne-1,2-diol (17): A mixture of magnesium turnings (4.745 g, 
195.2 mmol), mercury-(II)-chloride (269.1 mg, 0.991 mmol) and a single 
crystal of iodide in freshly distilled ether (100 mL) was carefully treated 
with propargyl bromide (80% in toluene, 10.5 mL, 11.59 g, 97.4 mmol) 
dissolved in freshly distilled ether (40 mL). After the reaction had started 
the mixture was cooled to 0 °C and the rest of the propargyl bromide 
solution was slowly added within 1 hour. The resulting mixture was stirred 
for another hour at 0 °C and one additional hour at room temperature. 
(R)-Glycidol (97%, 1.0 mL, 1.077 g, 14.53 mmol, 1.0 eq) dissolved in 
freshly distilled diethyl ether (290 mL) was cooled to -78 °C. Under 
vigorous stirring freshly prepared propargyl-magnesium bromide 
(112.5 mL, 72.788 mmol, 5.0 eq) was very slowly added within 1 hour. 
During the night the mixture was slowly warmed to room temperature. 
After 14 hours the reaction was quenched with saturated aqueous NH4Cl. 
For a better phase separation potassium sodium tartrate was added and the 
solution was extracted with ether (4x) and ethyl acetate (4x). The combined 
extracts were dried (Na2SO4) and concentrated in vacuo. Purification by 
chromatography (hexane/ethyl acetate 10/1 to pure ethyl acetate) provided 
1.560 g of compound 17 as clear yellow oil with 94% yield. 1H-NMR 
(400MHz, CDCl3, ppm): 3.89 (ddd, J=13.1 Hz, J=7.0 Hz, J=3.2 Hz, 1H), 
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3.68 (dd, J=11.1 Hz, J=3.2 Hz, 1H), 3.49 (dd, J=11.1 Hz, J=7.3 Hz, 1H), 
2.47 (bs, 1H), 2.36 (dt, J=7.0 Hz, J=2.7 Hz, 2H), 2.16 (bs, 1H), 1.99 (t, 
J=2.7 Hz, 1H), 1.66 (dd, J=13.6 Hz, J=6.8 Hz, 2H); 13C-NMR (100MHz, 
CDCl3, ppm): 83.9, 71.2, 69.2, 66.7, 31.7, 15.0; IR (film, cm
-1): 3296, 2924, 
2853, 1654, 1437, 1099, 1044, 944, 890, 636; HRMS (ESI, m/z): calcd for 
[M], C6H10O2: 114.0681; found: 114.0680; [α]D
20 = -19.9 (c = 0.72 
g/100mL, DCM). 
(S)-1-Tosylhex-5-yne-1,2-diol (18): Diol 17 (1.560 g, 13.667 mmol, 1.0 
eq) was dissolved in anhydrous DCM (140 mL) cooled to 0 °C and 
dibutyltin oxide (67.9 mg, 0.2728 mmol, 0.02 eq), triethylamine (2.08 mL, 
1.518 g, 15.005 mmol, 1.1 eq) and toluenesulfonyl chloride (2.864 g, 
15.022 mmol, 1.1 eq) were added. After 10 minutes the ice bath was 
removed and the reaction mixture was stirred for 22 hours. Then solids 
were removed by filtration and the filtrate concentrated in vacuo. 
Purification by chromatography (hexane/ethyl acetate 4/1) provided 2.95 g 
of compound 18 as clear colorless oil with 80% yield. 1H-NMR (400 MHz 
CDCl3, ppm): 7.81 (d, J=8.3 Hz, 2H), 7.36 (d, J=8.0 Hz, 2H), 4.10-3.99 (m, 
2H), 3.94 (dd, J=9.6 Hz, J=6.4 Hz, 1H), 2.46 (s, 3H), 2.38-2.28 (m, 2H), 
2.18 (d, J=4.6 Hz, 1H), 1.95 (t, J=2.7 Hz, 1H), 1.64 (dd, J=13.6 Hz, J=6.8 
Hz, 2H); 13C-NMR (100MHz, CDCl3, ppm): 145.3, 132.8, 130.1, 128.1, 
83.3, 73.7, 69.4, 68.4, 31.3, 21.8, 14.7; IR (film, cm-1): 3360, 2922, 2852, 
1654, 1458, 1355, 1174, 965, 668, 554, 421, 416; HRMS (ESI, m/z): calcd 
for [M], C13H16O4S: 268.0769; found: 268.0764; [α]D
20 = -0.4 (c = 1.24 
g/100mL, DCM). 
(S)-tert-Butyl(hept-1-en-6-yn-3-yloxy)dimethylsilane (13) (glycidol 
approach): A suspension of trimethylsulfonium iodide (4.032 g, 
19.758 mmol, 5.3 eq) in anhydrous THF (60 mL) was treated with 1.6 M 
n-BuLi (11.75 mL, 18.8 mmol, 5.0 eq) at -15 °C. After stirring for 30 
minutes tosylate 18 (1.002 g, 3.733 mmol, 1.0 eq) dissolved in anhydrous 
THF (30 mL) was added dropwise within 45 minutes. The resulting 
reaction mixture was stirred at the same temperature for 1 hour, slowly 
warmed to room temperature during the night, before it was quenched by 
the addition of water. The solution was extracted with ether (4x), the 
combined organic phases were washed with brine, dried (Na2SO4) and due 
to the volatility of (S)-hept-1-en-6-yne-3-ol carefully concentrated in 
reduced vacuo. The crude (S)-hept-1-en-6-yne-3-ol was dissolved in 
anhydrous DCM (37 mL) and cooled to 0 °C. Triethylamine (1.55 mL, 
1.132 g, 11.182 mmol, 3.0 eq) and tert-Butyldimethylsilyl triflate (2.15 mL, 
2.475 g, 9.362 mmol, 2.5 eq) were added and the solution was stirred for 1 
hour at 0 °C before it was warmed to room temperature. After stirring for 
another hour water was added and the solution was extracted with ether 
(4x). The combined organic phases were washed with brine, dried (Na2SO4) 
and concentrated in vacuo. Chromatography (pentane/ether 200/1) 
furnished 489 mg of compound 13 as clear colorless oil with 58% yield. 
Analytical data is consistent with the reported data for compound rac-13. 
[α]D
20 = -4.9 (c = 0.815 g/100mL, DCM). 
(S)-tert-Butyl(oct-1-en-6-yn-3-yloxy)dimethylsilane (14): Compound 
13 (1028 mg, 4.581 mmol, 1.0 eq) was dissolved in anhydrous THF 
(46 mL) and cooled to -78 °C before treated with 1.6 M n-BuLi (4.3 mL, 
6.88 mmol, 1.5 eq) dropwise. The resulting solution was stirred 15 minutes 
at the same temperature and then methyl iodide (1.15 mL, 18.48 mmol, 
4.0 eq) was added. During the night the mixture was slowly warmed to 
room temperature. The reaction was quenched with water. The solution was 
extracted with ether (3x), the combined extracts were washed with brine, 
dried (Na2SO4) and concentrated in vacuo. Purification by chromatography 
(hexane/ethyl acetate 100/1) provided 977 mg of compound 14 as clear 
colorless oil with 89% yield. 1H-NMR (400 MHz CDCl3, ppm): 5.78 (ddd, 
J=17.1 Hz, J=10.4 Hz, J=6.0 Hz, 1H), 5.20-5.01 (m, 2H), 4.21 (dt, J=6.8 Hz, 
J=5.8 Hz, 1H), 2.25-2.09 (m, 2H), 1.78 (t, J=2.6 Hz, 3H), 1.69-1.58 (m, 2H), 
0.90 (s, 9H), 0.07 (s, 3H), 0.04 (s, 3H); 13C-NMR (100MHz, CDCl3, ppm): 
141.4, 114.1, 79.1, 75.8, 72.6, 37.4, 26.0, 18.4, 14.8, 3.6, -4.2, -4.8; IR (film, 
cm-1): 2929, 2857, 1472, 1361, 1251, 1089, 989, 922, 837, 776; HRMS 
(ESI, m/z): calcd for [M-C4H9], C10H17OSi: 181.1049; found: 181.1052; 
[α]D
20 = -4.8 (c = 1.665 g/100mL, DCM). 
(S)-tert-Butyldimethyl(3-(prop-1-en-2-yl)cyclopent-2-enyloxy)silane 
(15): A solution of compound 14 (263.8 mg, 1.106 mmol, 1.0 eq) and 
freshly distilled and degassed DCM (37 mL) was cooled to -78 °C. The 
flask was flushed with ethylene gas over a period of 10 minutes before 
ethylene gas was bubbled through the solution itself for 3 additional 
minutes. Grubbs’ I catalyst (136.4 mg, 0.1657 mmol, 0.15 eq) was added 
and once again ethylene gas was bubbled through the resulting mixture for 
one minute. The dry ice bath was removed and the mixture stirred for 24 
hours. The flask was flushed with argon and the solvent was evaporated. 
Chromatography of the residue (pentane/diethyl ether 200/1) furnished 
226.6 mg of compound of 15 as clear colorless oil with 86% yield. 1H-
NMR (400 MHz CDCl3, ppm): 5.68 (d, J=1.4 Hz, 1H), 5.00-4.94 (m, 3H), 
2.69-2.59 (m, 1H), 2.39-2.25 (m, 2H), 1.93 (s, 3H), 1.80-1.69 (m, 1H), 0.91 
(s, 9H), 0.09 (s, 6H); 13C-NMR (100MHz, CDCl3, ppm): 146.0, 140.0, 
129.9, 114.2, 78.5, 34.3, 30.7, 26.2, 20.7, 18.5, -4.3, -4.4; IR (film, cm-1): 
3360, 2927, 2855, 1661, 1634, 1600, 1464, 1361, 1251, 1108, 1051, 1005, 
910, 835, 775; HRMS (ESI, m/z): calcd for [M], C14H26OSi: 238.1753; 
found: 238.1750; [α]D
20 = -98.6 (c = 1.96 g/100mL, DCM). 
(S)-3-(Prop-1-en-2-yl)cyclopent-2-enol (9) (glycidol approach): A 
solution of compound 15 (402.8 mg; 1.689 mmol, 1.0 eq) in anhydrous 
THF (34mL) was cooled to 0 °C and treated with 1.0 M 
tetrabutylammonium fluoride (2.55 mL, 2.55 mmol, 1.5 eq). The next 3½ 
hours the reaction mixture was stirred at room temperature and then 
quenched with saturated aqueous NH4Cl. The resulting solution was 
extracted with DCM (3x) and ethyl acetate (1x), dried (Na2SO4) and 
concentrated in vacuo. Purification by chromatography (pentane/ether 3/1 
to 2/1) provided 190.4 mg of compound 9 as clear slightly yellow oil with 
95% yield. 1H-NMR (400 MHz CDCl3, ppm): 5.80 (d, J=1.7 Hz, 1H), 5.02 
(s, 2H), 4.96-4.89 (m, 1H), 2.73-2.63 (m, 1H), 2.45-2.31 (m, 2H), 1.94 (s, 
3H), 1.80-1.73 (m, 1H), 1.44 (d, J=7.4 Hz, 1H); 13C-NMR (100MHz, 
CDCl3, ppm): 147.7, 139.8, 129.0, 114.9, 78.1, 34.1, 30.6, 20.7; IR (film, 
cm-1): 3324, 2924, 2854, 1599, 1458, 1032, 970, 888; HRMS (ESI, m/z): 
calcd for [M], C8H12O: 124.0888; found: 124.0884; [α]D
20 = -119.3 (c = 
0.825 g/100mL, DCM). 
3-(Prop-1-en-2-yl)cyclopent-2-enone (23): 2-Bromopropene (160 μL, 
1.801 mmol, 1.5 eq) was dissolved in anhydrous diethyl ether (5.1 mL) and 
cooled to -78 °C. Then 1.7 M tert-BuLi (2.12 mL, 3.604 mmol, 3.0 eq) was 
added. After stirring for 2 hours the slightly turbid solution was warmed to 
ambient temperature. After 15 minutes the resulting 2-propenyllithium was 
slowly added to a solution of cyclopent-2-enone (100 μL, 1.194 mmol, 1.0 
eq) and anhydrous diethyl ether (4.8 mL) at -78 °C. After 60 minutes the 
reaction was quenched by the addition of diluted aqueous NH4Cl and 
warmed to room temperature. The aqueous phase was extracted with 
diethyl ether (3x), the combined organic phases were washed with brine 
and dried with Na2SO4, followed by careful concentration in reduced vacuo 
(Attention: The tertiary alcohol 22 is volatile). The crude alcohol was then 
dissolved in anhydrous DCM (12 mL), Celite (930 mg) was added and the 
resulting mixture treated with pyridinium dichromate (905 mg, 2.406 mmol, 
2.0 eq). After stirring for 24 hours at room temperature solids were 
removed by filtration and the remaining solution was concentrated in vacuo. 
Purification by chromatography (pentane/diethyl ether 4/1 to 2/1) furnished 
71.5 mg of compound 23 as yellow solid with 49% over two steps. 1H-
NMR (400MHz, CDCl3, ppm): 6.10 (t, J=1.5 Hz, 1H), 5.55 (s, 1H), 5.32 (t, 
J=1.3 Hz, 1H), 2.79 (m, 2H), 2.48 (m, 2H), 2.02 (s, 3H).  13C-NMR 
(100MHz, CDCl3, ppm): 210.1, 174.2, 139.8, 128.8, 119.8, 35.4, 27.8, 20.5. 
IR (film, cm-1): 2925, 2362, 2341, 1707, 1693, 1673, 1622, 1576, 1441, 
1253, 1232, 1183, 919, 866. HRMS (EI, m/z): calcd for [M], C8H10O: 
122.0732; found: 122.0732. 
3-(Prop-1-en-2-yl)cyclopent-2-enol (rac-9) (oxidative rearrangement 
approach): A solution of dienone 23 (22.8 mg, 0.1866 mmol, 1.0 eq) and 
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anhydrous DCM (0.93 mL) was cooled to -78 °C and was treated with 
1.0 M diisobutylaluminium hydride (0.23, 0.230 mmol, 1.25 eq). After 
stirring for 1 hour the remaining DIBALH was quenched by the addition of 
methanol. After warming to room temperature a diluted potassium sodium 
tartrate solution was added and stirred over night. The aqueous phase was 
extracted with DCM (5x), the combined organic phases were dried with 
Na2SO4 and the solvent was evaporated. Purification of the residue by 
column chromatography (pentane/diethyl ether 3/1 to 1/1) provided 
22.9 mg of racemic alcohol rac-9 with 99% yield as slightly yellow oil. 
Analytical data is consistent with the reported data for compound 9 listed 
above. 
(S)-3-(Prop-1-en-2-yl)cyclopent-2-enol (9) and (R)-3-(prop-1-en-2-
yl)cyclopent-2-enyl acetate (24) (racemic resolution): To a solution of 
racemic dienol rac-9 (520.5 mg, 4.191 mmol, 1.0 eq) and anhydrous MTBE 
(14.5 mL) were added Amano lipase PS (111.0 mg) and vinyl acetate (0.4 
mL, 4.340 mmol, 1.0 eq). The resulting mixture was stirred at ambient 
temperature for 24 hours. After a small NMR-sample indicated conversion 
> 50% solids were removed by filtration and the resulting filtrate 
concentrated in vacuo. Purification of the residue by chromatography 
(H/EE = 10/1 to 1/1) using Merck aluminium oxide 90 (0.063-0.200 mm, 
70-230 mesh) provided 321.0 mg of ester 24 with 46% yield and 234.8 mg 
of optically enriched alcohol 9 with 45% yield and an enantiomeric excess 
> 95% (Attention: Ester 24 is acid-labile and should be stored below 0 °C.). 
Analytical data for compound 9 is consistent with racemic alcohol rac-9, 
see above. [α]D
20 = - 124.9 (c = 1.175 g/100 ml, DCM). Analytical data for 
ester 24: 1H-NMR (400MHz, CDCl3): 5.81-5.71 (m, 2H), 5.05 (s, 2H), 
2.74-2.65 (m, 1H), 2.52-2.33 (m, 2H), 2.04 (s, 3H), 1.95 (s, 3H), 1.93-1.85 
(m, 1H). 13C-NMR (100MHz, CDCl3, ppm): 171.2, 150.0, 139.5, 124.9, 
115.6, 81.0, 30.7, 30.3, 21.5, 20.6. IR (film, cm-1): 2947, 2857, 1732, 1600, 
1454, 1372, 1238, 1165, 1100, 1027, 962, 888. HRMS (ESI, m/z): calcd for 
[M], C10H14O2: 166.0994; found: 166.0995. [α]D
20 = + 213.7 (c = 1.110 
g/100 ml, DCM). 
3-(Prop-1-en-2-yl)cyclopent-2-enol (rac-9) (racemization): To a 
solution of acetate 24 (251.4 mg, 1.512 mmol, 1.0 eq) and THF (8 mL) 
cooled to 0 °C was added water (8 mL) and Merck silica gel (0.04-0.063 
mm, 240-400 mesh) (256.5 mg). The resulting mixture was vigorously 
stirred for 36 hours at ambient temperature before solids were removed by 
filtration. The filtrate was treated with saturated aqueous NaHCO3 and 
extracted with dichloromethane (4x). The combined organic extracts were 
washed with brine, dried (Na2SO4) and concentrated in vacuo. Purification 
of the residue by chromatography (H/EE = 4/1) provided 178.1 mg of 
3-isopropenylcyclopent-2-enol (rac-9) with 95% yield. For analytical data, 
see above. [α]D
20 = 0.000 (c =1.05 g/100 ml, DCM). 
3-(Prop-1-en-2-yl)cyclopent-2-enol (rac-9) (one-pot reaction 
approach): 2-Bromopropene (3.1 mL, 34.85 mmol, 2.0 eq) was dissolved 
in anhydrous diethyl ether (35.0 mL) and cooled to -78 °C. After treatment 
with 1.9 M tert-BuLi (36.0 mL, 68.4 mmol, 3.9 eq) the resulting slightly 
turbid solution was stirred for 2 hours at the same temperature before it was 
warmed to ambient temperature. After 15 minutes the clear yellow solution 
was transferred via canula to a solution of cyclopent-2-enone (98%, 1.5 mL, 
17.55 mmol, 1.0 eq) and anhydrous diethyl ether (140 mL) precooled to -
78 °C. The resulting turbid mixture was stirred for 60 minutes. Then it was 
warmed to 0 °C and water (175 mL) was added. The biphasic solution was 
slowly treated with trifluoroacetic acid (3.4 mL, 44.13 mmol, 2.5 eq) and 
then vigorously stirred for another hour at the same temperature. The 
reaction was quenched with saturated aqueous NaHCO3 and DCM was 
added. The aqueous phase was extracted with DCM (3x) and the combined 
organic phases were washed with brine, dried with Na2SO4 and reduced in 
vacuo. Column chromatography (hexane/ethyl acetate 5/1 to 3/1) furnished 
1.57 g of racemic alcohol rac-9 as colorless oil with 72% yield. Analytical 
data is consistent with the reported data for compound 9 listed above. 
General procedure for the preparation of 2,4-dienols: A solution of 
cycloalkenone (1.0 eq) and anhydrous diethyl ether (0.1 M) was cooled to 
0 °C and treated with 1.0 M vinylmagnesium bromide (2.0 eq). After TLC 
indicated full conversion (usually 1 hour) water (0.1 M) and trifluoroacetic 
or acetic acid (2.5 eq) were added. The biphasic solution was vigorously 
stirred at 0 °C or ambient temperature until full conversion was observed by 
TLC. Then saturated aqueous NaHCO3 was added and the organic layer 
separated. The aqueous layer was extracted with dichloromethane (3x) and 
the combined organic extracts were washed with brine, dried (Na2SO4) and 
concentrated in vacuo. Purification of the residue by chromatography 
provided the corresponding 2,4-dienol. 
3-Vinylcyclopent-2-enol (27): According to the general procedure 
described above reaction of 2-cyclopentenone (98%, 50 µL, 0.5853 mmol, 
1.0 eq) with 1.0 M vinylmagnesium bromide (1.16 mL, 1.16 mmol, 2.0 eq) 
in anhydrous diethyl ether (5.9 mL) and subsequent treatment with water 
(5.9 mL) and trifluoroacetic acid (113 µL, 1.4668 mmol, 2.5 eq) for 1.0 
hours at 0 °C provided 50.6 mg of 3-vinylcyclopent-2-enol as slightly 
yellow oil with 78% yield (column chromatography H/EE = 5/1). 
(Attention: Dienol 27 should be stored below 0 °C.) 1H-NMR (400MHz, 
CDCl3): 6.58 (dd, J=17.5 Hz, 10.6 Hz, 1H), 5.79-5.75 (m, 1H), 5.27-5.15 
(m, 2H), 4.94-4.85 (bs, 1H), 2.70-2.57 (m, 1H), 2.42-2.30 (m, 2H), 1.83-
1.72 (m, 1H), 1.43 (d, J=5.6 Hz, 1H). 13C-NMR (100MHz, CDCl3, ppm): 
146.1, 133.3, 132.1, 117.0, 77.6, 33.7, 29.2. IR (film, cm-1): 3297, 2922, 
2853, 2359, 1591, 1455, 1416, 1319, 1275, 1264, 1158, 1042, 986, 968, 
905, 750. HRMS (EI, m/z): calcd for [M], C7H10O: 110.0732; found: 
110.0728. 
3-Vinylcyclohex-2-enol (29): According to the general procedure 
described above reaction of 2-cyclohexenone (95%, 20 µL, 0.1957 mmol, 
1.0 eq) with 1.0 M vinylmagnesium bromide (0.40 mL, 0.40 mmol, 2.0 eq) 
in anhydrous diethyl ether (2.0 mL) and subsequent treatment with water 
(2.0 mL) and trifluoroacetic acid (38 µL, 0.4932 mmol, 2.5 eq) for 1.5 
hours at 0 °C provided 19.2 mg of 3-vinylcyclohex-2-enol as colorless oil 
with 79% yield (column chromatography H/EE = 5/1). 1H-NMR (400MHz, 
CDCl3): 6.35 (dd, J=17.5 Hz, J=10.8 Hz, 1H), 5.80-5.74 (m, 1H), 5.21 (d, 
J=17.5 Hz, 1H), 5.05 (d, J=10.8 Hz, 1H), 4.35-4.26 (m, 1H), 2.24-2.04 (m, 
2H), 1.97-1.76 (m, 2H), 1.69-1.54 (m, 2H), 1.53-1.42 (bs, 1H). 13C-NMR 
(100MHz, CDCl3, ppm): 139.4, 138.9, 130.9, 113.1, 66.4, 32.3, 23.9, 19.0. 
IR (film, cm-1): 3389, 2934, 2869, 1714, 1666, 1453, 1427, 1258, 1189, 
1056, 995, 966, 912, 749. HRMS (EI, m/z): calcd for [M], C8H12O: 
124.0888; found: 124.0884. 
3-Vinylcyclohept-2-enol (31): According to the general procedure 
described above reaction of 2-cycloheptenone (50 µL, 0.4484 mmol, 1.0 
eq) with 1.0 M vinylmagnesium bromide (0.90 mL, 0.90 mmol, 2.0 eq) in 
anhydrous diethyl ether (4.5 mL) and subsequent treatment with water (4.5 
mL) and trifluoroacetic acid (87 µL, 1.1293 mmol, 2.5 eq) for 1.5 hours at 
ambient temperature provided 49.7 mg of 3-vinylcyclohept-2-enol as 
colorless oil with 80% yield (column chromatography H/EE = 5/1). 1H-
NMR (400MHz, CDCl3): 6.30 (dd, J=17.4 Hz, J=10.7 Hz, 1H), 5.81-5.75 
(m, 1H), 5.15 (d, J=5.15 Hz, 1H), 4.98 (dd, J=10.7 Hz, J=0.58 Hz, 1H), 
4.56-4.47 (m, 1H), 2.54-2.43 (m, 1H), 2.10-2.00 (m, 1H), 2.00-1.89 (m, 
1H), 1.89-1.79 (m, 1H), 1.77-1.59 (m, 4H), 1.32-1.22 (m, 1H). 13C-NMR 
(100MHz, CDCl3, ppm): 140.2, 140.0, 139.3, 111.3, 71.8, 36.6, 27.8, 26.5, 
25.7. IR (film, cm-1): 3343, 2928, 2853, 1605, 1450, 1351, 1276, 1028, 989, 
891, 839. HRMS (EI, m/z): calcd for [M], C9H14O: 138.1045; found: 
138.1047. 
1-Methyl-3-vinylcyclopent-2-enol (33): A solution of 3-
methylcyclopent-2-enone (97%, 60 µL, 0.5879 mmol, 1.0 eq) and 
anhydrous diethyl ether (6.0 mL) was cooled to 0 °C. 1.0 M 
vinylmagnesium bromide (1.10 mL, 1.10 mmol, 2.0 eq) was slowly added 
and the resulting solution was stirred for 60 minutes. Then the solution was 
warmed to 0 °C and water (6.0 mL) was added. The biphasic solution was 
slowly treated with acetic acid (85 µL, 1.4863 mmol, 2.5 eq) and then 
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vigorously stirred for 45 minutes at the same temperature. The reaction was 
quenched with saturated aqueous NaHCO3 and DCM was added. The 
aqueous phase was extracted with DCM (3x) and the combined organic 
phases were washed with brine, dried with Na2SO4 and reduced in vacuo to 
provide 72.3 mg of racemic alcohol 33 as slightly yellow oil with 99% 
yield. (Purification by column chromatography was not necessary). 
(Attention: Dienol 33 should be stored below 0 °C.) 1H-NMR (400MHz, 
CDCl3): 6.53 (dd, J=17.5 Hz, J=10.6 Hz, 1H), 5.67-5.64 (m, 1H), 5.21 (dd, 
J=17.5 Hz, J=0.9 Hz, 1H), 5.16 (dd, J=10.6 Hz, J=1.3 Hz, 1H), 2.66-2.57 
(m, 1H), 2.47-2.37 (m, 1H), 2.13-1.95 (m, 2H), 1.55-1.48 (bs, 1H), 1.40 (s, 
3H). 13C-NMR (100MHz, CDCl3, ppm): 143.8, 136.5, 133.4, 116.5, 83.3, 
40.0, 29.3, 27.6. IR (film, cm-1): 3354, 2967, 2928, 2855, 2346, 1600, 1452, 
1368, 1304, 1180, 1133, 1084, 889, 851. HRMS (EI, m/z): calcd for 
[M-CH3], C7H9O: 109.0653; found: 109.0651. 
2-Methyl-3-vinylcyclopent-2-enol (35): According to the general 
procedure described above reaction of 2-methyl-2-cyclopentenone (98%, 
50 µL, 0.5097 mmol, 1.0 eq) with 1.0 M vinylmagnesium bromide (1.02 
mL, 1.02 mmol, 2.0 eq) in anhydrous diethyl ether (5.0 mL) and subsequent 
treatment with water (5.0 mL) and trifluoroacetic acid (98 µL, 1.2721 mmol, 
2.5 eq) for 0.75 hours at 0 °C provided 49.8 mg of 2-methyl-3-vinyl-
cyclopent-2-enol as colorless oil with 79% yield (column chromatography 
H/EE = 5/1). (Attention: Dienol 35 should be stored below 0 °C.) 1H-NMR 
(400MHz, CDCl3): 6.65 (dd, J=17.2 Hz, J=10.8 Hz, 1H), 5.21-5.13 (m, 2H), 
4.71-4.60 (m, 1H), 2.65-2.53 (m, 1H), 2.38-2.26 (m, 2H), 1.83 (s, 3H), 
1.71-1.62 (m, 1H), 1.45 (d, J=4.7 Hz, 1H). 13C-NMR (100MHz, CDCl3, 
ppm): 138.9, 136.7, 131.3, 115.4, 81.6, 32.5, 29.4, 11.3. IR (film, cm-1): 
3345, 2960, 2936, 2912, 2854, 1443, 1421, 1276, 1261, 1198, 1049, 1005, 
986, 900, 750. HRMS (APCI, m/z): calcd for [M-H2O+H]
+, C8H11+: 
107.0855; found: 107.0850. 
3-Phenylcyclohex-2-enol (37): According to the general procedure 
described above reaction of 2-cyclohexenone (95%, 50 µL, 0.4892 mmol, 
1.0 eq) with 1.0 M phenylmagnesium bromide (0.98 mL, 0.98 mmol, 2.0 
eq) in anhydrous diethyl ether (4.9 mL) and subsequent treatment with 
water (4.9 mL) and trifluoroacetic acid (95 µL, 1.2331 mmol, 2.5 eq) for 48 
hours at ambient temperature provided 80.5 mg of 3-phenylcyclohex-2-enol 
as colorless oil with 94% yield (column chromatography H/EE = 3/1). 1H-
NMR (400MHz, CDCl3): 7.44-7.39 (m, 2H), 7.36-7.30 (m, 2 H), 7.29-7.23 
(m, 1H), 6.17-6.09 (m, 1H), 4.45-4.34 (bs, 1H), 2.53-2.43 (m, 1H), 2.43-
2.32 (m, 1H), 2.01-1.86 (m, 2H), 1.82-1.63 (m, 2H), 1.55 (d, J=5.2 Hz, 1H). 
13C-NMR (100MHz, CDCl3, ppm): 141.5, 140.4, 128.5, 127.6, 126.7, 125.5, 
66.5, 31.9, 27.7, 19.6. IR (film, cm-1): 3336, 2934, 2862, 2358, 1494, 1446, 
1344, 1276, 1053, 973, 907, 757, 695. HRMS (ESI, m/z): calcd for 
[M+Na]+, C12H14NaO+: 197.0937; found: 197.0938. 
3-(Prop-1-en-2-yl)cyclopent-2-enyl acrylate (38): A solution of 
racemic hydroxyl-diene 9 (25.0 mg, 0.2013 mmol, 1.0 eq) and pyridine 
(0.28 mL, 3.469 mmol, 15 eq) in anhydrous DCM (2.0 mL) was cooled to 
0 °C and treated with acryloyl chloride (0.19 ml, 2.339 mmol, 10 eq). After 
stirring for 2 hours saturated aqueous NaHCO3 was added, the resulting 
solution diluted with diethyl ether and the aqueous phase extracted with 
DCM (3x). The combined organic phases were dried with Na2SO4 and 
reduced in vacuo. Chromatography using Merck aluminium oxide 90 
(0.063-0.200 mm, 70-230 mesh) (hexane/ethyl acetate 30/1) afforded 
12.9 mg of ester 38 as clear and colorless oil with 32% yield. 1H-NMR 
(400MHz, CDCl3, ppm): 6.39 (dd, J=17.3 Hz, J=1.5 Hz, 1H), 6.11 (dd, 
J=17.3 Hz, J=10.4 Hz, 1H), 5.86-5.76 (m, 3H), 5.06 (s, 2H), 2.80-2.65 (m, 
1H), 2.53-2.36 (m, 2H), 1.99-1.90 (m, 4H). 13C-NMR (100MHz, CDCl3, 
ppm): 166.4, 150.1, 139.6, 130.5, 129.0, 124.8, 115.6, 81.2, 30.8, 30.3, 20.6. 
IR (film, cm-1): 2948, 1721, 1600, 1406, 1295, 1269, 1192, 1165, 1041, 
1024, 984, 965, 890, 811. HRMS (EI, m/z): calcd for [M], C11H14O2: 
178.0994; found: 178.0997. 
(2aR,7aS,7bR)- 5-Methyl- 3,4,6,7,7a,7b-hexahydro-2aH-indeno[ 1,7-
bc]furan-2-one (8a): Anhydrous MgBr2•Et2O (977 mg, 3.783 mmol, 2.0 
eq) was suspended in anhydrous dichloromethane (4.5 mL), treated with 
diisopropylethylamine (1.3 mL, 7.644 mmol, 4.0 eq) and stirred for 15 
minutes until the suspension turns magenta. Then compound 9 (234.8 mg, 
1.891 mmol, 1.0 eq) dissolved in dichloromethane (14.5 mL) was added 
slowly via canula. After stirring for 1 hour methyl acrylate (0.34 mL, 3.776 
mmol, 2.0 eq) was added dropwise. The resulting mixture was stirred for 6 
hours before it was quenched with saturated aqueous NH4Cl. For a better 
phase separation potassium sodium tartrate was added and the solution 
extracted with diethyl ether (2x) and dichloromethane (3x). The combined 
extracts were dried (Na2SO4) and concentrated in vacuo. Purification by 
chromatography (H/EE = 6/1) furnished 273.7 mg of compound 8a as white 
solid with 81% yield. 1H-NMR (400 MHz CDCl3, ppm): 4.84 (dt, J=5.5 Hz, 
J=1.0 Hz, 1H), 3.02 (ddd, J=6.5 Hz, J=6.0 Hz, J=3.2 Hz, 1H), 2.88-2.80 (m, 
1H), 2.63-2.51 (m, 1H), 2.32-2.18 (m, 1H), 2.15-1.87 (m, 6H), 1.65 (s, 3H); 
13C-NMR (100MHz, CDCl3, ppm): 178.7, 130.4, 129.3, 83.4, 43.8, 39.7, 
29.1, 27.5, 27.2, 20.2, 20.0; IR (film, cm-1): 2925, 1763, 1449, 1335, 1142, 
1020, 985, 932, 877; HRMS (EI, m/z): calcd for [M], C11H14O2: 
178.0994; found: 178.0997; [α]D
20 = -94.4 (c = 0.71 g/100mL, DCM). 
(1S,7R,7aR)-7-(hydroxymethyl)-4-methyl-2,3,5,6,7,7a-hexahydro-
1H-inden-1-ol (40): Racemic compound 8a (19.6 mg, 0.1100 mmol, 1.0 
eq) was dissolved in anhydrous diethyl ether (1.5 mL) and cooled to 0 °C 
before it was treated with LiAlH4 (95%, 0.3304 mmol, 3.0 eq) in three 
portions. The resulting mixture was warmed to room temperature and 
stirred for 4 hours. After recooling to 0 °C the mixture was diluted with 
diethyl ether (1.5 mL) and the reaction was quenched with the subsequent 
addition of water (24 μL), 10% aqueous NaOH (24 μL) and again water (72 
μL). Then the mixture was warmed to room temperature and vigorously 
stirred for 30 minutes. The clear colorless solution was removed and 
filtered over Celite, whereas the white residue was once again treated with 
diethyl ether (2 mL), water (56 μL) and 10% aqueous NaOH (14 μL). After 
stirring for another 30 minutes the white precipitate was removed by 
filtration and the combined organic filtrates were dried with Na2SO4 and 
concentrated in vacuo. Purification by chromatography (hexane/ethyl 
acetate 1/1) provided 18.0 mg of racemic diol 40 as clear, colorless oil with 
90% yield. 1H-NMR (400MHz, CDCl3, ppm): 4.38 (t, J=3.6 Hz, 1H), 3.78 
(t, J=10.2 Hz, 1H), 3.54 (dd, J=10.8 Hz, J=2.3 Hz, 1H), 3.48-3.01 (bs, 2H), 
2.47 (m, 2H), 2.29 (m, 2H), 1.84 (m, 2H), 1.81-1.63 (m, 4H), 1.61 (s, 3H). 
13C-NMR (100MHz, CDCl3, ppm): 132.0, 124.8, 74.5, 63.5, 49.7, 37.5, 
33.4, 28.4, 27.9, 26.0, 19.4. IR (film, cm-1): 3234, 2925, 2333, 2158, 1439, 
1164, 1110, 1056, 1012, 959, 786. HRMS (EI, m/z): calcd for [M], 
C11H18O2: 182.1307; found: 182.1304. 
(1S,3aR,4R,7R,7aS)-7-(hydroxymethyl)-4-methyloctahydro-1H-
inden-1-ol (41): A solution of racemic diol 40 (18.0 mg, 0.0988 mmol, 1.0 
eq) and freshly distilled and degassed DCM (4 ml) was cooled to 0 °C. The 
flask was flushed with hydrogen over a period of 2 minutes before 
hydrogen was bubbled through the solution itself for one additional minute. 
After adding Crabtree’s catalyst (5.2 mg, 0.00646 mmol, 0.065 eq) the flask 
was once again flashed with hydrogen for 3 minutes before hydrogen was 
bubbled through the solution for 2 minutes until it became colorless. The 
ice bath was removed and the mixture stirred for 24 hours. Argon was 
bubbled through the reaction mixture and the solvent was evaporated. 
Chromatography (hexane/ethyl acetate 3/2) of the residue affords 16.5 mg 
of racemic compound 41 as white solid with 91% yield. 1H-NMR (400MHz, 
CDCl3, ppm): 4.26 (s, 1H), 4.07 (t, J=10.7 Hz, 1H), 3.77-3.49 (bs, 2H), 3.46 
(d, J=11.0 Hz, 1H), 2.33 (m, 1H), 2.15 (m, 2H), 1.88-1.52 (m, 5H), 1.49-
1.29 (m, 4H), 0.87 (d, J=7.1 Hz, 3H). 13C-NMR (100MHz, CDCl3, ppm): 
74.8, 63.3, 45.4, 39.7, 36.4, 33.6, 30.0, 29.5, 25.9, 23.6, 12.0. IR (film, cm-
1): 3190, 2957, 2926, 2903,2882, 2861, 1460, 1439, 1371, 1340, 1276, 1049, 
1009, 949, 764, 750. HRMS (EI, m/z): calcd for [M-H2O], C11H18O: 
166.1358; found: 166.1357. 
(3aS,4R,7R,7aR)- 7-methyl- 3-oxooctahydro- 1H-indene- 4-
carbaldehyde (42): Racemic diol 41 (16.5 mg, 0.0895 mmol, 1.0 eq) was 
dissolved in anhydrous DMSO (1.8 mL) and treated with a solution of IBX 
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(102.0 mg, 0.3643 mmol, 4.0 eq) in anhydrous DMSO (1.2 mL). After 
stirring for 5 hours water was added and the white precipitate removed by 
filtration. The precipitate was washed with DMSO/water 1/2 and 
pentane/diethyl ether 1/1. The filtrate was extracted with DCM (4x), the 
combined organic phases were dried (Na2SO4) and concentrated in vacuo. 
Purification by chromatography (hexane/ethyl acetate 5/1) provided 
12.8 mg of racemic compound 42 as clear colorless oil with 80% yield 
(Attention: Compound 42 tends to epimerize and should be stored below 
0 °C.). 1H-NMR (400MHz, CDCl3, ppm): 9.57 (s, 1H), 3.10 (m, 1H), 2.57-
2.03 (m, 5H), 2.01-1.85 (m, 2H), 1.72 (m, 1H), 1.62-1.48 (m, 2H), 1.39 (m, 
1H), 0.92 (d, J=7.0 Hz, 3H). 13C-NMR (100MHz, CDCl3, ppm): 217.2, 
201.9, 47.4, 47.3, 41.5, 37.9, 29.95, 29.85, 24.8, 19.6, 11.1. IR (film, cm-1): 
2934, 2877, 1738, 1458, 1389, 1306, 1262, 1161, 1142, 1082, 959, 878, 
750. HRMS (EI, m/z): calcd for [M-C2H4]
+, C9H12O2+: 152.0832; found: 
152.0835. 
(E)-Ethyl-2-methyl-3-((3aR,4S,7R,7aR)-7-methyl-3-oxooctahydro-
1H-inden-4-yl)-acrylate (6b): A solution of racemic diketo compound 42 
(12.8 mg, 0.0710 mmol, 1.0 eq) and anhydrous DCM (1.0 mL) was treated 
with (1-ethoxycarbonylethyliden)-triphenylphosphorane (94%, 54.6 mg, 
0.1416 mmol, 2.0 eq) and refluxed for 24 hours. Then silica gel was added 
and the solvent evaporated. Purification of the residue by chromatography 
(hexane/ethyl acetate 7/1) furnished 12.2 mg of compound 6b as white 
solid with 65% yield and 2.7 mg of slightly impure compound 6a with 14% 
yield. Analytical data for 6b: 1H-NMR (400MHz, CDCl3, ppm): 6.58 (dd, 
J=9.7 Hz, J=1.4 Hz, 1H), 4.18 (dq, J=7.1 Hz, J=4.2 Hz, 2H), 2.46-2.24 (m, 
3H), 2.15 (m, 1H), 2.03 (m, 1H), 1.96-1.77 (m, 3H), 1.73 (d, J=1.4 Hz, 3H), 
1.70-1.57 (m, 2H), 1.33-1.22 (m, 5H), 0.98 (d, J=6.9 Hz, 3H). 13C-NMR 
(100MHz, CDCl3, ppm): 218.1, 168.1, 143.6, 128.2, 60.7, 54.0, 41.8, 36.7, 
33.5, 31.1, 31.0, 28.3, 19.7, 19.2, 14.4, 12.9. IR (film, cm-1): 2954, 2926, 
2871, 1741, 1705, 1650, 1458, 1368, 1274, 1232, 1204, 1160, 1106, 1071, 
748. HRMS (EI, m/z): calcd for [M], C16H24O3: 264.1725; found: 
264.1723. 
(E)-3-((3S,3aR,4S)-3-Hydroxy-7-methyl-2,3,3a,4,5,6-hexahydro-1H-
inden-4-yl)-2-methyl-acrylic acid ethyl ester (7): A solution of compound 
8a (183.5 mg, 1.030 mmol, 1.0 eq) in DCM (10 mL) was cooled to -78 °C 
and 1.0 M diisobutylaluminium hydride (1.5 mL, 1.5 mmol, 1.5 eq) was 
added dropwise. After stirring the mixture for 2¼ hours the reaction was 
quenched by the addition of ethyl acetate (1 mL) and stirred for another 15 
minutes. Saturated aqueous potassium sodium tartrate was added and the 
mixture warmed to room temperature. The aqueous layer was separated and 
extracted with DCM (5x). The combined organic phases were dried 
(Na2SO4) and concentrated in vacuo. Filtration through a short pad of silica 
gel afforded a crude mixture of the two isomers of lactol 44 as clear slightly 
yellow oil. Lactol 44 was dissolved in benzene (10 mL), (1-
ethoxycarbonylethyliden)-triphenylphosphorane (94%, 794.2 mg, 2.060 
mmol, 2.0 eq) was added and heated under reflux for 24 hours. Saturated 
aqueous NH4Cl was added and the solution extracted with DCM (4x). The 
combined extracts were dried (Na2SO4) and concentrated in vacuo. 
Purification by chromatography (hexane/ethyl acetate 10/1 to 5/1) furnished 
226.9 mg of compound 7 as clear colorless oil with 83% yield. 1H-NMR 
(400 MHz CDCl3, ppm): 7.06 (dd, J=10.5 Hz, J=1.4 Hz, 1H), 4.29 (dd, 
J=6.0 Hz, J=3.4 Hz, 1H), 4.24-4.11 (m, 2H), 3.12 (ddd, J=10.2 Hz, J=8.8 
Hz, J=5.0 Hz, 1H), 2.58-2.22 (m, 3H), 2.09-1.59 (m, 12H), 1.31 (d, J=3.4 
Hz, 1H), 1.27 (t, J=7.1 Hz, 3H); 13C-NMR (100MHz, CDCl3, ppm): 168.2, 
143.5, 132.0, 127.6, 125.5, 75.3, 60.7, 50.2, 34.0, 33.1 29.3, 27.7, 26.0, 
19.5, 14.4, 12.7; IR (film, cm-1): 3480, 2926, 1704, 1645, 1447, 1367, 1246, 
1110, 1033, 753; HRMS (ESI, m/z): calcd for [M-H2O], C16H22O2: 
246.1620; found: 246.1614; [α]D
20 = -5.4 (c = 0.895 g/100mL, DCM). 
(E)-3-((3S,3aS,4S,7R,7aR)-3-Hydroxy-7-methyl-octahydro-inden-4-
yl)-2-methyl-acrylic acid ethyl ester (45): A solution of compound 7 
(223.8 mg, 0.8466 mmol, 1.0 eq) and freshly distilled and degassed DCM 
(34 mL) was cooled to 0 °C. The flask was flushed with hydrogen over a 
period of 2 minutes before hydrogen was bubbled through the solution itself 
for one additional minute. After adding Crabtree’s catalyst (68.0 mg, 
0.0845 mmol, 0.1 eq) the flask was once again flashed with hydrogen for 3 
minutes before hydrogen was bubbled through the solution for 2 minutes 
until it became colorless. The ice bath was removed and the mixture stirred 
for 2¼ hours. Argon was bubbled through the reaction mixture and the 
solvent was evaporated. Chromatography (hexane/ethyl acetate 7/1 to 3/1) 
of the residue furnished 162.7 mg of compound 45 as white solid with 72% 
yield. 1H-NMR (400 MHz CDCl3, ppm): 7.38 (dd, J=10.7 Hz, J=1.4 Hz, 
1H), 4.26-4.12 (m, 3H), 3.13-3.04 (m, 1H), 2.45-2.34 (m, 1H), 2.26-2.16 
(m, 1H), 1.94-1.46 (m, 9H), 1.41-1.24 (m, 7H), 0.90 (d, J=7.2 Hz, 3H); 13C-
NMR (100MHz, CDCl3, ppm): 168.2, 144.0, 127.0, 75.5, 60.7, 46.7, 37.2, 
35.3, 33.2, 29.8, 28.7, 27.0, 24.8, 14.5, 12.6, 12.1; IR (film, cm-1): 3483, 
2926, 1701, 1636, 1459, 1367, 1247, 1171, 1106, 1042, 750; HRMS (ESI, 
m/z): calcd for [M], C16H26O3: 266.1882; found: 266.1890; 
[α]D
20 = -118.7 (c = 0.715 g/100mL, DCM). 
(E)-2-Methyl-3-((3aS,4S,7R,7aR)-7-methyl-3-oxo-octahydro-inden-4-
yl)-acrylic acid ethyl ester (6a): Compound 45 (157.9 mg, 0.5928 mmol, 
1.0 eq) was dissolved in anhydrous DMSO (2.4 mL) and treated with a 
solution of IBX (335.6 mg, 1.199 mmol, 2.0 eq) in anhydrous DMSO (4.8 
mL). After stirring for 2½ hours water was added and the white precipitate 
removed by filtration. The precipitate was washed with DMSO/water 1/2 
and a small amount of ethyl acetate. The filtrate was extracted with DCM 
(4x), the combined organic phases were dried (Na2SO4) and concentrated in 
vacuo. Purification by chromatography (hexane/ethyl acetate 7/1) provided 
146.5 mg of compound of 6a as clear pale yellow oil with 93% yield. 1H-
NMR (400 MHz CDCl3, ppm): 6.83 (ddd, J=10.2Hz, J=2.8Hz, J=1.4Hz, 
1H), 4.16 (dq, J=7.1Hz, J=1.4Hz, 2H), 3.24-3.16 (m, 1H), 2.32-2.21 (m, 
3H), 2.14-1.86 (m, 6H), 1.79-1.68 (m, 2H), 1.63-1.39 (m, 3H), 1.27 (t, 
J=7.1Hz, 3H), 0.97 (d, J=6.9Hz, 3H); 13C-NMR (100MHz, CDCl3, ppm): 
217.4, 168.4, 139.9, 129.5, 60.6, 51.4, 40.1, 37.8, 32.6, 30.4, 28.4, 25.6, 
24.5, 14.4, 13.0, 11.6; IR (film, cm-1): 2925, 2855, 1743, 1713, 1465, 1366, 
1312, 1246, 1210, 1157, 1111, 1043, 752; HRMS (ESI, m/z): calcd for [M], 
C16H24O3: 264.1725; found: 264.1727; [α]D
20 = -160.9 (c = 0.86 g/100mL, 
DCM). 
Valerenic ethyl ester (46): A solution of compound 6a (16.1 mg, 0.0609 
mmol, 1.0 eq) and anhydrous DCM (2.4 mL) was cooled to 0 °C and 
treated with freshly distilled triflic anhydride (101 μL, 171.7 mg, 0.609 
mmol, 10.0 eq) and pyridine (49 μL, 48.1 mg, 0.608 mmol, 10 eq) under 
vigorous stirring. The ice bath was removed after 15 minutes and the 
mixture stirred for 24 hours. The reaction mixture was cooled to 0 °C and 
washed consecutively with saturated aqueous CuSO4 and saturated aqueous 
NaHCO3. Both aqueous layers were extracted with DCM (1x). The 
combined organic phases were washed with brine, dried (Na2SO4) and 
concentrated in vacuo. Filtration through a short pad of silica gel afforded a 
crude mixture of the two isomers as clear colorless oil. The mixture of 
isomers was dissolved in THF (1.2 mL) and cooled to 0 °C before 
tetrakis(triphenylphosphine)palladium (6.9 mg, 0.00597 mmol, 0.1 eq) was 
added. After stirring for 15 minutes the resulting brown solution was 
treated with 1.0 M dimethylzinc (0.24 mL, 0.24 mmol, 4.0 eq). The mixture 
was allowed to warm to room temperature after another 15 minutes and was 
stirred for 15½ hours. After cooling to 0 °C water and saturated aqueous 
NH4Cl were added and the solution was extracted with ether (3x). The 
combined extracts were washed with brine, dried (Na2SO4) and 
concentrated in vacuo. Purification by chromatography (hexane/ethyl 
acetate 50/1) with silica gel treated with 10% AgNO3 furnished 12.4 mg of 
compound 46 as clear colorless oil with 78%. 1H-NMR (600 MHz CDCl3, 
ppm): 7.01 (ddd, J=9.8 Hz, J=2.8 Hz, J=1.3 Hz, 1H), 4.18 (dq, J=7.1 Hz, 
J=1.1 Hz, 2H), 3.53 (dd, J=9.6 Hz, J=5.2 Hz, 1H), 2.96 (ddd, J=9.0 Hz, 
J=4.4 Hz, J=2.3 Hz, 1H), 2.19 (t, J=7.6 Hz, 2H), 2.02-1.96 (m, 1H), 1.90-
1.71 (m, 6H), 1.63 (td, J=2.1 Hz, J=1.1 Hz, 3H), 1.57-1.51 (m, 1H), 1.45-
1.36 (m, 2H), 1.29 (t, J=7.1 Hz, 3H), 0.78 (d, J=7.0 Hz, 3H); 13C-NMR 
(150 MHz, CDCl3, ppm): 168.8, 143.4, 133.6, 131.0, 126.1, 60.6, 47.5, 37.6, 
34.5, 33.2, 28.9, 25.6, 24.7, 14.5, 13.7, 12.5, 12.2; IR (film, cm-1): 2926, 
1712, 1645, 1455, 1379, 1238, 1131, 1104, 1061, 753; HRMS (ESI, m/z): 
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calcd for [M], C17H26O2: 262.1933; found: 262.1935; [α]D
20 = -106.1 (c = 
0.70 g/100mL, DCM). 
Valerenic acid (1): A solution of valerenic ethyl ester 46 (12.4 mg, 
0.0473 mmol, 1.0 eq), methanol (0.5 mL) and THF (0.5 mL) was treated 
with 1.0 molar aqueous LiOH (0.36 mL, 0.36 mmol, 7.5 eq). After stirring 
24 hours the resulting mixture was cooled to 0 °C, acidified with 10% citric 
acid and extracted with ethyl acetate (4x). The combined organic phases 
were washed with a small amount of brine, dried (Na2SO4) and 
concentrated in vacuo. Purification by chromatography (hexane/ethyl 
acetate 5/1 to pure ethyl acetate) afforded 11.0 mg of valerenic acid with 
99% yield. 1H-NMR (600 MHz CDCl3, ppm): 7.15 (ddd, J=10.0 Hz, J=2.7 
Hz, J=1.3 Hz, 1H), 3.54 (dd, J=9.7 Hz, J=5.0 Hz, 1H), 2.95 (ddd, J=8.3 Hz, 
J=4.0 Hz, J=1.9 Hz, 1H), 2.20 (t, J=7.6 Hz, 2H), 1.99 (dt, J=7.2 Hz, J=3.7 
Hz, 1H), 1.93-1.71 (m, 6H), 1.63 (td, J=2.0 Hz, J=1.0 Hz, 3H), 1.59-1.51 
(m, 1H), 1.48-1.36 (m, 2H), 0.78 (d, J=7.0 Hz, 3H); 13C-NMR (150 MHz, 
CDCl3, ppm): 173.0, 146.3, 133.3, 131.4, 125.2, 47.6, 37.6, 34.7, 33.2, 28.9, 
25.5, 24.7, 13.6, 12.2, 12.2; IR (film, cm-1): 2931, 1683, 1652, 1558, 1423, 
1299, 1256, 904, 671, 575; HRMS (ESI, m/z): calcd for [M], C15H22O2: 
234.1620; found: 234.1623; [α]D
20 = -159.9 (c = 0.76 g/100mL, DCM), 
authentic sample: [α]D
20 = -161.2 (c = 0.85 g/100mL, DCM); m.p.: 139-
141 °C, authentic sample: m.p.: 140-142 °C. 
Valerenic amide (47): Valerenic acid (104.3 mg, 0.4451 mmol, 1.0 eq) 
was dissolved in anhydrous dichloromethane (4.4 mL) cooled to 0°C and 
1-Chloro-N,N,2-trimethylpropenylamine (0.21 mL, 212,1 mg, 1.587 mmol, 
3.5 eq) was added dropwise. After 5 minutes the ice bath was removed and 
the reaction mixture stirred for 4 hours at room temperature before recooled 
to 0°C. 0.5M Ammonia in 1,4-dioxane (5.8 mL, 2.900 mmol, 6.5 eq) was 
rapidly added, the ice bath removed and the resulting mixture stirred over 
night. Diethyl ether was added and the white precipitate removed by 
filtration. The filtrate was concentrated in vacuo and chromatography 
(hexane/EtOAc 2/1 to 1/2) of the residue provided 99.8 mg of valerenic 
amide as white solid with 96% yield. 1H-NMR (400MHz, CDCl3, ppm): 
6.67 (dq, J=9.3Hz, J=0.8Hz, 1H), 5.58 (s, 2H), 3.50 (dd, J=9.4Hz, J=4.7Hz, 
1H), 2.93 (m, 1H), 2.19 (t, J=7.5Hz, 2H), 1.98 (m, 1H), 1.90 (d, J=3.3 Hz, 
3H), 1.78 (m, 3H), 1.63 (m, 3H), 1.55 (m, 1H), 1.40 (m, 2H), 0.77 (d, 
J=7.0Hz, 3H). 13C-NMR (100MHz, CDCl3, ppm): 171.8, 139.1, 133.7, 
130.9, 128.3, 47.6, 37.6, 34.3, 33.2, 28.9, 25.7, 24.7, 13.6, 12.9, 12.2. IR 
(film, cm-1): 3179, 3028, 2923, 2885, 2853, 1733, 1654, 1652, 1636, 1505, 
1458, 1418, 1378. HRMS (ESI, m/z): calcd for [M], C15H21N: 215.1674; 
found: 215.1661. [α]D
20 = -119.2 (c = 0.775 g/100mL, DCM) 
Valerenic N-methylamide (48): Using the same procedure as for the 
preparation of Valerenic amide Valerenic acid (49.7 mg, 0.2121 mmol, 1.0 
eq) was treated with 1-Chloro-N,N,2-trimethylpropenylamine (98 μL, 99.0 
mg, 0.7408 mmol, 3.5 eq) and methylamine (41% aqueous solution, 0.18 
mL, 2.131 mmol, 10.0 eq) to afford 49.9 mg of valerenic N-methylamide as 
white solid with 95% yield. 1H-NMR (400MHz, CDCl3, ppm): 6.54 (dq, 
J=9.5Hz, J=1.3Hz, 1H), 5.71 (s, 1H), 3.48 (dd, J=9.2Hz, J=4.7Hz, 1H), 2.93 
(m, 1H), 2.86 (d, J=4.9Hz, 3H), 2.19 (t, J=7.3Hz, 2H), 1.97 (m, 1H), 1.89 (d, 
J=1.4 Hz, 3H), 1.78 (m, 3H), 1.62 (m, 3H), 1.55 (m, 1H), 1.39 (m, 2H), 
0.77 (d, J=7.0Hz, 3H). 13C-NMR (100MHz, CDCl3, ppm): 170.7, 137.0, 
134.0, 130.7, 129.5, 47.6, 37.6, 34.1, 33.3, 28.9, 26.7, 25.8, 24.7, 13.6, 12.9, 
12.2. IR (film, cm-1): 3326, 2925, 1655, 1616, 1539, 1456, 1379, 1311, 670, 
667, 409. HRMS (ESI, m/z): calcd for [M], C16H25NO: 247.1936; found: 
247.1932. [α]D
20 = -129.3 (c = 0.825 g/100mL, DCM) 
Valerenic N-ethylamide (49): Using the same procedure as for the 
preparation of Valerenic amide Valerenic acid (20.9 mg, 0.0892 mmol, 1.0 
eq) was treated with 1-Chloro-N,N,2-trimethylpropenylamine (35 μL, 35.4 
mg, 0.2646 mmol, 3.0 eq) and 2.0M ethylamine in THF (0.45 mL, 0.9000 
mmol, 10.0 eq) to afford 21.9 mg of valerenic N-ethylamide as slightly 
yellow solid with 94% yield. 1H-NMR (400MHz, CDCl3, ppm): 6.55 (dq, 
J=9.5Hz, J=1.3Hz, 1H), 5.66 (s, 1H), 3.49 (dd, J=9.3Hz, J=4.9Hz, 1H), 3.34 
(dq, J=7.2Hz, J=5.6Hz, 2H), 2.95 (m, 1H), 2.19 (t, J=7.5Hz, 2H), 1.98 (m, 
1H), 1.89 (d, J=1.4 Hz, 3H), 1.78 (m, 3H), 1.62 (m, 3H), 1.54 (m, 1H), 1.40 
(m, 2H), 1.17 (t, J=7.3Hz, 3H), 0.78 (d, J=7.0Hz, 3H). 13C-NMR (100MHz, 
CDCl3, ppm): 169.9, 136.9, 134.0, 130.6, 129.6, 47.6, 37.6, 34.8, 34.1, 33.3, 
28.9, 25.8, 24.7, 15.1, 13.6, 12.9, 12.2. IR (film, cm-1): 3308, 2925, 2884, 
2855, 1653, 1639, 1616, 1533, 1456, 1379, 1309. HRMS (ESI, m/z): calcd 
for [M]+, C17H28NO+: 262.2165; found: 262.2161. [α]D
20 = -118.7 (c = 
1.58 g/100mL, DCM). 
Valerenic N,N-diethylamide (50): Using the same procedure as for the 
preparation of Valerenic amide Valerenic acid (30.2 mg, 0.1289 mmol, 1.0 
eq) was treated with 1-Chloro-N,N,2-trimethylpropenylamine (51 μL, 51.5 
mg, 0.3855 mmol, 3.0 eq) and diethylamine (135 μL, 95.9 mg, 1.311 mmol, 
10.0 eq) to afford 35.2 mg of Valerenic N,N-diethylamide as slightly 
yellow oil with 94% yield. 1H-NMR (400MHz, CDCl3, ppm): 5.75 (dq, 
J=7.6Hz, J=0.5Hz, 1H), 3.46 (dd, J=8.5Hz, J=3.9Hz, 1H), 3.34 (m, 4H), 
2.85 (m, 1H), 2.17 (t, J=7.4Hz, 2H), 1.96 (m, 1H), 1.87 (d, J=1.5 Hz, 3H), 
1.77 (m, 3H), 1.63 (m, 3H), 1.52 (m, 1H), 1.41 (m, 2H), 1.13 (t, J=7.1Hz, 
6H), 0.77 (d, J=7.0Hz, 3H). 13C-NMR (100MHz, CDCl3, ppm): 173.8, 
134.3, 131.0, 130.3, 130.1, 47.7, 37.6, 33.5, 33.3, 29.0, 25.8, 24.8, 14.6, 
13.6, 12.2. IR (film, cm-1): 2926, 2866, 2855, 1628, 1458, 1396, 1380, 1333, 
1291, 1221, 1097. HRMS (ESI, m/z): calcd for [M]+, C19H32NO+: 
290,2478; found: 290,2488. [α]D
20 = -109.8 (c = 1.63 g/100mL, DCM). 
Valerenic piperidine amide (51): A solution of Valerenic acid (43.5 mg, 
0.1856 mmol, 1.0 eq) and anhydrous dichloromethane (1.8 mL) was cooled 
to 0°C and 1-Chloro-N,N,2-trimethylpropenylamine (86 μL, 86.9 mg, 
0.6500 mmol, 3.5 eq) was added dropwise. After 5 minutes the ice bath was 
removed and the reaction mixture stirred for 4 hours at room temperature. 
Then the solvent and volatile byproducts were removed in vacuo (3 Torr for 
1 hour) and the crude acid chloride was redissolved in dichloromethane (1.8 
mL). After cooling to 0°C piperidine (74 μL, 63.6 mg, 0.7474 mmol, 4.0 
eq) was added at once, the ice bath removed and the resulting mixture 
stirred for 1 hour. Diethyl ether was added and the white precipitate 
removed by filtration. The filtrate was concentrated in vacuo and 
chromatography (hexane/EtOAc 5/1 to 2/1) of the residue provided 50.7 mg 
of Valerenic piperidine amide as slightly yellow oil with 91% yield. 1H-
NMR (400MHz, CDCl3, ppm): 5.78 (dq, J=9.1Hz, J=1.5Hz, 1H), 3.45 (m, 
5H), 2.84 (m, 1H), 2.18 (t, J=4.9Hz, 2H), 1.96 (m, 1H), 1.85 (d, J=1.5 Hz, 
3H), 1.77 (m, 3H), 1.63 (m, 5H), 1.54 (m, 5H), 1.40 (m, 2H), 0.77 (d, 
J=7.0Hz, 3H). 13C-NMR (100MHz, CDCl3, ppm): 172.8, 134.3, 131.9, 
130.0, 129.8, 47.7, 37.6, 33.5, 33.4, 29.0, 25.9, 24.9, 24.8, 14.5, 13.6, 12.2. 
IR (film, cm-1): 2925, 2854, 1629, 1443, 1379, 1256, 425, 423, 420, 412. 
HRMS (ESI, m/z): calcd for [M], C20H31NO: 301.2406; found: 301.2398. 
[α]D
20 = -90.0 (c = 0.35 g/100mL, DCM). 
Valerenic morpholine amide (52): Using the same procedure as for the 
preparation of Valerenic amide Valerenic acid (43.4 mg, 0.1852 mmol, 1.0 
eq) was treated with 1-Chloro-N,N,2-trimethylpropenylamine (74 μL, 74.7 
mg, 0.5593 mmol, 3.0 eq) and morpholine (160 μL, 160.0 mg, 1.837 mmol, 
10.0 eq) to afford 50.4 mg of Valerenic morpholine amide as colorless oil 
with 90% yield. 1H-NMR (400MHz, CDCl3, ppm): 5.82 (dq, J=9.1Hz, 
J=1.5Hz, 1H), 3.66 (t, J=4.5Hz, 4H), 3.56 (m, 4H), 3.47 (dd, J=9.0Hz, 
J=2.8Hz, 1H), 2.82 (m, 1H), 2.18 (t, J=7.4Hz, 2H), 1.97 (m, 1H), 1.87 (d, 
J=1.5 Hz, 3H), 1.78 (m, 3H), 1.64 (m, 3H), 1.55 (m, 1H), 1.41 (m, 2H), 
0.77 (d, J=7.0Hz, 3H). 13C-NMR (100MHz, CDCl3, ppm): 172.9, 134.0, 
133.6, 130.4, 128.9, 67.1, 47.8, 37.6, 33.6, 33.4, 29.0, 25.9, 24.8, 14.5, 13.6, 
12.2. IR (film, cm-1): 2923, 1654, 1652, 1628, 1420, 1393, 1379, 1245, 
1116, 1028, 842. HRMS (ESI, m/z): calcd for [M], C19H29NO2: 
303.2198; found: 303.2194. [α]D
20 = -110.5 (c = 0.8 g/100mL, DCM). 
Supporting Information (see footnote on the first page of this article): 
Copies of the 1H NMR and 13NMR spectra of all compounds. 
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2.7 Derivatization of Valerenic Acid 
2.7.1 Introduction 
 
As potent modulator of the GABAA receptor subtype (see also chapter 2.3.2) valerenic acid has also 
attracted the interest of several pharmacological research groups.1,2,3 In cooperation with the 
department of pharmacology and toxicology of the University of Vienna several derivatives of 
valerenic acid were tested.6 
 
Immediately after completion of the synthesis of valerenic acid, several simple substrates based on 
derivatization of the carboxyl group were synthesized (see Table 1). 
 
Table 1: Preparation of simple derivatives from valerenic acid. 
 
RH yield [%] substance 
NH3 96 87 
NH2Me 95 88 
NH2Et 94 89 
NH2iPr 
a 78 90 
NH2nBu 
a 70 91 
NHMe2 
a 85 92 
NHEt2 94 93 
piperidine 91 94 
morpholine 90 95 
H2N-NH2 87 96 
EtOH 91 97 
a
 Key: Synthesized by T. Schwarz according to the procedure 
devised during this PhD thesis. 
 
Interestingly, activation of the carboxylic acid with chloroformate or other coupling reagents failed or 
gave only moderate yields, so Ghosez’ reagent (86) was used instead.25 After preparation of valerenic 
acid chloride under mild conditions, various nucleophiles were added. Fortunately, in most cases 
38 
 
isolation of the acid chloride was not necessary, but the in situ formed intermediate was simply 
treated with an excess of the corresponding nucleophile to deliver the desired derivatives in 
excellent yield. 
 
A summary and detailed discussion about the results of in vitro and in vivo SAR studies can be found 
in the following publication. 
 
2.7.2 Valerenic Acid Derivatives as Novel Subunit-Selective GABAA Receptor Ligands 
 
Khom, S.; Strommer B.; Ramharter J.; Schwarz T.; Schwarzer C.; Erker T.; Ecker G. F.; Mulzer, J.; 
Hering S. British J. Pharm. 2010, 161, 65 
 
Comment of the author: Please note, that both in vitro and in vivo tests were carried out by Sophia 
Khom and Barbara Strommer, who are also the principle authors of this manuscript, under the 
supervision of Prof. Steffen Hering in the Department of Pharmacology and Toxicology, University of 
Vienna. 
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BACKGROUND AND PURPOSE
Subunit-specific modulators of g-aminobutyric acid (GABA) type A (GABAA) receptors can help to assess the physiological
function of receptors with different subunit composition and also provide the basis for the development of new drugs.
Valerenic acid (VA) was recently identified as a b2/3 subunit-specific modulator of GABAA receptors with anxiolytic potential.
The aim of the present study was to generate VA derivatives as novel GABAA receptor modulators and to gain insight into the
structure–activity relation of this molecule.
EXPERIMENTAL APPROACH
The carboxyl group of VA was substituted by an uncharged amide or amides with different chain length. Modulation of
GABAA receptors composed of different subunit compositions by the VA derivatives was studied in Xenopus oocytes by means
of the two-microelectrode voltage-clamp technique. Half-maximal stimulation of GABA-induced chloride currents (IGABA)
through GABAA receptors (EC50) and efficacies (maximal stimulation of IGABA) were estimated. Anxiolytic activity of the VA
derivatives was studied in mice, applying the elevated plus maze test.
KEY RESULTS
Valerenic acid amide (VA-A) displayed the highest efficacy (more than twofold greater IGABA enhancement than VA) and
highest potency (EC50 = 13.7  2.3 mM) on a1b3 receptors. Higher efficacy and potency of VA-A were also observed on a1b2g2s
and a3b3g2s receptors. Anxiolytic effects were most pronounced for VA-A.
CONCLUSIONS AND IMPLICATIONS
Valerenic acid derivatives with higher efficacy and affinity can be generated. Greater in vitro action of the amide derivative
correlated with a more pronounced anxiolytic effect in vivo. The data give further confidence in targeting b3 subunit
containing GABAA receptors for development of anxiolytics.
Abbreviations
IGABA, GABA-induced chloride currents; VA, valerenic acid; VA-A, valerenic acid amide; VA-BA, valerenic acid butylamide;
VA-DEA, valerenic acid diethylamide; VA-DMA, valerenic acid dimethylamide; VA-EA, valerenic acid ethylamide; VA-EE,
valerenic acid ethyl ester; VA-IPA, valerenic acid isopropylamide; VA-MA, valerenic acid methylamide; VA-MO, valerenic
acid morpholine amide; VA-PIP, valerenic acid piperidine amide
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DOI:10.1111/j.1476-5381.2010.00865.x
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Introduction
g-Aminobutyric acid (GABA) mediates fast synaptic,
inhibitory neurotransmission in the mammalian
brain acting on GABA type A (GABAA) receptors.
GABAA receptors represent ligand gated chloride
channels, assembled from different subunits
forming a pentameric structure. Nineteen subunits
of mammalian GABAA receptors have been cloned:
a1–6, b1–3, g1–3, d, e, p, r1–3 and q (Barnard et al., 1998;
Simon et al., 2004; Olsen and Sieghart, 2008; recep-
tor nomenclature follows Alexander et al., 2009).
The distribution of these subunits in the brain is
highly distinct, suggesting differential functional
roles for different GABAA receptors. The subunit
composition determines the GABA sensitivity and
the pharmacological properties of the GABAA recep-
tor (Sieghart, 1995; D’Hulst et al., 2009; Olsen and
Sieghart, 2009).
g-Aminobutyric acid type A receptors play a
major role in controlling the excitability of the CNS.
A disturbance of the balance between excitatory and
inhibitory neurotransmission is associated with
neurological disorders such as insomnia, anxiety
disorders, epilepsy and schizophrenia (Sieghart and
Sperk, 2002, Möhler, 2006a). Consequently, GABAA
receptors represent the molecular target of many
clinically important drugs such as benzodiazepines,
barbiturates, general anaesthetics or the anticonvul-
sant loreclezole (see Sieghart 2006, Möhler, 2006b;
Olsen and Sieghart, 2008). GABAA receptors are also
modulated by natural compounds of plant origin
(see Johnston et al., 2006).
We have recently identified valerenic acid (VA), a
major constituent of Valeriana officinalis L., as a
subunit-specific modulator of GABAA receptors
interacting exclusively with GABAA receptors com-
prising b2/3 subunits, with no significant effect on
GABA-induced chloride currents (IGABA) through
GABAA receptors containing b1 subunits (Khom
et al., 2007). Moreover, enhancement of inhibitory,
GABAergic neurotransmission by VA reduces
anxiety-related behaviour in vivo (Benke et al.,
2009). Based on this subtype selectivity in vitro and
anxiolytic effects in vivo, VA and its derivatives rep-
resent interesting drug candidates. In order to gain
insight into the structure–activity relationship of
these derivatives, we have synthesized 10 VA deriva-
tives (Figure 1) and analysed their in vitro and in vivo
effects. VA was converted into various amides with
different lipophilicity and bulkiness. VA ethyl ester
(VA-EE) emerged from the total synthesis described
by Ramharter and Mulzer (2009).
The modulation of IGABA by these VA derivatives
through GABAA receptors expressed in Xenopus
oocytes was analysed by means of the two-
microelectrode voltage-clamp technique and a fast
perfusion system. The behavioural effects of selected
compounds were studied in the elevated plus maze
test that allowed the identification of anxiolytic and
sedative effects.
In vitro, short-chain VA amides such as VA amide
(VA-A); VA methylamide (VA-MA) and VA ethyla-
mide (VA-EA) revealed a stronger potentiation of
IGABA compared with VA itself, whereas side chain
prolongation resulted in derivatives exhibiting a
Figure 1
Chemical structures of VA derivatives. VA-A, valerenic acid amide; VA-MA, valerenic acid methlyamide; VA-DMA, valerenic acid dimethylamide;
VA-EA, valerenic acid ethylamide; VA-DEA, valerenic acid diethylamide; VA-IPA, valerenic acid isopropylamide; VA-BA, valerenic acid butylamide;
VA-PIP, valerenic acid piperidine amide; VA-MO, valerenic acid morpholine amide; VA-EE, valerenic acid ethylate.
BJP S Khom et al.
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comparable or weaker enhancement of IGABA. VA-A
was more potent than VA in vitro and displayed the
greatest anxiolytic effect in vivo.
Methods
Synthesis of VA derivatives
All reactions were carried out in oven-dried glass-
ware under an argon atmosphere. Anhydrous
CH2Cl2 was distilled under argon from P2O5. Com-
mercially available reagents (purchased from Sigma,
Vienna, Austria or Acros Organics, Vienna, Austria)
were used without further purification. Reaction
mixtures were magnetically stirred and monitored
by thin layer chromatography with silica gel 60 F254
plates (E. Merck, Darmstadt, Germany). Flash
column chromatography was performed with Merck
silica gel (0.04–0.063 mm, 240–400 mesh) under
pressure. Yields refer to chromatographically and
spectroscopically pure compounds. 1H NMR
(400 MHz) and 13C NMR (100 MHz) spectra were
either recorded on Bruker Avance 400, or DRX 400
spectrometers. All NMR spectra were measured in
CDCl3 solutions. The chemical shifts d are reported
relative to the residual solvent peaks. All 1H and 13C
shifts are given in ppm (s = singlet; d = doublet; t =
triplet; q = quadruplet; m = multiplet). If possible,
assignments of proton resonances were confirmed
by correlated spectroscopy. Optical rotations were
measured at 20°C on a P 341 Perkin-Elmer polarim-
eter. IR spectra were recorded of samples prepared as
films on silicium plates on a Perkin-Elmer Spectrum
1600 Series FTIR spectrometer. MS spectra were mea-
sured on a Finnigan MAT 8230 apparatus with a
resolution of 10 000.
VA-A
Valerenic acid (104.3 mg, 0.4451 mM) was dissolved
in anhydrous CH2Cl2 (4.4 mL) cooled to 0°C and
1-chloro-N,N,2-trimethylpropenylamine (0.21 mL,
212.1 mg, 1.587 mM) was added dropwise. After
5 min the icebath was removed and the reaction
mixture stirred for 4 h at room temperature before
being re-cooled to 0°C. Ammonia (0.5 M) in 1,4-
dioxane (5.8 mL, 2.900 mM) was rapidly added, the
icebath removed and the resulting mixture stirred
overnight. Diethylether was added and the white
precipitate removed by filtration. The filtrate was
concentrated in vacuo and chromatography
(hexane/EtOAc 2/1 to 1/2) of the residue provided
99.8 mg of VA-A as a white solid with 96% yield.
1H-NMR (400 MHz, CDCl3, ppm): 6.67 (dq, 1 H, J
= 0.8 Hz, J = 9.3 Hz), 5.58 (s, 2 H), 3.50 (dd, 1 H, J =
4.7 Hz, J = 9.4 Hz), 2.93 (m, 1 H), 2.19 (t, 2 H, J =
7.5 Hz), 1.98 (m, 1 H), 1.90 (d, 3 H, J = 3.3 Hz), 1.78
(m, 3 H), 1.63 (m, 3 H), 1.55 (m, 1 H), 1.40 (m, 2 H),
0.77 (d, 3 H, J = 7.0 Hz)
13C-NMR (100 MHz, CDCl3, ppm): 171.8, 139.1,
133.7, 130.9, 128.3, 47.6, 37.6, 34.3, 33.2, 28.9,
25.7, 24.7, 13.6, 12.9, 12.2
IR (film, cm-1): 3179, 3028, 2923, 2885, 2853,
1733, 1654, 1652, 1636, 1505, 1458, 1418, 1378
HRMS (ESI, m/z): [M]+ calc. 215.1674; found:
215.1661
[a]D20 = -119.2 (c = 0.775 g per 100 mL, DCM)
VA-MA
Using the same procedure as for the preparation of
VA-A, VA (49.7 mg, 0.2121 mM) was treated with
1-chloro-N,N,2-trimethylpropenylamine
(0.098 mL, 99.0 mg, 0.7408 mM) and methylamine
(41% aqueous solution, 0.18 mL, 2.131 mM) to
afford 49.9 mg of VA-MA as a white solid with 95%
yield.
1H-NMR (400 MHz, CDCl3, ppm): 6.54 (dq, 1 H, J
= 1.3 Hz, J = 9.5 Hz), 5.71 (s, 1 H), 3.48 (dd, 1 H, J =
4.7 Hz, J = 9.2 Hz), 2.93 (m, 1 H), 2.86 (d, 3 H, J =
4.9 Hz), 2.19 (t, 2 H, J = 7.3 Hz), 1.97 (m, 1 H), 1.89
(d, 3 H, J = 1.4 Hz), 1.78 (m, 3 H), 1.62 (m, 3 H), 1.55
(m, 1 H), 1.39 (m, 2 H), 0.77 (d, 3 H, J = 7.0 Hz)
13C-NMR (100 MHz, CDCl3, ppm): 170.7, 137.0,
134.0, 130.7, 129.5, 47.6, 37.6, 34.1, 33.3, 28.9,
26.7, 25.8, 24.7, 13.6, 12.9, 12.2
IR (film, cm-1): 3326, 2925, 1655, 1616, 1539,
1456, 1379, 1311, 670, 667, 409
HRMS (ESI, m/z): [M]+ calc. 247.1936; found:
247.1932
[a]D20 = -129.3 (c = 0.825 g per 100 mL, DCM)
VA-EA
Using the same procedure as for the preparation of
VA-A, VA (20.9 mg, 0.0892 mM) was treated with
1-chloro-N,N,2-trimethylpropenylamine (0.035 mL,
35.4 mg, 0.2646 mM) and 2.0 M ethylamine in THF
(0.45 mL, 0.9000 mM) to afford 21.9 mg of VA EA as
a slightly yellow solid with 94% yield.
1H-NMR (400 MHz, CDCl3, ppm): 6.55 (dq, 1 H, J
= 1.3 Hz, J = 9.5 Hz), 5.66 (s, 1 H), 3.49 (dd, 1 H, J =
4.9 Hz, J = 9.3 Hz), 3.34 (dq, 2 H, J = 5.6 Hz, J =
7.2 Hz), 2.95 (m, 1 H), 2.19 (t, 2 H, J = 7.5 Hz), 1.98
(m, 1 H), 1.89 (d, 3 H, J = 1.4 Hz), 1.78 (m, 3 H), 1.62
(m, 3 H), 1.54 (m, 1 H), 1.40 (m, 2 H), 1.17 (t, 3 H, J
= 7.3 Hz), 0.78 (d, 3 H, J = 7.0 Hz)
13C-NMR (100 MHz, CDCl3, ppm): 169.9, 136.9,
134.0, 130.6, 129.6, 47.6, 37.6, 34.8, 34.1, 33.3,
28.9, 25.8, 24.7, 15.1, 13.6, 12.9, 12.2
IR (film, cm-1): 3308, 2925, 2884, 2855, 1653,
1639, 1616, 1533, 1456, 1379, 1309
BJPGABAA modulation by valerenic acid derivatives
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HRMS (ESI, m/z): [M]+ calc. 262.2171; found:
262.2161
[a]D20 = -118.7 (c = 1.58 g per 100 mL, DCM)
Valerenic N,N-diethylamide (VA-DEA)
Using the same procedure as for the preparation of
VA-A, VA (30.2 mg, 0.1289 mM) was treated with
1-chloro-N,N,2-trimethylpropenylamine (0.051 mL,
51.5 mg, 0.3855 mM) and diethylamine (0.135 mL,
95.9 mg, 1.311 mM) to afford 35.2 mg of VA-DEA as
a slightly yellow oil with 94% yield.
1H-NMR (400 MHz, CDCl3, ppm): 5.75 (dq, 1 H, J
= 0.5 Hz, J = 7.6 Hz), 3.46 (dd, 1 H, J = 3.9 Hz, J =
8.5 Hz), 3.34 (m, 4 H), 2.85 (m, 1 H), 2.17 (t, 2 H, J
= 7.4 Hz), 1.96 (m, 1 H), 1.87 (d, 3 H, J = 1.5 Hz),
1.77 (m, 3 H), 1.63 (m, 3 H), 1.52 (m, 1 H), 1.41 (m,
2 H), 1.13 (t, 6 H, J = 7.1 Hz), 0.77 (d, 3 H, J = 7.0 Hz)
13C-NMR (100 MHz, CDCl3, ppm): 173.8, 134.3,
131.0, 130.3, 130.1, 47.7, 37.6, 33.5, 33.3, 29.0,
25.8, 24.8, 14.6, 13.6, 12.2
IR (film, cm-1): 2926, 2866, 2855, 1628, 1458,
1396, 1380, 1333, 1291, 1221,1097
HRMS (ESI, m/z): [M]+ calc. 290,2484; found:
290,2488
[a]D20 = -109.8 (c = 1.63 g per 100 mL, DCM)
Valerenic acid morpholine amide (VA-MO)
Using the same procedure as for the preparation of
VA-A, VA (43.4 mg, 0.1852 mM) was treated with
1-chloro-N,N,2-trimethylpropenylamine (0.074 mL,
74.7 mg, 0.5593 mM) and morpholine (0.160 mL,
160.0 mg, 1.837 mM) to afford 50.4 mg of VA-MO as
a colourless oil with 90% yield.
1H-NMR (400 MHz, CDCl3, ppm): 5.82 (dq, 1 H, J
= 1.5 Hz, J = 9.1 Hz), 3.66 (t, 4 H, J = 4.5), 3.56 (m,
4 H), 3.47 (dd, 1 H, J = 2.8 Hz, J = 9.0 Hz), 2.82 (m,
1 H), 2.18 (t, 2 H, J = 7.4 Hz), 1.97 (m, 1 H), 1.87 (d,
3 H, J = 1.5 Hz), 1.78 (m, 3 H), 1.64 (m, 3 H), 1.55
(m, 1 H), 1.41 (m, 2 H), 0.77 (d, 3 H, J = 7.0 Hz)
13C-NMR (100 MHz, CDCl3, ppm): 172.9, 134.0,
133.6, 130.4, 128.9, 67.1, 47.8, 37.6, 33.6, 33.4,
29.0, 25.9, 24.8, 14.5, 13.6, 12.2
IR (film, cm-1): 2923, 1654, 1652, 1628, 1420,
1393, 1379, 1245, 1116, 1028, 842
HRMS (ESI, m/z): [M]+ calc. 303.2198; found:
303.2194
[a]D20 = -110.5 (c = 0.8 g per 100 mL, DCM)
Valerenic N,N-dimethylamide (VA-DMA)
A solution of VA (117 mg, 0.5 mM) in anhydrous
CH2Cl2 (5 mL) was cooled to 0°C and 1-chloro-
N,N,2-trimethylpropenylamine (0.67 mL, 2 mM)
was added dropwise. After 5 min the icebath was
removed and the reaction mixture stirred for 4 h at
room temperature. Then the solvent and volatile
by-products were removed in vacuo (3 Torr for 1 h),
and the crude acid chloride was redissolved in
CH2Cl2 (5 mL). After cooling to 0°C, dimethylamine
(0.51 mL, 5 mM) was added at once, the icebath
removed and the resulting mixture stirred for 1 h.
Diethylether was added and the white precipitate
removed by filtration. The filtrate was concentrated
in vacuo and chromatography (toluol/EtOAc 3/2) of
the residue provided 111 mg of VA-DMA as a
slightly yellow oil with 85% yield.
1H-NMR (200 MHz, CDCl3, ppm): 5.83 (dd, 1 H,
J = 1.5 Hz, J = 9.1 Hz), 3.48 (m, 1 H), 2.98 (s, 6 H),
2.86 (m, 1 H), 2.20 (t, 2 H, J = 7.2 Hz), 1.87 (m, 7 H),
1.49 (m, 5 H), 0.77 (dd, 3 H, J = 6.9 Hz)
13C-NMR (50 MHz, CDCl3, ppm): 174.0, 134.0,
132.8, 129.9, 129.5, 47.5, 37.4, 33.3, 33.2, 28.8,
25.7, 24.6, 14.1, 13.4, 12.0
IR (film, cm-1): 2926, 1627, 1496, 1448, 1390,
1091
HRMS (ESI, m/z): [M]+ calc. 262.2171 found:
262.2189
[a]D20 = -104.3 (c = 0.54 g per 100 mL, DCM)
Valerenic acid piperidine amide (VA-PIP)
A solution of VA (43.5 mg, 0.1856 mM) in anhy-
drous CH2Cl2 (1.8 mL) was cooled to 0°C and
1-chloro-N,N,2-trimethylpropenylamine (0.086 mL,
86.9 mg, 0.6500 mM) was added dropwise. After
5 min the icebath was removed and the reaction
mixture stirred for 4 h at room temperature. Then
the solvent and volatile by-products were removed
in vacuo (3 Torr for 1 h), and the crude acid chloride
was redissolved in CH2Cl2 (1.8 mL). After cooling to
0°C, piperidine (0.074 mL, 63.6 mg, 0.7474 mM)
was added at once, the icebath removed and the
resulting mixture stirred for 1 h. Diethylether was
added and the white precipitate removed by filtra-
tion. The filtrate was concentrated in vacuo and
chromatography (hexane/EtOAc 5/1 to 2/1) of the
residue provided 50.7 mg of VA-PIP as a slightly
yellow oil with 91% yield.
1H-NMR (400 MHz, CDCl3, ppm): 5.78 (dq, 1 H, J
= 1.5 Hz, J = 9.1 Hz), 3.45 (m, 5 H), 2.84 (m, 1 H),
2.18 (t, 2 H, J = 4.9 Hz), 1.96 (m, 1 H), 1.85 (d, 3 H,
J = 1.5 Hz), 1.77 (m, 3 H), 1.63 (m, 5 H), 1.54 (m,
5 H), 1.40 (m, 2 H), 0.77 (d, 3 H, J = 7.0 Hz)
13C-NMR (100 MHz, CDCl3, ppm): 172.8, 134.3,
131.9, 130.0, 129.8, 47.7, 37.6, 33.5, 33.4, 29.0,
25.9, 24.9, 24.8, 14.5, 13.6, 12.2
IR (film, cm-1): 2925, 2854, 1629, 1443, 1379,
1256, 425, 423, 420,412
HRMS (ESI, m/z): [M]+ calc. 301.2406; found:
301.2398
[a]D20 = -90.0 (c = 0.35 g per 100 mL, DCM)
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Valerenic N-isopropylamide (VA-IPA)
A solution of VA (117 mg, 0.5 mM) in anhydrous
CH2Cl2 (5 mL) was cooled to 0°C, and 1-chloro-
N,N,2-trimethylpropenylamine (0.2 mL, 0.6 mM)
was added dropwise. After 5 min the icebath was
removed and the reaction mixture stirred for 4 h at
room temperature. Then the solvent and volatile
by-products were removed in vacuo (3 Torr for 1 h)
and the crude acid chloride was redissolved in CH2Cl2
(5 mL). After cooling to 0°C n-isopropylamine
(0.43 mL, 5 mM) was added at once, the icebath
removed and the resulting mixture stirred for 1 h.
Diethylether was added and the white precipitate
removed by filtration. The filtrate was concentrated
in vacuo and chromatography (toluole/EtOAc 3/2) of
the residue provided 108 mg of VA-IPA as slightly
yellow crystals with 78% yield.
1H-NMR (200 MHz, CDCl3, ppm): 6.55 (dd, 1 H,
J = 1.3 Hz, J = 9.5 Hz), 5.53 (m, 1 H), 4.12 (m, 1 H),
3.49 (m, 1 H), 2.95 (m, 1 H), 2.20 (t, 2 H, J = 7.4),
1.75 (m, 11 H), 1.39 (m, 2 H), 1.18 (d, 6 H, J =
6.6 Hz), 0.77 (d, 3 H, J = 6.9 Hz)
13C-NMR (50 MHz, CDCl3, ppm): 168.9, 136.6,
133.8, 130.4, 129.4, 47.4, 41.4, 37.4, 33.9, 33.1,
28.7, 25.6, 24.5, 22.8, 13.4, 12.7, 12.0
IR (film, cm-1): 3306, 2930, 1652, 1611, 1533,
1456
HRMS (ESI, m/z): [M]+ calc. 276.2327; found:
276.2332
[a]D20 = -126.6 (c = 0.50 g per 100 mL, DCM)
Valerenic N-butylamide (VA-BA)
A solution of VA (117 mg, 0.5 mM) in anhydrous
CH2Cl2 (5 mL) was cooled to 0°C and 1-chloro-
N,N,2-trimethylpropenylamine (0.2 mL, 0.6 mM)
was added dropwise. After 5 min the icebath was
removed and the reaction mixture stirred for 4 h at
room temperature. Then the solvent and volatile
by-products were removed in vacuo (3 Torr for 1 h),
and the crude acid chloride was redissolved in
CH2Cl2 (5 mL). After cooling to 0°C, n-butylamine
(0.28 mL, 5 mM) was added at once, the icebath
removed and the resulting mixture stirred for 1 h.
Diethylether was added and the white precipitate
removed by filtration. The filtrate was concentrated
in vacuo and chromatography (toluole/EtOAc 3/2) of
the residue provided 102 mg of VA-BA as slightly
yellow crystals with 70% yield.
1H-NMR (200 MHz, CDCl3, ppm): 6.55 (dd, 1 H,
J = 1.3 Hz, J = 9.3 Hz), 5.72 (s, 1 H), 3.48 (m, 1 H),
3.29 (q, 2 H, J = 6.82), 2.93 (m, 1 H), 1.86 (t, 2 H, J =
7.3), 1.86 (m, 7 H), 1.49 (m, 10 H), 0.93 (t, 3 H, J =
7.2), 0.77 (d, 3 H, J = 6.9)
13C-NMR (50 MHz, CDCl3, ppm): 169.7, 136.7,
133.8, 130.4, 129.3, 47.4, 39.5, 37.4, 33.9, 33.1,
31.8, 28.7, 25.6, 24.5, 20.1, 13.8, 13.4, 12.8, 12.0
IR (film, cm-1): 3306, 2929, 1652, 1616, 1538,
1380
HRMS (ESI, m/z): [M]+ calc. 290.2484; found:
290.2488
[a]D20 = -121.5 (c = 0.47 g per 100 mL, DCM)
Molecular modelling studies
Molecules used for the Free-Wilson analysis were
built in MOE (version 2009.10) and energy mini-
mized using standard conditions (MMFF94x force
field, adjust H and LP, gradient = 0.01, calculate
force field partial charges). A database was built and
logP(o/w), TPSA and mr were calculated as descrip-
tors. Correlation analyses were performed with the
correlation plot tool implemented in MOE.
Pharmacological characterization of
VA derivatives
For in vitro and in vivo experiments, stock solutions
(100 mM) were prepared in dimethyl sulphoxide
(DMSO; Sigma, Vienna, Austria). In voltage-clamp
experiments equal amounts of DMSO were present
in control and compound-containing solutions. The
maximum DMSO concentration in the bath (0.3%)
did not affect IGABA (Khom et al., 2007). For in vivo
experiments, working concentrations were adjusted
by dilution with 0.9% sodium chloride. pH was
adjusted to 7.2–7.4 with NaOH. All solutions were
freshly prepared every day prior to experiments.
Expression and functional characterization of
GABAA receptors
Preparation of stage V–VI oocytes from Xenopus
laevis, synthesis of capped off run-off poly(A+) cRNA
transcripts from linearized cDNA templates (pCMV
vector) was performed as described (Khom et al.,
2006). Briefly, female X. laevis (NASCO, USA) were
anaesthetized by exposing them for 15 min to a
0.2% solution of MS-222 (methane sulphonate salt
of 3-aminobenzoic acid ethyl ester; Sigma) before
surgically removing parts of the ovaries. Follicle
membranes from isolated oocytes were enzymati-
cally digested with 2 mg·mL-1 collagenase (Type 1A,
Sigma). One day after isolation, the oocytes were
injected with about 10–50 nL of DEPC-treated water
(diethyl pyrocarbonate, Sigma) containing the dif-
ferent cRNAs at a concentration of approximately
150–3000 ng·mL-1·subunit-1. The amount of cRNA
was determined by means of a NanoDrop ND-1000
(Kisker-biotech, Steinfurt, Germany).
To ensure expression of the gamma-subunit in
the case of a1b2g2S and a3b3g2S receptors, cRNAs were
mixed in a ratio of 1:1:10 and for receptors compris-
ing only a- and b-subunits (a1b2, a1b3) in a ratio 1:1
(Khom et al., 2007). cRNAs for a1b1 channels were
injected in a ratio of 3:1 to avoid formation of b1
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homo-oligomeric GABAA receptors (Krishek et al.,
1996). Oocytes were stored at 18°C in ND96 solu-
tion (Methfessel et al., 1986). Electrophysiological
experiments were done using the two-
microelectrode voltage-clamp method at a holding
potential of -70 mV making use of a TURBO TEC
01C amplifier (npi electronic, Tamm, Germany) and
an Axon Digidata 1322A interface (Molecular
Devices, Sunnyvale, CA). Data were acquired using
pCLAMP v.9.2. The bath solution contained 90 mM
NaCl, 1 mM KCl, 1 mM MgCl2·6H2O, 1 mM CaCl2
and 5 mM HEPES (pH 7.4). Microelectrodes were
filled with 2 M KCl and had resistances between 1
and 3 MW (Khom et al., 2007).
Perfusion system
g-Aminobutyric acid and VA derivatives were
applied by means of a fast perfusion system (see
Baburin et al., 2006 for details). Drug or control
solutions were applied by means of a TECAN Mini-
prep 60 permitting automation of the experiments.
To elicit IGABA the chamber was perfused with 120 mL
of GABA-containing solution at a rate of 300–
1000 mL·s-1. The IGABA rise time ranged between 100
and 250 ms (Baburin et al., 2006; Khom et al., 2006).
Care was taken to account for possible slow recovery
from increasing levels of desensitization in the pres-
ence of high GABA and drug concentrations. The
duration of washout periods was therefore extended
from 1.5 min (1–20 mM GABA, <10 mM drug) to
30 min (100 mM GABA, 10 mM drug) respec-
tively. Oocytes with maximal current amplitudes
>3 mA were discarded to exclude voltage-clamp
errors (Khom et al., 2007).
Analysing concentration–response curves
Stimulation of chloride currents by modulators of
the GABAA receptor was measured at a GABA con-
centration eliciting between 3% and 5% of the
maximal current amplitude (EC3–5). The EC3–5 was
determined at the beginning of each experiment.
Enhancement of the chloride current was
defined as [I(GABA+Comp)/IGABA] - 1, where I(GABA+Comp) is
the current response in the presence of GABA and a
given compound (VA or VA derivative), and IGABA is
the control GABA current. To measure the sensitiv-
ity of the GABAA receptor for a given compound, it
was applied for an equilibration period of 1 min
before applying GABA (EC3–5). Concentration–
response curves were generated, and the data were
fitted by non-linear regression analysis using Origin
software (OriginLab Corporation, USA). Data were
fitted to the equation:
1
1 50+ [ ]
⎛⎝⎜ ⎞⎠⎟
EC
Comp
nH , where nH is the
Hill coefficient. Each data point represents the mean
 SE from at least four oocytes and 2 oocyte
batches. Statistical significance was calculated using
paired Student’s t-test with a confidence interval of
P < 0.05.
Animals
All animal care and experimental procedures were
approved by the Austrian Animal Experimentation
Ethics Board in compliance with the European con-
vention for the protection of vertebrate animals
used for experimental and other scientific purposes
ETS no. 123. Every effort was taken to minimize the
number of animals used. Male mice (c57Bl/6N) were
obtained from Charles River Laboratories (Sulzfeld,
Germany). For breeding and maintenance, mice
were group-housed with free access to food and
water. Temperature (23  1°C) and humidity (60%)
were fixed and the animals housed with a 12 h
light–dark cycle (lights on 0700–1900 h). Male mice
at 3–6 months age were tested in all experiments.
Elevated plus maze test
Explorative behaviour was tested over 5 min on an
elevated plus maze 1 m above ground. The maze
consisted of two closed and two open arms, each 50
¥ 5 cm in size as previously described by Wittmann
et al. (2009). The test instrument was built from gray
PVC; the height of closed arm walls was 20 cm.
Illumination was set to 180 lx. Animals were placed
in the centre, facing an open arm. Open and closed
arm entries and time spent on open arm was auto-
matically analysed using Video-Mot 2 equipment
and software (TSE, Bad Homburg, Germany).
Statistical analysis of behavioural
experiments
For comparison of control groups and compound-
treated groups, the unpaired Student’s t-test was
used. Comparison of more than two groups was
done by one-way ANOVA. P-values of <0.05 were
accepted as statistically significant. All data are
given as mean  SEM (n).
Materials
Valerenic acid was obtained from Extrasynthese
(Lyon, France) and DMSO was purchased from
Sigma. VA-EE was an intermediate of the total VA
synthesis described by Ramharter and Mulzer
(2009). The other tested derivatives were synthe-
sized as described above.
Results
We have synthesized a series of novel VA derivatives
(for structures, see Figure 1) to study the structure–
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activity relationship of these molecules on GABAA
receptors composed of a1 and b3 subunits, expressed
in Xenopus oocytes.
Modulation of IGABA by the VA derivatives
We measured modulation of IGABA by the VA deriva-
tives by the two-microelectrode voltage-clamp tech-
nique. As shown in Figure 2A–C, all VA derivatives
enhanced IGABA. We observed, however, significant
differences in efficacies and potencies.
Unsubstituted VA-A. VA-A was identified as the
most effective and most potent VA derivative. Rep-
resentative IGABA modulated by VA-A are shown in
Figure 2D. Relative to the parent compound, amida-
tion resulted in an increased potency and a more
than twofold enhanced maximal stimulation of
IGABA at GABA EC3–5 concentrations (see Figure 2A
and Table 1).
Alkylated VA-amides. Introduction of aliphatic,
alkyl residues resulted in a stronger modulation of
IGABA compared with VA. This effect was, however,
less pronounced than for VA-A. Moreover, the
nature of the alkyl residue significantly affected the
efficacy of the amides: VA derivatives comprising
residues such as monomethyl and monoethyl dis-
played a stronger IGABA potentiation compared with
VA. Bulkier residues such as dimethyl, diethyl, butyl
and isopropyl, either decreased IGABA enhancement
or enhancement was not statistically different from
VA (for details, see Figure 2 and Table 1).
Figure 2
Concentration–effect curves for the enhancement of IGABA through GABAA receptors composed of a1b3 subunits by (A) VA, VA-A, VA-MA, VA-EA and
VA-DMA; (B) VA, VA-DEA, VA-BA, VA-IPA and VA-EE; (C) VA, VA-PIP and VA-MO, using a GABA EC3–5 (EC50 and nH values are given in Table 1). IGABA
at 300 mM (VA and VA-A) (Figure B) (grey symbols) were excluded from the fit. (D) Typical IGABA recordings illustrating concentration-dependent
modulation by VA-A of GABA elicited chloride currents through a1b3 subunit-containing receptors. An open channel block at high VA-A
concentrations was evident from the initial rapid current decay at 100 and 300 mM. GABA, g-aminobutyric acid; IGABA, GABA-induced chloride
currents; VA, valerenic acid; VA-A, valerenic acid amide; VA-BA, valerenic acid butylamide; VA-DEA, valerenic acid diethylamide; VA-DMA, valerenic
acid dimethylamide; VA-EA, valerenic acid ethylamide; VA-EE, valerenic acid ethyl ester; VA-IPA, valerenic acid isopropylamide; VA-MA, valerenic
acid methylamide; VA-MO, valerenic acid morpholine amide; VA-PIP, valerenic acid piperidine amide.
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Interestingly, introduction of cyclic residues on
the amide nitrogen induced a significant loss of
potency for VA-PIP and VA-MO (Table 1). Enhance-
ment of IGABA by VA-PIP was, however, comparable to
that of VA-A, while potentiation of IGABA by VA-MO
was less pronounced, comparable to that of VA.
VA-EE displayed the lowest efficacy and a reduced
potency (Table 1).
b Subunit-specific modulation of IGABA
by VA-A
According to our previous study, VA selectively
enhances IGABA through GABAA receptors comprising
either b2 or b3 subunits. Even high concentrations of
VA (100 mM) induce no significant (P < 0.05) poten-
tiation of IGABA through receptors containing b1 sub-
units. A similar study was performed with VA-A and
IGABA potentiation analysed for GABAA receptors
composed of a1b1, a1b2 and a1b3 subunits. VA-A dis-
played high selectivity for a1b2 and a1b3 receptors
(Figure 3). Enhancement of IGABA by VA-A was most
pronounced through GABAA receptors composed of
a1 and b3 subunits (maximal stimulation 2021 
231% at a concentration of 100 mM, EC50 = 13.7 
2.3 mM). VA-A also potentiated IGABA through GABAA
channels comprising b2 subunits (maximal stimula-
tion 1204  270% at a concentration of 100 mM;
EC50 = 8.2  5.1 mM), but did not significantly
enhance IGABA through a1b1 containing receptors
even at 300 mM VA-A (P < 0.05).
Modulation of IGABA through a3b3g2S and
a1b2g2S GABAA receptors by VA-A
As shown in Figure 3, VA-A induced the most effi-
cient IGABA enhancement on receptors composed of
a1b3 receptors (a1b3 > a1b2 >> a1b1, see similar data
for VA in Khom et al., 2007).
To gain insight into modulation of more physi-
ological GABAA receptors (McKernan and Whiting,
1996; Olsen and Sieghart, 2008) we investigated the
modulation of a1b2g2S and a3b3g2S receptors by VA-A.
As illustrated in Figure 4A, a1b2g2S receptors were
more efficiently modulated by VA-A than by VA.
Co-expression of a g2S subunit had no significant
effects on efficacy or on potency (P > 0.05; compare
Figures 3A and 4A, see Khom et al., 2006 for compa-
rable data obtained with VA). VA-A displayed also a
higher efficacy than VA on receptors composed of
a3b3g2S subunits (Figure 4B, P < 0.05, see also
Table 2). On this receptor subtype, only a trend
towards a higher potency was observed for VA-A,
compared with VA (Tables 2, P > 0.05).
In vivo effects of selected VA derivatives
In order to get insights into the in vivo effects of VA
derivatives, the effect of selected compounds on
anxiety-related behaviour in mice was studied in the
elevated plus maze test. Thirty minutes after i.p.
injection of either solvent (=control) or drug con-
taining solution (3 mg drug·kg-1), the mice were
tested for 5 min in the elevated plus maze. Mice
treated with VA spent significantly more (P < 0.05)
Table 1
Summary of efficacies and potencies of tested VA derivatives
EC50 (mM)
Maximum stimulation
of IGABA (EC3–5) (%)
Hill coefficient
(nH)
Number of
experiments (n)
VA 22.8  5.6 858  153 1.9  0.3 5
VA-A 13.7  2.3* 2247  252* 1.6  0.2 7
VA-MA 26.3  6.6 2298  312* 1.4  0.1 6
VA-DMA 28.4  7.1 1383  211 2.1  0.5 5
VA-EA 23.4  6.9 1678  258* 1.3  0.3 5
VA-DEA 23.7  6.3 901  120 1.4  0.1 6
VA-BA 18.8  6.9 569  57 1.1  0.2 5
VA-IPA 22.5  6.0 506  76 1.5  0.3 4
VA-PIP 54.6  17.0* 1698  266* 1.6  0.3 6
VA-MO 64.2  13.8* 1064  132 1.6  0.2 7
VA-EE 49.2  26.3 250  65* 1.4  0.6 5
*P < 0.05, significantly different from corresponding values for VA.
GABA, g-aminobutyric acid; IGABA, GABA-induced chloride currents; VA, valerenic acid; VA-A, valerenic acid amide; VA-BA, valerenic acid
butylamide; VA-DEA, valerenic acid diethylamide; VA-DMA, valerenic acid dimethylamide; VA-EA, valerenic acid ethylamide; VA-EE, valerenic
acid ethyl ester; VA-IPA, valerenic acid isopropylamide; VA-MA, valerenic acid methylamide; VA-MO, valerenic acid morpholine amide; VA-PIP,
valerenic acid piperidine amide.
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of the total time on the open arms, than the control
littermates (injected with solvent), indicating anxi-
olytic potential of VA (Figure 5). More marked anxi-
olytic effects were observed after VA-A treatment (P
< 0.01 vs. control and P < 0.05 vs. VA). Treatment
with VA-EA, VA-DEA and VA-EE induced anxiolytic
effects comparable to VA, while VA-MO did not
show any anxiolytic response at the tested dose
(Figure 5).
Dose-dependent reduction of anxiety in mice
by VA and VA-A
Valerenic acid and VA-A were studied in more detail.
As shown in Figure 6A,B, both compounds dis-
played similar anxiolytic activity at a dose of
1 mg·kg-1. However, the anxiolytic effect was signifi-
cantly more pronounced for VA-A at 3 mg·kg-1. At
higher doses, a reduction of the time spent in the
open arms was observed for both compounds.
Figure 3
(A) Concentration-dependent effects for VA-A on a1b1, a1b2 and a1b3 receptors using a GABA EC3–5 concentration. (B) Typical traces for modulation
of chloride currents through a1b1, a1b2 and a1b3 channels by 30 mM VA-A at GABA EC3–5. Control currents (GABA, single bar) and corresponding
currents elicited by co-application of GABA and the indicated VA-A concentration (double bar) are shown. GABA, g-aminobutyric acid; IGABA,
GABA-induced chloride currents; VA-A, valerenic acid amide.
Figure 4
Concentration–effect curves for the enhancement of IGABA through GABAA receptors composed of (A) a1b2g2S subunits and (B) of a3b3g2S subunits
by VA-A and VA using a GABA EC3–5 (EC50 and maximal stimulation are given in Table 2). IGABA at 300 mM (grey symbols) were excluded from the
fit. GABA, g-aminobutyric acid; GABAA, GABA type A; IGABA, GABA-induced chloride currents; VA, valerenic acid; VA-A, valerenic acid amide.
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Reduced exploratory drive after the highest dose of
VA-A (30 mg·kg-1) was accompanied by a reduction
of closed arm entries and total distance. The number
of closed arm entries and total distance of
VA-treated mice were not significantly different
from control values, at doses between 1 and
10 mg·kg-1. At the highest dose (30 mg·kg-1 VA), the
number of closed arm entries was reduced (see
Figure 6C–F).
Discussion
Synthesis of high efficacy VA derivatives
We and others have recently identified VA (a major
constituent of V. officinalis L.) as an allosteric modu-
lator of GABAA receptors selectively enhancing IGABA
through channels comprising b2 or b3 (but not b1)
subunits (Khom et al., 2007; Benke et al., 2009). In
the present study, we have analysed the structure–
activity relationship of VA by modifying its carboxyl
group (Figure 1). This approach allowed us to gen-
erate VA derivatives modulating GABAA receptors
with higher efficacy than the natural parent com-
pound. Significantly higher efficacies in the stimu-
lation of IGABA through a1b3 receptors were observed
for VA-A (2247 252%), VA-MA (2298 312%) and
VA-EA (1678  258%). All values were significantly
different from those for VA (P < 0.05). VA-A was even
more potent than VA (P < 0.05; Table 1). Introduc-
tion of bulkier residues or cyclic residues resulted in
either a less efficient potentiation of IGABA compared
with VA or even a significantly reduced potency (for
details, see Table 1 and Figure 2).
With respect to structure–activity relationships
we observed no correlation between potency and
efficacy of the compounds. The unsubstituted amide
VA-A displayed the lowest EC50 (highest potency) at
the GABAA receptors investigated. Notably, all
mono- and dialkyl-substituted amides and VA itself
exhibited almost identical EC50 values. This indi-
cates, that, for this part of the molecule, neither
charge nor H-bond donor properties nor lipophilic-
ity influence drug receptor binding. In an activity
ranking, this cluster of equally active compounds is
followed by the ethyl ester, which was slightly less
active than the respective ethyl amide. Interestingly,
both the piperidine and the morpholine analogues
wee significantly less potent than all the other com-
pounds. This might either indicate a steric hin-
drance caused by the rigid six membered rings or an
unfavourable entropic contribution caused by the
greater rigidity of the amide substituent.
With respect to maximum stimulation, the dif-
ferences are more pronounced with almost one
order of magnitude difference (ester vs. unsubsti-
tuted amide). In addition, a different structure–
activity relationship was observed. Open chain
Table 2
Summary of potencies (as EC50) and efficacies (as maximum stimulation of IGABA) of VA and VA-A on different GABAA receptor subtypes
Subunit
composition Compound EC50 (mM)
Maximum stimulation
of IGABA (%)
Number of
experiments (n)
a1b2g2S VA-A 16.0  4.4 1517  234 5
a1b2g2S VA 18.9  8.5 838  157 4
a3b3g2S VA-A 7.3  1.9 775  62 6
a3b3g2S VA 17.6  9.8 265  68 4
GABA, g-aminobutyric acid; GABAA, GABA type A; IGABA, GABA-induced chloride currents; VA, valerenic acid; VA-A, valerenic acid amide.
Figure 5
Behaviour in the elevated plus maze test for control and drug-treated
mice at a dose of 3 mg·kg-1 of the indicated VA derivative. Bars
indicate the time spent on the open arms (OA) in % of the total time.
Bars represent means  SEM from at least eight different mice. *P <
0.05; **P < 0.01, significantly different from control. VA, valerenic
acid; VA-A, valerenic acid amide; VA-DEA, valerenic acid diethyla-
mide; VA-EA, valerenic acid ethylamide; VA-EE, valerenic acid ethyl
ester; VA-MO, valerenic acid morpholine amide.
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Figure 6
Behaviour in the elevated plus maze test for control (shaded bars in A–F) and drug-treated mice at the indicated dose and compound. Bars indicate
in (A) time spent in open arms (OA), in % of the total time after application of the indicated dose of VA, (B) time spent in open arms in % of the
total time after application of the indicated dose of VA-A, (C) number of closed arm (CA) entries after application of the indicated dose of VA, (D)
number of closed arm entries after application of the indicated dose of VA-A, (E) total distance after application of the indicated dose of VA and
(F) total distance after application of the indicated dose of VA-A. Bars represent means  SEM from at least eight different mice. *P < 0.05; **P
< 0.01, significantly different from control. VA, valerenic acid; VA-A, valerenic acid amide.
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secondary and tertiary amides show a clear inverse
correlation between logP values and maximum
stimulation (r2 = 0.83, n = 7), with the unsubstituted
amide and the methylamide being the most active
compounds. Pairwise comparison of mono- and
di-substituted amides also reveals that the latter gen-
erally show lower maximum stimulation. This
might point towards a potential importance of
H-bond donor features in this region. Furthermore,
the ethyl ester is almost one order of magnitude less
efficient than the analogous ethyl amide, which
might indicate that the carbonyl group functions as
an H-bond acceptor. However, this data set needs to
be interpreted very cautiously, as it is too limited to
derive any quantitative (QSAR) models.
Derivatization preserves subunit specificity
Derivatization might influence the pharmacological
properties of the compounds, which could lead to a
loss of subunit specificity. We have therefore inves-
tigated the effects of VA-A (the most potent and
effective derivative) on a1b1, a1b2 and a1b3 receptors.
Compared with VA, the selectivity for VA-A for
GABAA receptors comprising b2 or b3 subunits was
conserved. As shown in Figure 3, VA-A induced pro-
nounced modulation of a1b3 and a1b2 receptors, and
no significant effect was observed for a1b1 receptors
(300 mM; P < 0.05). Benke et al. (2009) reported, that
a1b2 receptors were not modulated by VA. This is in
contrast to our previous data (Khom et al., 2007)
and was also not observed for VA-A in the present
study (see Figure 3).
VA-A efficiently enhances IGABA through
a1b2g2S and a3b3g2S receptors
In line with the data obtained on a1b3 receptors
(Figure 2), we found that IGABA through a1b2g2S recep-
tors were more effectively enhanced by VA-A than
by VA (Figure 4A, Table 2). However, our data also
show that VA-A was more potent on GABAA recep-
tors comprising a3 subunits than a1 subunits (P <
0.05, see Table 2, Figure 4A,B) that could, by
analogy with the effects of the benzodiazepines
(Rudolph et al., 1999; McKernan et al., 2000; Atack,
2005; Dias et al., 2005), contribute to the anxiolytic
action of VA-A (Figure 6).
VA-A showed the most marked anxiolytic
effects in mice
Effects on anxiety were investigated in the elevated
plus maze for five VA derivatives (VA-A, VA-EA,
VA-DEA, VA-EE and VA-MO), selected on the basis of
their in vitro properties.
In this test, all compounds except VA-MO
induced significantly increased ambulation of the
open arms. This anxiolytic effect was most pro-
nounced for VA-A, as mice treated with VA-A spent
about twice the time in the open arms of the
elevated plus maze. Of note is the fact, that
increasing lipophilicity did not directly translate
into increased behavioural effects. VA-MO was
inactive at the dose tested, but effects at higher
doses cannot be excluded. Interestingly, VA-EE
(the weakest modulator in vitro) displayed pro-
nounced anxiolytic responses comparable to that
of VA.
In vivo effects of VA and VA-A were compared
over a broader range of doses. Both compounds
induced comparable anxiolytic effects at 1 mg·kg-1.
At doses of 10 and 30 mg·kg-1, VA treatment failed
to increase time spent in the open arms (Figure 6).
The lack of increased open arm ambulation after
higher doses of VA or VA-A were paralleled by
reduced motor activity as indicated by reduced
closed arm entries and distance travelled (Figure 6).
As this test depends on motor activity, any sedative
effects may camouflage anxiolytic effects at higher
doses of VA-A.
In conclusion, we report here the synthesis of
novel VA derivatives that enabled to gain insights
into the structure–activity relationship of this mol-
ecule. Amidation was found to increase potency
and efficacy of VA. Greater IGABA enhancement by
VA-A through receptors comprising b3 (b2) subunits
in vitro correlated with significantly stronger in vivo
effects as compared with VA. Benke et al. (2009)
have shown that the anxiolytic activity of VA is
absent in b3(N265M) point-mutated mice. It is
therefore likely that the anxiolytic effect of the
studied VA derivatives was caused by interaction
with GABAA receptors containing b3 subunits. Our
data thus support the hypothesis that b3 subunit
containing GABAA receptors are interesting targets
for the development of anxiolytics. We can not
exclude, however, that the higher potency of VA-A
on GABAA receptors comprising a3 subunits
(Figure 4B) contributes to its anxiolytic action.
Some b2/3-selective GABAA receptor ligands have
also been shown to induce anticonvulsant (Win-
grove et al., 1994; Groves et al., 2006) and anaes-
thetic effects (Li et al., 2006; Drexler et al., 2009). It
will be interesting to study if such effects can be
detected for VA or its derivatives.
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2.8 Summary 
 
The synthetic strategy devised during this PhD thesis has led to the first total synthesis of valerenic 
acid. After optimization a ten step sequence has been elaborated, which utilized a novel one-pot 
reaction to provide key intermediate 85 and two hydroxy-directed reactions (HDDA, Crabtree 
hydrogenation) as further key steps to stereo- and regioselectively provide valerenic acid with an 
overall yield of 25 % (see Scheme 17). 
 
 
Scheme 17: Keysteps of the synthesis of valerenic acid. 
 
Importantly, in contrast to other approaches towards valerenanes, it was possible to avoid instable 
intermediates prone to epimerization. Up to date this approach represents the shortest total 
synthesis and delivers valerenic acid with the highest overall yield. 
 
Based on this synthetic strategy also a series of simple derivatives has been synthesized and tested 
by the Department of Pharmacology and Toxicology. Both in vitro and in vivo tests have led to 
promising results, so both departments are confident that the results from this thesis will provide the 
basis for future developments. 
  
54 
 
3 [1,3]-Isomerization of Allylic Alcohols 
3.1 Introduction to Anionotropic Isomerizations 
 
Rearrangements based on migration of functional groups, which can also exist as stable anions or 
cations, are often referred to anionotropic or cationotropic reactions.26 One well known example for 
an anionotropic rearrangement is the isomerization of allylic alcohols. Migration of the hydroxy 
group and simultaneous transposition of one or more π-bonds lead to another allylic alcohol in this 
transformation. 
 
 
Scheme 18: [1,3]-Isomerization of allylic alcohols. 
 
As outlined in Scheme 18, [1,3]-isomerizations are reversible processes, so product distribution is 
mainly dependent on the thermodynamic stability of both isomers. Often mixtures of starting 
material and product are obtained, but if substituents favor the formation of one of the isomers the 
equilibrium is shifted selectively. Nonetheless, because of a considerable activation barrier this type 
of anionotropic reaction requires a catalyst. 
 
3.1.1 Brønsted Acid Induced Isomerizations 
 
In pioneering studies mostly sulfuric acid was used to isomerize allylic alcohols.27 However, the yields 
were often only moderate because the occurrence of cationic intermediates sometimes resulted in 
the formation of unwanted byproducts or decomposition. The Brønsted acid induced rearrangement 
was rationalized by two slightly different mechanisms. 
 
 
Scheme 19: Proposed mechanism for the acid induced allylic isomerization. 
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Because the initial protonation of alcohol 101 is very fast, the overall isomerization is a simple first 
order reaction and independent on the acid concentration.27 After activation of the alcohol two 
different pathways seem plausible. Starting from 103 either carbenium ion 104 is formed (via an SN1 
mechanism), which immediately reacts with water to form the protonated isomeric alcohol 106, or 
water substitutes the protonated hydroxy group according to a SN2’ mechanism. 
 
Although most of the early investigations concentrated on mechanistic considerations, also some 
applications of sulfuric acid induced isomerizations in natural product synthesis have been published.  
The most prominent example was probably the total synthesis of vitamin A by Isler and coworkers.28 
 
3.1.2 Metal Oxo Complex Catalyzed Isomerizations 
 
More recently metal oxo catalysts were used to carry out [1,3]-isomerizations.29 In 1977 the group of 
Chabardes reported the first example for a metal oxo complex catalyzed rearrangement of 
unsaturated alcohols.30 They observed that catalytic amounts of vanadate esters (VO(OR)3) 
effectively catalyze [1,3]-isomerizations at elevated temperatures (see Scheme 20). 
 
 
Scheme 20: Metal oxo complex catalyzed [1,3]-isomerization. 
 
In the first substep transesterification of catalyst 107 with allylic alcohol 101 leads to formation of 
mixed vanadate ester 108. In analogy to the [3,3]-sigmatropic Claisen rearrangement this substrate 
undergoes isomerization to afford intermediate 109. After a second transesterification the 
isomerized alcohol 102 is obtained and the catalytic species regenerated. As in the acid induced 
isomerization all steps are reversible and a mixture of both isomers 101 and 102 is obtained. In 
agreement to the Woodward-Hoffmann rules this pericyclic reaction proceeds strictly suprafacial and 
is therefore stereoselective. Consequently formation of the new C-O bond proceeds from the 
hemisphere in which the original C-O bond is located. This mechanistic explanation is in agreement 
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with the findings by Takai and coworkers, who used a slightly different vanadium catalyst (VO(acac)2) 
to isomerize enantioenriched substrate 110.31 
 
 
Scheme 21: Conversion of a chiral substrate with catalytic amounts of VO(acac)2. 
 
As outlined in Scheme 21, the reaction proceeds mostly stereoselectively. Minor losses in the 
enantiomeric excess of both alcohols can be rationalized by competing reaction pathways involving 
allylic carbenium ions. 
 
In the subsequent years several different catalysts have been developed (see Scheme 22). 
 
 
Scheme 22: [1,3]-isomerization catalysts. 
 
Shortly after introduction of vanadate ester 107 by Chabardes and coworkers, the groups of Fujita 
and Takai reported other catalytic species in the form of oxo vanadium, tungsten and molybdenum 
complexes.31,32 Whereas the catalysts developed by Chabardes and Fujita need high temperature for 
suitable conversion, the vanadium and molybdenum acetylacetonate complexes used by Takai 
catalyze allylic isomerization already at room temperature. The last contribution on this field so far 
has been the oxo rhenium catalyst developed by Osborn and coworkers.33 Noteworthy, this species 
was also used in natural product synthesis to provide galanthamine in the final step.34 Although the 
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isomerization generally proceeds with good yields, sometimes also side reactions are observed. For 
example reduction of the highly oxidized catalysts leads to oxidation of the alcohol and more 
importantly to a loss of catalytic activity (Compare tungsten or molybdenum catalyzed isomerizations 
with the well known oxidation of tertiary allylic alcohols to enones by pyridinium dichromate or 
pyridinium chlorochromate.35). 
 
3.2 One-Pot Synthesis of 2,4-Dienols 
3.2.1 Introduction 
 
During the efforts to optimize the first generation synthesis of valerenic acid (1) the preparation of 
two simple substrates has been envisaged (see Scheme 23). 
 
 
Scheme 23: It began with an error… 
 
To synthesize compound 118 enone 98 was converted with isopropenyl lithium and the in situ 
formed tertiary alkoxide was treated with acetyl chloride or acetic acid anhydride. However, all 
attempts to isolate any product failed and only a brown tarry residue was obtained, which smelled of 
acetic acid. Most likely autocatalytic generation of acetic acid led to decomposition. After this failure 
the synthesis of compound 119 was attempted. Although it was possible to isolate substrate 119, the 
obtained yields were low and difficult to reproduce. Therefore, we rationalized that diallylic alcohol 
119 was only of moderate stability. However, what might have been disadvantageous on first sight, 
became beneficially in the end, because we reasoned that the in situ formed tertiary alkoxide 117 
should be an ideal substrate for a subsequent [1,3]-isomerization (see Scheme 24). 
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Scheme 24: One-pot synthesis of key intermediate 85. 
 
After several experiments, it eventually turned out, that not only isomerization of 117 was possible, 
but the same concept could be applied to a broad scope of different substrates. For a more detailed 
discussion, including also the conversion of chiral substrates, see the following communication. 
 
3.2.2 Efficient and Scalable One-Pot Synthesis of 2,4-Dienols from Cycloalkenones 
 
Ramharter, J.; Mulzer J. Org. Lett. 2011, 13, 5310 
 
The supporting information of this communication includes experimental and analytical data of all 
discussed compounds. This data can be found in chapter 5.2. 
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ABSTRACT
A mild and selective one-pot procedure to provide 2,4-dienols from simple cycloalkenones in high yields is described. This transformation is based on
the in situ formationof acid-labile allylic alcohols, which on treatmentwith trifluoroacetic acid undergoa formal [1,3]-hydroxymigration to formdiastereo-
and enantiomerically enriched 2,4-dienols. The usefulness of this protocol is demonstrated in a short synthesis of valerenic acid.
2,4-Dienols are very important building blocks in nat-
ural product synthesis.1 However, as even simple 2,4-
dienols require several steps for their synthesis, a general
and efficient access to these compounds would be
welcome.
A straightforward access to 2,4-dienols is the [1,3]-
hydroxy isomerization of tertiary allylic alcohols. This
thermodynamically driven reaction has been known for
several decades and has often been based on the use of
metaloxo catalysts,2 although the pioneering investiga-
tions were carried out with sulfuric acid.3 However, one of
the disadvantages of this reaction type is the moderate
stability of the required precursors. Therefore, we devised
an effective and mild one-pot procedure that combines the
preparation of the precursors with the [1,3]-hydroxy
isomerization.4,5
As a proof of concept, 2-cyclopentenone (1) was
chosen as a simple test substrate (see Table 1). After
treatment with vinylmagnesium bromide, the in situ
formed tertiary alkoxide 2 was treated with different
aqueous Brønsted acids to trigger the transformation
into 3-vinylcyclopent-2-enol (3a). The difference be-
tween sulfuric acid and hydrochloric acid was margin-
al, and at best, the isolated yields were only slightly
higher than 40% (entries 13). After applying inor-
ganic Brønsted acids, we switched to organic Brønsted
acids instead (entries 46). Gratifyingly, when acetic
acid or trifluoroacetic acid was used, decomposition
and side reactions seemed to be much less competitive,
in both cases, and much better results were obtained.
(1) For examples, see: (a) Corey, E. J.; Da Silva Jardine, P.; Rohloff,
J. C. J. Am. Chem. Soc. 1988, 110, 3672. (b) He, F.; Bo, Y.; Altom, J. D.;
Corey, E. J. J. Am. Chem. Soc. 1999, 121, 6771. (c) Ramharter, J.;
Mulzer, J. Org. Lett. 2009, 11, 1151.
(2) For a review, see: Bellemin-Laponnaz, S.; Le Ny, J.-P. Compt.
Rend. Chim. 2002, 5, 217.
(3) For a review, see: Braude, E. A. Q. Rev. Chem. Soc. 1950, 4, 404.
(4) For reviews about one-pot reactions, see: (a) Posner, G. H.Chem.
Rev. 1986, 86, 831. (b) Albrecht, Ł.; Jiang, H.; Jørgensen, K. A. Angew.
Chem., Int. Ed. 2011, 50, in press. (c) Vaxelaire, C.;Winter, P.; Christmann,
M. Angew. Chem., Int. Ed. 2011, 50, 3605.
(5) For a recent application of one-pot reactions in natural product
synthesis from our group, see: Ramharter, J.; Weinstabl, H.; Mulzer, J.
J. Am. Chem. Soc. 2010, 132, 14338.
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Unfortunately, in the case of acetic acid, it took much
longer to reach full conversion, and 1-acetoxy-2,4-dienol
3b was isolated as side product (entry 4). Finally com-
plete and selective isomerization to the desired 2,4-
dienol 3a was observed when trifluoroacetic acid was
used (entry 5). The reaction was scalable, and nearly the
same yield was obtained on a larger scale (entry 6).
After these initial results, the isomerization of other
substrates was studied (see Table 2). The conversion of
cycloalkenones with larger ring size was also highly selec-
tive (entries 1 and 2). Whereas treatment of 2-cyclopent-
enone (1) with 2-propenylmagnesium bromide led to the
formation of considerable amounts of the 1,4-addition
product, use of the corresponding organolithium com-
pound and subsequent treatment with trifluoroacetic acid
resulted in clean formation of the desired 2,4-dienol 8.
Scale up to gram scale did not reduce the yield (entry 4).
Interestingly,while the substituent in2-methylcyclopent-2-
enone did not affect the transposition of the hydroxy
group, the conversion of 3-methylcyclopent-2-enone
was much more acid sensitive than most other sub-
strates. As a consequence, better results were obtained
when acetic acid was used instead of trifluoroacetic
acid (entries 6 and 7). Remarkably, no other products
were obtained in this case. Finally, also an aryl
Grignard was used instead of an alkenyl Grignard
(entry 8). Although the subsequent isomerization
was much slower than before, a very selective forma-
tion of the expected 3-phenylhex-2-enol was observed
in nearly quantitative yield.
Because metaloxo-catalyzed 1,3-isomerizations of
allylic alcohols often proceed stereoselectively,6 the con-
version of chiral substrates was investigated as well (see
Table 3). According to our results, the limiting factor in
the selectivity of the overall transformation appears to
be the 1,2-addition. When a single intermediate was
formed, high diastereomeric ratios were obtained for
the resulting products (entries 2 and 3).7 However, when
the 1,2-addition was not selective, roughly the same
diastereomeric ratio was observed for the rearranged
dienols (entry 1).
Interestingly, cis intermediates led to the formation of
trans products, indicating that a different mechanism is
operating than for metaloxo catalyst mediated reactions.8
To account for the observed stereoselectivity, we propose
that trifluoroacetic acid does not only protonate the
tertiary alcohol but also blocks the site of the molecule
syn to the alcohol (see Figure 1). The interaction of acid
and hydroxyl group may result either in the formation of
an instable trifluoroacetate followed by SN2 hydrolysis or
Table 1. Screening of Different Brønsted Acids
entry acid (equiv) temp (C) time (h) product, yield (%)
1 H2SO4 (2.5) 25 1 3a, traces
2 H2SO4 (2.5) 0 1 3a, 45
3 HCl (2.5) 0 1 3a, 42
4 CH3COOH (2.5) 25 24 3a, 68 þ 3b, 27
5 CF3COOH (2.5) 0 1 3a, 78
6 CF3COOH (2.5) 0 1.5 3a, 73 (gram scale)
Table 2. Conversion of Simple Substratesa
aKey: (i) 0.1 M in Et2O at 0 C or 78 C, 2.0 equiv of nucleophile;
(ii) 0 C or rt, H2O, 2.5 equiv of acid.
(6) (a)Matsubara, S.; Okazoe, T.; Oshima,K.; Takai, K.; Nozaki,H.
Bull. Chem. Soc. Jpn. 1985, 58, 844. (b) Trost, B.M.; Toste, F. D. J. Am.
Chem.Soc. 2000, 122, 11262. (c)Morrill, C.;Grubbs,R.H. J.Am.Chem.
Soc. 2005, 127, 2842.
(7) Diastereomers were separated by means of HPLC. cis- and trans-
configurations were assigned by NOE experiments.
(8) Bellemin-Laponnaz, S.; Le Ny, J.-P.; Dedieu, A. Chem.;Eur. J.
1999, 5, 57.
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in the formation of a contact ion pair,which immediately is
attacked by water from the opposite ring face.
Although, so far, all isomerizations have proven
regioselective, some limitations must be taken into
account. As outlined in Scheme 1, treatment of 2-
cyclohexenone (4) with 2-methyl-1-propenylmagnesium
bromide and subsequent addition of aqueous trifluoro-
acetic acid led to compounds 25 and 26 as a 1:1 mixture.
This can be rationalized by assuming a significant car-
benium character in the isomerization. Normally, a
stereoelectronic preference for the endocyclic position
is observed. If, however, the exocyclic position can
stabilize a positive charge, nucleophilic attack can occur
there too. A pronounced carbenium character also sup-
ports the proposed formation of a contact ion pair as
intermediate (see discussion above).
Finally, we highlight the usefulness of the described one-
pot procedure by improving our previous synthesis of
valerenic acid (see Scheme 2).1c,9 We began with the one-
pot synthesis of racemicdienol8 (seeTable 2, entries 3 and4).
Chiral resolution provided the optically enriched alcohol
28 and ester 27.10 The ester could easily be recycled to
racemic dienol 8 by treatment with silica gel. Interestingly,
during this reaction, the optical activity was completely
lost,11 indicating an SN1 displacement of the acetate was
occurring by water. With enantioenriched alcohol 28
in hand, a hydroxy-directed DielsAlder reaction
(HDDA), according to a modified protocol by the
group of Barriault and co-workers, was conducted to
provide tricyclic lactone 29.12 This compound is a
Table 3. Selective Conversion of Chiral Substratesa
aKey: (i) 0.1 M in Et2O at 0 C, 2.0 equiv of vinylmagnesium
bromide; (ii) rt, H2O, 2.5 equiv of CF3COOH.
bOnly the major isomer
is depicted. cCombined yield of cis and trans products. dA 5-fold excess
of CF3COOH is used to speed up the reaction.
Figure 1. Proposed reaction mechanism for the diastereoselec-
tive [1,3]-hydroxy isomerization.
Scheme 1. Limitationsa
aKey: (i) 0.1 M in Et2O at 0 C, 2.0 equiv of 2-methyl-1-propenyl-
magnesium bromide; (ii) 0 C, H2O, 2.5 equiv of CF3COOH.
Scheme 2. Optimized Synthesis of Valerenic Acida
aAbbreviations: TFA, trifluoroacetic acid; MTBE, methyl tert-butyl
ether; DIPEA, diisopropylethylamine.
(9) For a different total synthesis of valerenic acid, see: Kopp, S.;
Schweizer, W. B.; Altmann, K.-H. Synlett 2009, 11, 1769.
(10) Sumi, S.; Matsumoto, K.; Tokuyama, H.; Fukuyama, T. Tetra-
hedron 2003, 59, 8571.
(11) Proven by optical rotation: [R]20D = 0.000.
(12) Barriault, L.; Thomas, J. D. O.; Clement, R. J. Org. Chem. 2003,
68, 2317.
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key intermediate in our recently published synthesis of
valerenic acid and only seven steps away from
the target. The simplified access to dienol 8 shortens
the route by five steps and increases the overall yield
from 8% to 13% (25% if compound 27 is fully
recycled).
In conclusion, we have developed a selective, flex-
ible, and scalable one-pot synthesis of optically en-
riched 2,4-dienols from simple cycloalkenones. The
underlying [1,3]-hydroxy isomerization is simple and
stereoselective. Stereochemically, it complements the
well-known oxo-metal-catalyzed [1,3]-hydroxy iso-
merization. An application in the synthesis of valerenic
acid has led to a significant reduction in the overall
number of steps.
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Nasufi for HPLC analysis, all at the University of Vienna,
and the Austrian Science Fund (FWF) for financial sup-
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pounds. This material is available free of charge via the
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3.3 Summary 
 
Attempts to optimize the synthesis of valerenic acid (see chapter 2) have led to the development of a 
novel one-pot reaction. Because of the anticipated impact of such transformations a series of simple 
substrates was converted in analogy to the preparation of 3-isopropenyl-2-cyclopentenol (85) (see 
also Scheme 25). 
 
 
Scheme 25: Extension to other substrates. 
 
Fortunately, the reaction was scalable and provided dienols 3 in good to excellent yields for a broad 
scope of substrates. Besides the conversion of non-chiral compounds, also the [1,3]-isomerization of 
chiral substrates has been studied. Interestingly, very selective transformations of the substrates 
were observed and products complementary to the metal oxo complex catalyzed isomerization were 
obtained (see Scheme 26). 
 
 
Scheme 26: Comparison of metal oxo catalyzed and TFA catalyzed [1,3]-isomerization. 
 
According to our proposal trifluoroacetic acid does not only protonate the tertiary alcohol, but also 
blocks nucleophilic attack from the syn hemisphere of the alcohol. Therefore the substitution of the 
alcohol proceeds in an anti selective SN2’ reaction. 
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4 Total Synthesis of Lycoflexine 
4.1 Introduction to Lycopodium Alkaloids 
 
Lycopodium plants encompass a large group of nearly thousand species better known as club 
mosses.36 Endemic to temperate subarctic climates they can only be found in very specialized 
habitats and seldom in abundance. Until today, no attempt to cultivate Lycopodium species has been 
successful. Nonetheless, Lycopodium species are well known because of their use in traditional folk 
medicine. Especially in China dried plants and extracts are applied against contusions, strains and 
swellings. More recently pharmacological investigations identified several constituents of 
Lycopodium to act as reversible acetyl cholinesterase inhibitor.37,38 Eventually the most potent among 
them (huperzine A) has been approved as drug for treatment against Alzheimer disease.39 
 
Because of their origin, nitrogen containing constituents of Lycopodium plants like huperzine A are 
called Lycopodium alkaloids.40 This class of natural products includes a variety of different but 
structurally and biosynthetically related compounds. The first representative of this group is 
lycopodine (127), which has already been identified by Bödeker in 1881.41 Until today more than two 
hundred natural products have been isolated from about fifty different species of Lycopodium. 
Despite the huge overall number nearly all of these compounds are built up by 16 or 32 carbons 
(monomeric / dimeric forms), respectively. They structurally feature a quinolizine, pyridine or 
α-pyridone based skeleton. 
 
4.1.1 Classification of Lycopodium Alkaloids 
 
 
Scheme 27: The four classes of Lycopodium alkaloids. 
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According to a proposal by Ayer Lycopodium alkaloids are divided into four subclasses with increasing 
structural complexity (see Scheme 27).42 The group of phlegmarine related Lycopodium alkaloids 
covers the structurally simplest compounds, which cannot be placed in any other class. Pyridine or 
pyridone based compounds belong to the lycodine class and include the most potent acetyl 
cholinesterase inhibitors like the already mentioned huperzine A. The largest group, which spans 
more than 70 alkaloids, is named after its most important member lycopodine (127). Members of 
this group have a tetracyclic skeleton similar to lycodine (126), but lack the pyridine ring. The 
quinolizine core is annulated by an additional six membered ring instead. Finally the last group covers 
fawcettimine related compounds. Members of this class are formally derived by bond migration of 
lycopodine precursors to form a hemiaminal. As it has already been confirmed by Heathcock, 
fawcettimine (128) exists in two tautomeric forms (see Scheme 28).43 
 
 
Scheme 28: The two different subclasses of fawcettimine related Lycopodium alkaloids. 
 
Although the equilibrium is shifted to the left, both the carbinolamine form 128 and the keto-amine 
form 129 are observed. Therefore, further division of the fawcettimine class gives rise to another two 
different subclasses. 
 
4.1.2 Biosynthesis of Lycopodium Alkaloids 
 
Since more than 50 years the biosynthesis of Lycopodium alkaloids has been intensively studied and 
several revised biosyntheses have been proposed. Although most efforts concentrated on the 
formation of lycopodine (the most prominent member of Lycopodium alkaloids), the obtained results 
and gathered information can be easily extended to the biosynthesis of all other Lycopodium 
alkaloids as well. Already in 1968, Spenser and coworkers were able to prove by feeding experiments 
with 14C-labeled substrates, that lysine serves as precursor of lycopodine.44 In agreement with these 
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results they proposed a biosynthetic pathway, that has only slightly been alterated and extended in 
the following years (see Scheme 29 and Scheme 30).45 
 
 
Scheme 29: Proposed biosynthesis of Phlegmarine. 
 
As outlined in Scheme 29, the proposed biosynthesis of Lycopodium alkaloids starts with enzymatic 
decarboxylation of lysine (130) and oxidative degradation of one of the amino groups. The resulting 
aldehyde 132 is most likely labile and dehydrates to provide Δ1-piperideine (133). In the next step 
electrophile 133 reacts with nucleophilic diketo acid 135, which is derived by Claisen condensation of 
two equivalents of malonic acid derivative 134. After decarboxylation coupling of pelletierene (137) 
with keto acid 136 provides phlegmarine (125) by bond formation between C7 and C12 as well as C8 
and C15. 
 
Whereas the first steps of the biosynthesis of Lycopodium alkaloids are well established, suggestions 
about the subsequent transformations to deliver lycodine, lycopodine and fawcettimine are 
comparatively vague (see Scheme 30).44,46 Oxidation of phlegmarine most likely provides enamine 
138, which undergoes intramolecular nucleophilic addition to deliver the tetracyclic core of lycodine. 
In the next step the resulting imine 139 is either oxidized to lycodine (126) or transformed into amino 
aldehyde 141 by loss of ammonia. The latter compound undergoes dehydrative cyclization to form 
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iminium cation 142, which upon reduction provides lycopodine (127). Finally the formation of 
fawcettimine can be rationalized by fragmentation and subsequent oxidative enol enamine coupling 
of intermediate 143. 
 
 
Scheme 30: Proposed biosynthesis of Lycodine, Lycopodine and Fawcettimine. 
 
4.2 About Lycoflexine 
 
Together with four other alkaloids (lycopodine, dihydrolycopodine, lycodoline and fawcettimine) 
lycoflexine (4) was isolated in 1973 by Ayer and coworkers from Lycopodium clavatum var. inflexum, 
which was collected in South Africa.47 
 
 
Scheme 31: Structure of lycoflexine. 
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As depicted in Scheme 31 lycoflexine possesses an unprecedented tetracyclic core with four 
stereogenic centers. Noteworthy, two of them are adjacent quaternary carbons and one of the 
six-membered rings is spiro-annulated. Although at first sight lycoflexine and fawcettimine do not 
seem to be related, in fact the two compounds only differ in the methylene bridge C17. This 
apparent association to fawcettimine (128) also prompted Ayer and coworkers to propose the 
following biosynthesis, which is outlined in Scheme 32.47 
 
 
Scheme 32: Proposed biosynthesis of lycoflexine. 
 
They reasoned, that a transannular Mannich reaction of imminium species 144, available by either 
oxidation of N-methylfawcettimine (145) or condensation of fawcettimine (129) with formaldehyde, 
leads to the formation of lycoflexine (4). This hypothesis was also supported by synthetic 
transformation of natural fawcettimine into lycoflexine, albeit the observed yield was only moderate.  
 
4.3 Contributions by Other Groups 
 
Despite the unique and interesting structure of lycoflexine no total synthesis of this natural product 
was achieved before 2010.8 One year after completion of the first total synthesis of lycoflexine 
(accomplished during this PhD thesis) a second one was published by Yang and coworkers in 2011 
(see chapter 4.3.4).48 Contrary to lycoflexine, three total syntheses and several formal total syntheses 
of fawcettimine, as well as the first total synthesis of fawcettidine have already been completed by 
the time this PhD thesis was begun. The first total synthesis of racemic fawcettimine was 
accomplished in 1979 by Inubushi and coworkers (see chapter 4.3.1).49 Seven years later one of the 
classical Lycopodium alkaloid syntheses was published by the group of Heathcock43,50 (see 
chapter 4.3.2) and in 2007 Toste51 concluded the first asymmetric approach. Further syntheses of 
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fawcettimine were published by Mukai52 in 2010 and Yang48 and Lei53 both in 2011. Also worth 
mentioning, the first total synthesis of fawcettidine, a Lycopodium alkaloid nearly identical to 
fawcettimine, was achieved by Dake and Kozak in 2008 (see chapter 4.3.3).54 Very recently also a 
second successful approach was accomplished by Lei and coworkers.53 Although not all of these 
syntheses can be discussed in detail, the following subchapters will provide an overview of the most 
significant contributions by other groups. 
 
4.3.1 Total Synthesis of (+/-)-Fawcettimine by Inubushi 
 
Already more than thirty years ago Inubushi and coworkers were able to complete the first total 
synthesis of fawcettimine (128).49 An overview of the applied strategy is outlined in Scheme 33. 
 
 
Scheme 33: First total synthesis of fawcettimine by Inubushi. 
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The sequence began with Diels-Alder reaction of racemic 146 with butadiene. Because the methyl 
substituent shielded the syn hemisphere of dienophile 146 effectively, compound 147 was obtained 
as single product, albeit in low yield. After protection of the carbonyl group via acetalization, 
hydroboration with disiamylborane provided the primary alcohol 150, which was protected as benzyl 
ether before the double bond was cleaved to provide dialdehyde 152. With this intermediate in 
hands an interesting one-pot protocol was applied to furnish cyano diene 155. At first, aldol 
condensation with morpholine and camphoric acid led to an α,β-unsaturated aldehyde. Without 
isolation this intermediate was treated with 154 to yield compound 155. After reduction of the less 
substituted double bond with Wilkinson’s catalyst, treatment with LiAlH4 and BOC azide afforded 
BOC-protected amine 156. Macrocyclization was accomplished in a five step sequence including 
cleavage of the benzyl protecting group, subsequent oxidation with Jones’ reagent, activation of the 
resulting carboxylic acid and finally intramolecular N-alkylation. After reduction of amide 158 the 
corresponding amino alcohol was treated with trifluoroacetic acid anhydride to protect the amine 
functionality. During the last step also esterification of the alcohol was observed, so it was treated 
with base to get the free alcohol again, which was oxidized with Jones’ reagent to provide keto 
compound 159. Unselective epoxidation of the double bond led to two diastereomers in a ratio of 
nearly one to one. Unfortunately, only transformation of epoxide 160 resulted in formation of an 
allylic alcohol, which was oxidized to get the α,β-unsaturated keto compound 162 in the next step. 
Finally stereoselective hydrogenation and deprotection furnished racemic fawcettimine (128). 
 
Inubushi and coworkers accomplished the first total synthesis of fawcettimine in 24 steps starting 
from literature known 146. Unfortunately, the yield of several steps was only moderate, so in 
summary the overall yield of this approach was below 1 %. Interestingly, the unselective epoxidation 
of 159 had also a positive side effect, because the side product 161 could be used to synthesize 8-
deoxyserratinine (163), which is another Lycopodium alkaloid (see Scheme 34).49 
 
 
Scheme 34: Conversion of epoxide 161 to 8-deoxyserratinine. 
 
Under basic conditions the protecting group was cleaved and an intramolecular opening of the 
epoxide induced. Oxidation of the alcohol and selective reduction of one carbonyl group eventually 
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delivered 8-deoxyserratinine (163). Noteworthy, this approach provided the first synthesis of 
8-deoxyserratinine as well. 
 
4.3.2 Total Synthesis of (+/-)-Fawcettimine by Heathcock 
 
Several years later, also the group of Heathcock accomplished a straight forward synthesis of 
fawcettimine (see Scheme 35).43,50 
 
 
Scheme 35: Total synthesis of fawcettimine by Heathcock. 
 
The synthesis began with a Sakurai reaction of cyano enone 164 with allylsilane 165. After oxidation 
of the resulting alcohol, Wittig olefination afforded unsaturated ester 168, which was immediately 
treated with base to generate the five-membered ring in a one-pot operation. Sidechain-elongation 
was implemented in form of saponification of ester 169 and subsequent Arndt-Eistert homologation 
to provide cyano ester 170. Threefold reduction and selective twofold tosylation of the resulting 
amino diol afforded ditosylate 171, which was treated with base to generate the nine-membered 
macrocycle of 172. After cleavage of the tosyl group and oxidation under acidic conditions, 
ozonolysis of the resulting amine 173 and epimerization under basic conditions finally provided 
racemic fawcettimine in a remarkably short sequence of 13 steps and an overall yield of 17 %. 
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In summary Heathcock and coworkers devised a very practical and high yielding strategy to provide 
fawcettimine. Although it was not the first total synthesis, this approach is one of the most significant 
synthetic contributions in this field by now. Worth mentioning, this group was also the first to apply 
the diastereoselective 1,4-addition to substituted α,β-unsaturated cyclohexenones.55 In stark 
contrast to thermodynamics, cuprate or allylsilane addition afforded in most cases nearly exclusively 
the less stable product 177, whereas the formation of the all equatorial product 178 was almost 
completely suppressed (see Scheme 36). 
 
 
Scheme 36: Selective 1,4-addition. 
 
This was rationalized by the unfavorable intermediate boat conformation 176, which would lead to 
the thermodynamically more stable all equatorial product 178. Because such transformations 
generally provide simple access to intermediates suitable for the synthesis of fawcettimine related 
Lycopodium alkaloids, similar strategies have been applied in various other approaches towards 
Lycopodium alkaloids (including the synthesis of lycoflexine developed during this PhD thesis). 
 
4.3.3 Total Synthesis of Fawcettidine by Dake 
 
In nature fawcettidine (179) is most probably derived by dehydration of fawcettimine. The first total 
synthesis of this interesting Lycopodium alkaloid was completed by Dake and Kozak in 2008.54 Dake’s 
approach started with epoxidation of commercially available pulegone (72) and subsequent 
treatment of the epoxide with thiophenol to afford acetone and the corresponding thiophenol ether, 
which was oxidized to provide sulfoxide 180. Deprotonation and 1,4-addition to methyl acrylate, 
followed by heat induced elimination of the sulfoxide, delivered cyclohexenone 181. In the next step 
regioselective cuprate addition and subsequent cleavage of the TMS group furnished alkyne 183. 
After amide formation with fragment 184, platinum dichloride catalyzed cyclization afforded the 
desired tricylic amide 186 in the first key step of this sequence. Allylic oxidation of 186 led to the 
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α,β-unsaturated keto compound 187, which was used as Michael acceptor in the following 
macrocyclization. After protection of the carbonyl group, oxidation furnished sulfone 189. Ramberg-
Bäcklund reaction of this substrate provided compound 190, which was converted into fawcettidine 
(179) in a three step sequence including hydrogenation reduction and removal of the protecting 
group. A detailed overview of the synthesis of fawcettidine is presented in Scheme 37. 
 
 
Scheme 37: First total synthesis of fawcettidine by Dake. 
 
In conclusion, Dake and Kozak developed a very elegant synthetic strategy that applies modern 
methodology to approach a long known class of substances. Contrary to most of the other 
Lycopodium syntheses a remarkable thio-Michael/Ramberg-Bäcklund sequence was used instead of 
N-alkylation to provide the seven-membered ring of fawcettidine. Although the overall yield with 
about 1 % is only moderate, the number of steps starting from inexpensive pulegone is reasonable 
(16 steps).  
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4.3.4 Total Synthesis of Lycoflexine by Yang 
 
One year after the completion of the first total synthesis of lycoflexine by our group, Yang and 
coworkers published a different approach to the same molecule. A detailed overview of the synthesis 
can be seen in Scheme 38.48 
 
 
Scheme 38: Total synthesis of lycoflexine by Yang. 
 
As starting material Yang and coworkers chose 146, which had already been used by the group of 
Heathcock in their synthesis of fawcettimine.43,50 Regioselective cuprate addition and subsequent 
treatment of the resulting enolate provided silyl enol ether 192. By means of an intramolecular aldol 
reaction this substrate led to the formation of an alcohol that was further oxidized to yield diketo 
compound 193. After selective protection of one carbonyl group, Grignard addition and subsequent 
dehydration furnished diene 196. With this compound in hands, hydroboration of both double bonds 
and Appel reaction of the resulting hydroxy groups provided diiodide 197. Treatment of this 
compound with tosylamide led to macrocyclization. Subsequent removal of the tosyl group was 
followed by protection of the resulting amine as carbamate and cleavage of the acetal furnished 
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compound 199. Probably to avoid an endgame that has been used by other groups, a rather lengthy 
four step sequence including dihydroxylation of the double bond, oxidation of the secondary alcohol 
and removal of the redundant alcohol by samarium diiodide was used to furnish fawcettimine (128). 
Finally fawcettimine was transformed into lycoflexine (4) in a way very similar to the final step of our 
synthesis and in agreement with the already discussed biosynthetic proposal by Ayer and 
coworkers.8,47 
 
The strategy applied by Yang and coworkers has some similarities to known synthetic strategies 
towards Lycopodium alkaloids. Although mostly based on well known and long established 
methodologies, this approach appears robust and avoids pricey reagents to a great extent. A 
sequence of 16 steps was needed to provide lycoflexine from literature known compound 146 with 
7 % overall yield. 
 
4.4 First Total Synthesis of Lycoflexine 
4.4.1 Introduction 
 
In 2010 the first total synthesis of lycoflexine developed during this PhD thesis was completed. This 
approach was focused on the step count and originality of the individual steps (see Scheme 39). 
 
 
Scheme 39: First total synthesis of lycoflexine. 
 
A highly concise sequence of five steps (discussed in more detail in the following publication) 
furnished key intermediate 201. In the subsequent tandem catalyzed reaction, which combines an 
ene-yne-ene RCM and a selective hydrogenation, the latter compound was transformed into tricyclic 
carbamate 207 in a single step. As the following communication does not include an elaborate 
discussion of the keystep, an illustrative overview is given in Scheme 40. The first catalytic cycle starts 
with selective activation of the less substituted double bond of substrate 201 by Grubbs’ second 
generation catalyst (202). For kinetic reasons the subsequent ene-yne reaction with the triple bond is 
much faster than the corresponding reaction with the second double bond, therefore intermediate 
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204 is formed exclusively.56 Because the subsequent intramolecular metathesis reaction is preferred 
over cross metathesis of carbene 204 with starting material 201, also the macrocycle of diene 205 is 
closed and the catalytic species regenerated. After complete conversion of precursor 201 into 
substrate 205 the argon atmosphere has to be exchanged for dihydrogen. This results in the 
formation of a new catalytic species (LyRuH2), which is a selective hydrogenation catalyst.
57 
Consequently the catalyst binds to the less substituted double bond to form complex 206, which 
finally is hydrogenated to form the desired product 207. 
 
 
Scheme 40: Keystep of the synthesis of lycoflexine. 
 
With this compound in hands, just two steps were missing to complete the synthesis of lycoflexine. 
 
For a more extensive description of the individual steps, specific reaction conditions and 
experimental details see the following communication. 
 
4.4.2 Synthesis of the Lycopodium Alkaloid (+)-Lycoflexine 
 
Ramharter, J.; Weinstabl, H.; Mulzer J. J. Am. Chem. Soc. 2010, 132, 14338 
 
The supporting information of this communication includes experimental and analytical data of all 
discussed compounds. This data can be found in chapter 5.3.  
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Abstract: The first total synthesis of (+)-lycoflexine (1), a con-
stituent of Lycopodium clavatum var. inflexum, has been ac-
complished in eight steps with 13% overall yield. Our synthesis
covers four one-pot reactions, including a tandem Sakurai/aldol
sequence, a novel hydroboration/oxidation procedure, a depro-
tection/transannular Mannich reaction, and as a highlight, a
tandem catalysis cascade combining an enynene ring-closing
metathesis and a selective hydrogenation.
Lycopodium alkaloids1 are a huge family of diverse but structur-
ally related compounds (see Figure 1 for some examples) with
impressive and challenging structures and interesting biological
activities, such as acetylcholinesterase inhibition [e.g., huperzine
A (2),2 lycojapodine A (3),3 or sieboldine A4].
Lycoflexine (1) (also known as lycobergine) belongs to the class
of fawcettimine-related alkaloids and was isolated by Ayer et al.5
in the early 1970s by extraction of Lycopodium claVatum var.
inflexum collected in the Eastern Transvaal (Republic of South
Africa). Its structure consists of an exceptional tetracyclic
carbon-nitrogen skeleton including a spiro-annulated six-membered
ring and four stereogenic centers, of which two are adjacent
quaternary carbons. Despite the interesting, complex molecular
architecture of lycoflexine, no total synthesis has been reported to
date.
Our retrosynthetic analysis of lycoflexine (1) is outlined in
Scheme 1. The final step of our synthesis refers to the biosynthetic
proposal of Ayer et al.5 As a suitable substrate for such a
conversion, we identified the tricyclic diketo compound 4, which
can be generated from substrate 5.6 The latter compound can be
accessed via an enynene ring-closing metathesis (RCM) reaction
of precursor 6, which is easily obtained from diketone 7 derived
from the well-known optically active enone 9.7
As is depicted in Scheme 2, the synthesis of key intermediate 6
started with a tandem Sakurai/aldol sequence that converted enone
9 into alcohol 10 as an inconsequential diastereomeric mixture.8
After mild oxidation with IBX,9 the resulting diketo compound 7
was alkylated with iodocarbamate 810 to provide compound 11 with
satisfying yield. After some optimization, triflation of the less-
hindered carbonyl moiety was achieved with Comins’ reagent.11
Treatment of the resulting vinyl triflate 12 with pyridine at elevated
temperature finally yielded dienyne 6.12
In our first attempts, the envisaged enynene RCM was carried
out under standard conditions with Grubbs’ second-generation
catalyst.13 Although the formation of the desired tricyclic diene 13
was observed, the yield was only slightly higher than 30%. As no
other byproducts could be isolated, we rationalized that the diene
is probably of moderate stability and prone to decomposition. On
the basis of Grubbs’ findings that metathesis catalysts can be
converted into active hydrogenation catalysts by treatment with
dihydrogen,14,15 we decided instead to attempt a tandem catalysis
sequence and selectively hydrogenate the less-substituted double
bond in situ. Gratifyingly, the desired tricyclic carbamate 5 was
formed in 52% yield from 6 (Scheme 3).
To complete our synthesis, only two steps were missing. Direct
oxidation of organoboranes to the corresponding ketones is known,
Figure 1. Selected Lycopodium alkaloids.
Scheme 1. Retrosynthetic Analysis
Scheme 2. Synthesis of Precursor 6a
a Conditions: (a) (i) TiCl4, allyltrimethylsilane, DCM, -78 °C; (ii)
acetaldehyde, 70%. (b) IBX, EtOAc, reflux. (c) Cs2CO3, 8, DMF, -15 °C,
68% (two steps). (d) Comins’ reagent, KHMDS, THF, -78 °C, 85%. (e)
Pyridine, 60 °C, 99%.
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though mostly based on rather aggressive and toxic chromium
reagents.16 We thus developed a novel protocol that allowed us to
oxidize the organoborane in situ with IBX to obtain an inconse-
quential diastereomeric mixture of diketo compounds 4. It is
noteworthy that both diastereomers also can be used to synthesize
fawcettimine (16), another prominent member of the Lycopodium
alkaloid family.17 Our total synthesis of lycoflexine was concluded
by a final tandem reaction. The N-Boc protecting group was
removed using dilute aqueous HCl, and by analogy to the
biomimetic conversion of fawcettimine to lycoflexine, excess
formaldehyde was used to generate an iminium species, which
smoothly underwent a transannular Mannich reaction to furnish (+)-
lycoflexine (1).18,19
The identity of our compound with authentic lycoflexine was
established by comparison with the spectroscopic data (1H and 13C
NMR as well as CD) kindly provided by Professor Takayama, who
had reisolated and characterized the compound.20 In this way, the
absolute configuration of 1 also was confirmed by total synthesis.
In conclusion, we have achieved the first total synthesis of (+)-
lycoflexine. The extensive use of tandem and one-pot reactions
(Sakurai/aldol, enynene RCM/hydrogenation tandem catalysis,
hydroboration/oxidation, N-Boc deprotection/transannular Mannich
cyclization) makes the sequence remarkably concise and efficient
(eight steps from 9 with an overall yield of 13%). It is flexible and
therefore should be suitable for the synthesis of several other
Lycopodium alkaloids as well.
Acknowledgment. We are very grateful to Professor Hiromitsu
Takayama of Chiba University for providing us spectroscopic data
for authentic lycoflexine. We thank S. Felsinger, L. Brecker, and
H. P. Ka¨hlig for NMR analysis, R. Konrat and G. Platzer for CD
spectra, and R. Schuecker for technical support, all at the University
of Vienna.
Supporting Information Available: Experimental procedures and
analytical data for all new compounds. This material is available free
of charge via the Internet at http://pubs.acs.org.
References
(1) For reviews of Lycopodium alkaloids, see: (a) Ayer, W. A.; Trifonov, L. S.
In The Alkaloids; Cordell, G. A., Brossi, A., Eds.; Academic Press: New
York, 1994; Vol. 45, pp 233-266. (b) Hirasawa, Y.; Kobayashi, J.; Morita,
H. Heterocycles 2009, 77, 679. (c) Ma, X.; Gang, D. R. Nat. Prod. Rep.
2004, 21, 752.
(2) Liu, J.-S.; Zhu, Y.-L.; Yu, C.-M.; Zhou, Y.-Z.; Han, Y.-Y.; Wu, F.-W.;
Qi, B.-F. Can. J. Chem. 1986, 64, 837.
(3) He, J.; Chen, X.-Q.; Li, M.-M.; Zhao, Y.; Xu, G.; Cheng, X.; Peng, L.-Y.;
Xie, M.-J.; Zheng, Y.-T.; Wang, Y.-P.; Zhao, Q.-S. Org. Lett. 2009, 11,
1397.
(4) (a) Hirasawa, Y.; Morita, H.; Shiro, M.; Kobayashi, J. Org. Lett. 2003, 5,
3991. For a recently published total synthesis of sieboldine A, see: (b)
Canham, S. M.; France, D. J.; Overman, L. E. J. Am. Chem. Soc. 2010,
132, 7876.
(5) Ayer, W. A.; Fukazawa, Y.; Singer, P. P. Tetrahedron Lett. 1973, 14, 5045.
(6) Compound 5 has been synthesized by the Toste group via a totally different
route. See: Linghu, X.; Kennedy-Smith, J. J.; Toste, F. D. Angew. Chem.,
Int. Ed. 2007, 46, 7671.
(7) (a) Carlone, A.; Marigo, M.; North, C.; Landa, A.; Jørgensen, K. A. Chem.
Commun. 2006, 4928. (b) Carpenter, R. D.; Fettinger, J. C.; Lam, K. S.;
Kurth, M. J. Angew. Chem., Int. Ed. 2008, 47, 6407. (c) Caine, D.; Procter,
K.; Cassell, R. A. J. Org. Chem. 1984, 49, 2647.
(8) Hosomi, A.; Hashimoto, H.; Kobayashi, H.; Sakurai, H. Chem. Lett. 1979,
245.
(9) More, J. D.; Finney, N. S. Org. Lett. 2002, 4, 3001.
(10) Iodocarbamate 8 was prepared from N-Boc-protected allylamine in two
steps and 52% overall yield (see the Supporting Information for more
details).
(11) Comins, D. L.; Dehghani, A. Tetrahedron Lett. 1992, 33, 6299.
(12) Hargrove, R. J.; Stang, P. J. J. Org. Chem. 1974, 39, 581.
(13) Kim, S.-H.; Zuercher, W. J.; Bowden, N. B.; Grubbs, R. H. J. Org. Chem.
1996, 61, 1073.
(14) (a) Louie, J.; Bielawski, C. W.; Grubbs, R. H. J. Am. Chem. Soc. 2001,
123, 11312. For another example of RCM/hydrogenation tandem catalysis,
see: (b) Fu¨rstner, A.; Leitner, A. Angew. Chem., Int. Ed. 2003, 42, 308.
(15) Tandem catalysis in general has not found widespread application in
synthesis, despite the potential of such transformations. For a general review,
see: Wasilke, J.-C.; Obrey, S. J.; Baker, R. T.; Bazan, G. C. Chem. ReV.
2005, 105, 1001.
(16) (a) Brown, H. C.; Garg, C. P. J. Am. Chem. Soc. 1961, 83, 2951. (b) Brown,
H. C.; Kulkarni, S. U.; Rao, C. G. Synthesis 1980, 151.
(17) Heathcock, C. H.; Blumenkopf, T. A.; Smith, K. M. J. Org. Chem. 1989,
54, 1548.
(18) A similar reaction was applied by Ayer et al. in their isolation paper5 for
the conversion of fawcettimine to lycoflexine.
(19) For a review of the Mannich reaction, see: Arend, M.; Westermann, B.;
Risch, N. Angew. Chem., Int. Ed. 1998, 37, 1044.
(20) Takayama, H.; Katakawa, K.; Kitajima, M.; Yamaguchi, K.; Aimi, N.
Tetrahedron Lett. 2002, 43, 8307.
JA107533M
Scheme 3. Final Steps toward Lycoflexine (1)a
a Conditions: (a) (i) Grubbs’ second-generation (20 mol %), 1,2-
dichloroethane, reflux; (ii) H2, 10 atm, 70 °C, 52%. (b) (i) BH3 ·THF, THF,
50 °C; (ii) IBX, EtOAc, reflux. (c) HCHO(aq), 0.5 M HCl, EtOH, reflux,
64% (two steps).
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4.5 Total Syntheses of Fawcettimine and Fawcettidine 
 
To extend the scope of the synthetic strategy presented in chapter 4.4, also two other Lycopodium 
alkaloids were synthesized. As those results have not been published yet, a short summary is given in 
this chapter. 
 
During optimization of the last step of the synthesis not only lycoflexine was obtained, but also the 
formation of two other Lycopodium alkaloids was observed (see Scheme 41). 
 
 
Scheme 41: Three Lycopodium alkaloids from the same precursor. 
 
To achieve full conversion of carbamate 209 into lycoflexine (4), a prolonged reaction time of about 
48 hours was needed. However, when the reaction was quenched after 14 hours, a complex mixture 
was obtained. After careful purification and separation by column chromatography, three different 
Lycopodium alkaloids were isolated. 1H-NMR spectra of the crude material and the individual 
Lycopodium alkaloids are depicted in Scheme 42. 
 
 
Scheme 42: 
1
H-NMR reveals lycoflexine, fawcettimine and fawcettidine. 
5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
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As expected, one of them was lycoflexine, but also fawcettimine and small amounts of fawcettidine 
were obtained. A mechanistic rationalization for the formation of the latter two compounds is 
depicted in Scheme 43. 
 
 
Scheme 43: Mechanistic considerations about the formation of lycoflexine. 
 
Obviously, acid induced cleavage of the BOC-group provides a diastereomeric mixture of amines 210 
and 129. As Heathcock has already noticed, diastereomer 210 is thermodynamically less stable than 
the keto-amine form of fawcettimine 129.43 Consequently, intermediate 210 is rapidly epimerized 
under acidic conditions to provide the keto-amine form of fawcettimine (129). In the next step of this 
cascade the resulting natural product is either converted in a biomimetic Mannich reaction to deliver 
lycoflexine (4) or dehydrated to furnish fawcettidine (179). Noteworthy, also the dehydration of 
fawcettimine seems to be reversible, if an aqueous acid is used. Therefore, all intermediates are in 
equilibrium and only the final transannular Mannich reaction is irreversible. Consequently, a 
prolonged reaction time leads to the formation of lycoflexine (4) as sole product. 
 
 
Scheme 44: Synthesis of fawcettimine and fawcettidine. 
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Nonetheless, the temporary formation of two other natural products encouraged us to attempt the 
selective synthesis of fawcettimine (128) and fawcettidine (179) as well (see Scheme 44). To achieve 
the synthesis of both compounds TMSCl was added to a methanolic solution of carbamate 208. The 
in situ generated hydrochloric acid caused deprotection and epimerization to furnish fawcettimine 
(128) in good yield. Treatment of this natural product with sulfonic acid and removal of water 
eventually provided fawcettidine (179) as single product in a final biomimetic transformation. 
 
4.6 Summary 
 
In conclusion, we have accomplished the first total synthesis of (+)-lycoflexine in eight steps starting 
from literature known (R)-5-methyl-2-cyclohexenone with an overall yield of 13 %. Incorporation of 
several tandem and one-pot reactions has provided a highly concise and flexible general approach 
towards Lycopodium alkaloids, which has led to the total synthesis of two additional Lycopodium 
alkaloids (fawcettimine and fawcettidine). With eight and nine steps, respectively, we have 
developed by far the shortest approach towards fawcettimine related Lycopodium alkaloids up to 
date (see also Table 2). 
 
Table 2: Comparison of known total syntheses of lycoflexine, fawcettimine and fawcettidine. 
 year selectivity lycoflexine fawcettimine fawcettidine steps overall yield 
PhD thesis 2010 (+) x   8 13% 
Yang 2011 (+) x   16 7% 
Inubushi 1979 (+/-)  x  24 <1% 
Heathcock 1983 (+/-)  x  13 17% 
Toste 2007 (+)  x  13 15% 
Mukai 2010 (+)  x  27 1% 
Yang 2011 (+)  x  15 7% 
Lei 2011 (+)  x  12 6% 
PhD thesis 2011 (+)  x  8 13% 
Dake 2008 (+)   x 16 1% 
Lei 2011 (+)   x 12 11% 
PhD thesis 2011 (+)   x 9 10% 
 
Besides the advantageous number of steps, the synthetic strategy developed during this PhD thesis 
also ranges among the highest yielding syntheses of these three Lycopodium alkaloids. Remarkably, 
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Heathcock’s total synthesis of fawcettimine in 1983 is still ranking highest with respect to its overall 
yield of 17 %.  
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5 Supporting Information 
5.1 Total Synthesis of Valerenic Acid, SI 
 
1H-NMR and 13C-NMR spectra of all compounds discussed in chapter 2.6.2 (From Planning to 
Optimization: Total Synthesis of Valerenic Acid and some Bioactive Derivatives) are depicted in the 
following supporting information. 
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1. NMR Spectra 
 
(S)-tert-Butyl(hept-1-en-6-yn-3-yloxy)dimethylsilane (13) 
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(S)-tert-Butyl(oct-1-en-6-yn-3-yloxy)dimethylsilane (14) 
 
 
 
87 
 
(S)-tert-Butyldimethyl(3-(prop-1-en-2-yl)cyclopent-2-enyloxy)silane (15) 
 
 
 
88 
 
(S)-Hex-5-yne-1,2-diol (17) 
 
 
 
89 
 
(S)-1-Tosylhex-5-yne-1,2-diol (18): 
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(S)-3-(Prop-1-en-2-yl)cyclopent-2-enol (9) 
 
 
 
91 
 
3-(Prop-1-en-2-yl)cyclopent-2-enone (23) 
 
 
 
92 
 
(R)-3-(prop-1-en-2-yl)cyclopent-2-enyl acetate (24) 
 
 
 
93 
 
3-Vinylcyclopent-2-enol (27) 
 
 
 
94 
 
3-Vinylcyclohex-2-enol (29) 
 
 
 
95 
 
3-Vinylcyclohept-2-enol (31) 
 
 
 
96 
 
1-Methyl-3-vinylcyclopent-2-enol (33) 
 
 
 
97 
 
2-Methyl-3-vinylcyclopent-2-enol (35) 
 
 
 
98 
 
3-Phenylcyclohex-2-enol (37) 
 
 
 
99 
 
3-(Prop-1-en-2-yl)cyclopent-2-enyl acrylate (38) 
 
 
 
 
100 
 
(2aR,7aS,7bR)- 5-Methyl- 3,4,6,7,7a,7b-hexahydro-2aH-indeno[ 1,7-bc]furan-2-one (8a) 
 
 
 
101 
 
(1S,7R,7aR)-7-(hydroxymethyl)-4-methyl-2,3,5,6,7,7a-hexahydro-1H-inden-1-ol (40) 
 
 
 
 
102 
 
(1S,3aR,4R,7R,7aS)-7-(hydroxymethyl)-4-methyloctahydro-1H-inden-1-ol (41) 
 
 
 
103 
 
(3aS,4R,7R,7aR)- 7-methyl- 3-oxooctahydro- 1H-indene-4-carbaldehyde (42) 
 
 
 
104 
 
(E)-Ethyl-2-methyl-3-((3aR,4S,7R,7aR)-7-methyl-3-oxooctahydro-1H-inden-4-yl)-
acrylate (6b) 
 
 
 
105 
 
(E)-3-((3S,3aR,4S)-3-Hydroxy-7-methyl-2,3,3a,4,5,6-hexahydro-1H-inden-4-yl)-2-
methyl-acrylic acid ethyl ester (7) 
 
 
106 
 
(E)-3-((3S,3aS,4S,7R,7aR)-3-Hydroxy-7-methyl-octahydro-inden-4-yl)-2-methyl-acrylic 
acid ethyl ester (45) 
 
 
107 
 
(E)-2-Methyl-3-((3aS,4S,7R,7aR)-7-methyl-3-oxo-octahydro-inden-4-yl)-acrylic acid  
ethyl ester (6a) 
 
 
108 
 
Valerenic ethyl ester (46) 
 
 
 
109 
 
Valerenic acid (1) 
 
 
 
110 
 
Valerenic amide (47) 
 
 
 
111 
 
Valerenic N-methylamide (48) 
 
 
 
112 
 
Valerenic N-ethylamide (49) 
 
 
 
113 
 
Valerenic N,N-diethylamide (50) 
 
 
 
114 
 
Valerenic piperidine amide (51) 
 
 
 
115 
 
Valerenic morpholine amide (52) 
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5.2 [1,3]-Isomerization of Allylic Alcohols, SI 
 
Experimental procedures and analytical data of all compounds discussed in chapter 3.2.2 (Efficient 
and Scalable One-Pot Synthesis of 2,4-Dienols from Cycloalkenones; Optimized Total Synthesis of 
Valerenic Acid) can be found in the following supporting information. 
 
 
 
  
117 
 
 
Efficient and Scalable One-Pot Synthesis of  
2,4-Dienols from Cycloalkenones; 
Optimized Total Synthesis of Valerenic Acid 
 
Supporting Information 
 
Juergen Ramharter, Johann Mulzer* 
 
Institute of Organic Chemistry, University of Vienna 
Währinger Strasse 38 
1090 Vienna 
Austria 
 
E-mail: johann.mulzer@univie.ac.at 
 
 
 
 
 
Table of Contents: 
 
1. Procedures         S2 
1.1. General Information       S2 
1.2. Experimental Procedures      S3 
2. NMR Spectra         S14 
118 
 
1. Procedures 
 
1.1 General Information: 
 
All reactions were carried out in oven-dried glassware under an argon atmosphere unless 
stated otherwise. Diisopropylethylamine was distilled under Argon from CaH2, anhydrous 
diethyl ether (99.9%) and anhydrous Methyl-tert-butyl ether (MTBE, 99.8%) were purchased 
from Aldrich. All other solvents were HPLC grade. Commercially available reagents were 
used without further purification. Racemic 6-methylcyclohex-2-enone and racemic  
5-methylcyclohex-2-enone were prepared according to literature known procedures.
1,2
 
Reactions were magnetically stirred and monitored by thin layer chromatography with E. 
Merck silica gel 60 F254 plates. Flash column chromatography was performed with Merck 
silica gel (0.04-0.063 mm, 240-400 mesh) under pressure besides stated otherwise. Yields 
refer to chromatographically and spectroscopically pure compounds unless stated otherwise. 
1
H NMR (400 MHz or 600 MHz) and 
13
C NMR (100 MHz or 150 MHz) spectra were either 
recorded on Bruker Avance 400, DRX 400, or DRX 600 spectrometers at 400.13 MHz 
(100.61 MHz) or 600.13 MHz (150.90 MHz). All NMR spectra were measured in CDCl3 
solutions. The chemical shifts δ are reported relative to the residual solvent peaks (1H, δCDCl3 
= 7.26 ppm; 
13C, δCDCl3 = 77.16 ppm). All 
1
H and 
13
C shifts are given in ppm (s = singulet; d 
= doublet; t = triplet; q = quadruplet; m = multiplet; bs = broad signal). If possible, 
assignments of proton resonances were confirmed by correlated spectroscopy. Optical 
rotations were measured at 20°C on a P 341 Perkin-Elmer polarimeter at 589 nm. IR spectra 
were recorded of samples prepared as films on silicium plates on a Perkin-Elmer Spectrum 
2000 Series FTIR spectrometer. High resolution mass spectra (HRMS) were measured on a 
Finnigan MAT 8230 apparatus with a resolution of 10000. 
                                                          
1  For preparation of racemic 6-methylcyclohex-2-enone, see: F. A. Marques; Lenz, C. A.; Simonelli, F.; Noronha Sales 
Maia, B. H. L.; Vellasco, A. P.; Eberlin, M. N. J. Nat. Prod. 2004, 67, 1939 
2  For preparation of racemic 5-methylcyclohex-2-enone see: Chong, B.-D.; Ji, Y.-I.; Oh, S.-S.; Yang, J.-D.; Baik, W.;  
Koo, S. J. Org. Chem. 1997, 62, 9323 
119 
 
1.2 Experimental Procedures 
 
General Procedure (method A) 
 
A solution of cycloalkenone (1.0 eq) and anhydrous diethyl ether (0.1 M) was cooled to 0 °C 
and treated with 1.0 M vinylmagnesium bromide (2.0 eq). After TLC indicated full 
conversion (usually 1 hour) water (0.1 M) and trifluoroacetic or acetic acid (2.5 eq) were 
added. The biphasic solution was vigorously stirred at 0 °C or ambient temperature until full 
conversion was observed by TLC. Then saturated aqueous NaHCO3 was added and the 
organic layer separated. The aqueous layer was extracted with dichloromethane (3x) and the 
combined organic extracts were washed with brine, dried (Na2SO4) and concentrated in 
vacuo. Purification of the residue by chromatography provided the corresponding 2,4-dienol. 
 
General Procedure (method B) 
 
tert-Butyllithium (3.9 eq) was slowly added to solution of 2-bromopropene (2.0 eq) and 
anhydrous diethyl ether (1.0 M) precooled to -78 °C. The resulting slightly turbid solution 
was stirred for 2 hours at the same temperature before it was warmed to ambient temperature. 
After 15 minutes the clear yellow solution was transferred via canula to a solution of 
cycloalkenone (1.0 eq) and anhydrous diethyl ether (0.1 M) precooled to -78 °C. After TLC 
indicated full conversion (usually 1 hour) the resulting turbid mixture was warmed to 0°C 
before water (0.1 M) and trifluoroacetic or acetic acid (2.5 eq) were added. The vigorously 
stirred biphasic solution was stirred at the same temperature until full conversion was 
observed by TLC. Saturated aqueous NaHCO3 was added and the organic layer separated. 
The aqueous layer was extracted with dichloromethane (3x) and the combined organic 
extracts were washed with brine, dried (Na2SO4) and concentrated in vacuo. Purification of 
the residue by chromatography provided the corresponding 2,4-dienol. 
 
 
3-Vinylcyclopent-2-enol (3a)
3
 
 
 
 
According to “method A” reaction of 2-cyclopentenone (98%, 50 µL, 0.5849 mmol, 1.0 eq) 
with 1.0 M vinylmagnesium bromide (1.16 mL, 1.16 mmol, 2.0 eq) in anhydrous diethyl ether 
(5.9 mL) and subsequent treatment with water (5.9 mL) and trifluoroacetic acid (113 µL, 
1.4668 mmol, 2.5 eq) for 1.0 hours at 0 °C provides 50.6 mg of 3-vinylcyclopent-2-enol as 
slightly yellow oil with 78% yield (column chromatography H/EE = 5/1). (Attention: Dienol 
3a should be stored below 0°C.) 
                                                          
3 In agreement with: Fisher, M. J.; Hehre, W. J.; Kahn, S. D.; Overmann, L. E. J. Am. Chem. Soc. 1988, 110, 4625. 
120 
 
1
H-NMR (400MHz, CDCl3): 6.58 (dd, J=17.5 Hz, 10.6 Hz, 1H), 5.79-5.75 (m, 1H), 5.27-5.15 
(m, 2H), 4.94-4.85 (bs, 1H), 2.70-2.57 (m, 1H), 2.42-2.30 (m, 2H), 1.83-1.72 (m, 1H), 1.43 
(d, J=5.6 Hz, 1H). 
13
C-NMR (100MHz, CDCl3, ppm): 146.1, 133.3, 132.1, 117.0, 77.6, 33.7, 29.2. 
IR (film, cm
-1
): 3297, 2922, 2853, 2359, 1591, 1455, 1416, 1319, 1275, 1264, 1158, 1042, 
986, 968, 905, 750. 
HRMS (EI, m/z): [M]
+
 calc.: 110.0732; found: 110.0728. 
 
 
3-Vinylcyclopent-2-enol (3a) (large scale) 
 
 
 
According to “method A” reaction of 2-cyclopentenone (98%, 0.6 mL, 7.019 mmol, 1.0 eq) 
with 1.0 M vinylmagnesium bromide (14.0 mL, 14.0 mmol, 2.0 eq) in anhydrous diethyl ether 
(70 mL) and subsequent treatment with water (70 mL) and trifluoroacetic acid (1.35 mL, 
17.52 mmol, 2.5 eq) for 1.5 hours at 0 °C provides 562 mg of 3-vinylcyclopent-2-enol as 
slightly yellow oil with 73% yield (column chromatography H/EE = 5/1). (Attention: Dienol 
3a should be stored below 0°C.) 
For analytical data, see above. 
 
 
3-Vinylcyclohex-2-enol (5)
4
 
 
 
 
According to “method A” reaction of 2-cyclohexenone (95%, 20 µL, 0.1957 mmol, 1.0 eq) 
with 1.0 M vinylmagnesium bromide (0.40 mL, 0.40 mmol, 2.0 eq) in anhydrous diethyl ether 
(2.0 mL) and subsequent treatment with water (2.0 mL) and trifluoroacetic acid (38 µL, 
0.4932 mmol, 2.5 eq) for 1.5 hours at 0 °C provides 19.2 mg of 3-vinylcyclohex-2-enol as 
colorless oil with 79% yield (column chromatography H/EE = 5/1). 
1
H-NMR (400MHz, CDCl3): 6.35 (dd, J=17.5 Hz, J=10.8 Hz, 1H), 5.80-5.74 (m, 1H), 5.21 (d, 
J=17.5 Hz, 1H), 5.05 (d, J=10.8 Hz, 1H), 4.35-4.26 (m, 1H), 2.24-2.04 (m, 2H), 1.97-1.76 (m, 
2H), 1.69-1.54 (m, 2H), 1.53-1.42 (bs, 1H). 
13
C-NMR (100MHz, CDCl3, ppm): 139.4, 138.9, 130.9, 113.1, 66.4, 32.3, 23.9, 19.0. 
IR (film, cm
-1
): 3389, 2934, 2869, 1714, 1666, 1453, 1427, 1258, 1189, 1056, 995, 966, 912, 
749. 
HRMS (EI, m/z): [M]
+
 calc.: 124.0888; found: 124.0884. 
                                                          
4 In agreement with: Datta, S. C.; Franck, R. W.; Tripathy, R.; Quigley, G. J.; Huang, L.; Chen, S.; Sihaed, A. J. Am. Chem. 
Soc. 1990, 112, 8472. 
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3-Vinylcyclohept-2-enol (7) 
 
 
 
According to “method A” reaction of 2-cycloheptenone (50 µL, 0.4484 mmol, 1.0 eq) with 
1.0 M vinylmagnesium bromide (0.90 mL, 0.90 mmol, 2.0 eq) in anhydrous diethyl ether  
(4.5 mL) and subsequent treatment with water (4.5 mL) and trifluoroacetic acid (87 µL, 
1.1293 mmol, 2.5 eq) for 1.5 hours at ambient temperature provides 49.7 mg of 3-
vinylcyclohept-2-enol as colorless oil with 80% yield (column chromatography H/EE = 5/1). 
1
H-NMR (400MHz, CDCl3): 6.30 (dd, J=17.4 Hz, J=10.7 Hz, 1H), 5.81-5.75 (m, 1H), 5.15 (d, 
J=5.15 Hz, 1H), 4.98 (dd, J=10.7 Hz, J=0.58 Hz, 1H), 4.56-4.47 (m, 1H), 2.54-2.43 (m, 1H), 
2.10-2.00 (m, 1H), 2.00-1.89 (m, 1H), 1.89-1.79 (m, 1H), 1.77-1.59 (m, 4H), 1.32-1.22 (m, 
1H). 
13
C-NMR (100MHz, CDCl3, ppm): 140.2, 140.0, 139.3, 111.3, 71.8, 36.6, 27.8, 26.5, 25.7. 
IR (film, cm
-1
): 3343, 2928, 2853, 1605, 1450, 1351, 1276, 1028, 989, 891, 839. 
HRMS (EI, m/z): [M]
+
 calc.: 138.1045; found: 138.1047. 
 
 
3-Isopropenylcyclopent-2-enol (8)
5
 
 
 
 
According to “method B” reaction of 2-cyclopentenone (98%, 25 µL, 0.2924 mmol, 1.0 eq) 
with 2-propenyllithium, prepared from 2-bromopropene (52 µL, 0.5846 mmol, 2.0 eq) and 
tert-butyllithium (1.6 M, 0.71 mL, 1.136 mmol, 3.9 eq), in anhydrous diethyl ether (3.0 mL) 
and subsequent treatment with water (3.0 mL) and trifluoroacetic acid (58 µL, 0.7529 mmol, 
2.5 eq) for 1 hour at 0 °C provides 29.5 mg of 3-isopropenylcyclopent-2-enol as colorless oil 
with 81% yield (column chromatography H/EE = 5/1 to 3/1). (Attention: Dienol 8 should be 
stored below 0°C.) 
1
H-NMR (400MHz, CDCl3): 5.83-5.78 (m, 1H), 5.02 (s, 2H), 4.97-4.88 (m, 1H), 2.74-2.64 
(m, 1H), 2.46-2.32 (m, 2H), 1.94 (s, 3H), 1.80-1.73 (m, 1H), 1.48-1.41 (bs, 1H). 
13
C-NMR (100MHz, CDCl3, ppm): 147.7, 139.8, 129.0, 114.9, 78.1, 34.1, 30.6, 20.7. 
IR (film, cm
-1
): 3324, 2924, 2854, 1599, 1458, 1032, 970, 888. 
HRMS (EI, m/z): [M]
+
 calc.: 124.0888; found: 124.0884. 
 
 
  
                                                          
5 In agreement with: Ramharter, J.; Mulzer, J. Org. Lett. 2009, 11, 1151. 
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3-Isopropenylcyclopent-2-enol (8) (large scale) 
 
 
 
According to “method B” reaction of 2-cyclopentenone (98%, 1.5 mL, 17.55 mmol, 1.0 eq) 
with 2-propenyllithium, prepared from 2-bromopropene (3.1 mL, 34.85 mmol, 2.0 eq) and 
tert-butyllithium (1.9 M, 36.0 mL, 68.4 mmol, 3.9 eq), in anhydrous diethyl ether (175 mL) 
and subsequent treatment with water (175 mL) and trifluoroacetic acid (3.4 mL, 44.13 mmol, 
2.5 eq) for 1 hour at 0 °C provides 1.57 g of 3-isoprpenylcyclopent-2-enol as colorless oil 
with 72% yield (column chromatography H/EE = 5/1 to 3/1). (Attention: Dienol 8 should be 
stored below 0°C.) 
For analytical data, see above. 
 
 
2-Methyl-3-vinylcyclopent-2-enol (10)
6
 
 
 
 
According to “method A” reaction of 2-methyl-2-cyclopentenone (98%, 50 µL, 0.4990 mmol, 
1.0 eq) with 1.0 M vinylmagnesium bromide (1.02 mL, 1.02 mmol, 2.0 eq) in anhydrous 
diethyl ether (5.0 mL) and subsequent treatment with water (5.0 mL) and trifluoroacetic acid 
(98 µL, 1.2721 mmol, 2.5 eq) for 0.75 hours at 0 °C provides 49.8 mg of 2-methyl-3-
vinylcyclopent-2-enol as colorless oil with 79% yield (column chromatography H/EE = 5/1). 
(Attention: Dienol 10 should be stored below 0°C.) 
1
H-NMR (400MHz, CDCl3): 6.65 (dd, J=17.2 Hz, J=10.8 Hz, 1H), 5.21-5.13 (m, 2H), 4.71-
4.60 (m, 1H), 2.65-2.53 (m, 1H), 2.38-2.26 (m, 2H), 1.83 (s, 3H), 1.71-1.62 (m, 1H), 1.45 (d, 
J=4.7 Hz, 1H). 
13
C-NMR (100MHz, CDCl3, ppm): 138.9, 136.7, 131.3, 115.4, 81.6, 32.5, 29.4, 11.3. 
IR (film, cm
-1
): 3345, 2960, 2936, 2912, 2854, 1443, 1421, 1276, 1261, 1198, 1049, 1005, 
986, 900, 750. 
HRMS (APCI, m/z): [M-H2O+H]
+
 calc.: 107.0855; found: 107.0850. 
 
 
1-Methyl-3-vinylcyclopent-2-enol (12) 
 
 
 
According to “method A” reaction of 3-methyl-2-cyclopentenone (97%, 60 µL, 0.5879 mmol, 
1.0 eq) with 1.0 M vinylmagnesium bromide (1.10 mL, 1.10 mmol, 2.0 eq) in anhydrous 
                                                          
6 In agreement with: Kita, Y.; Furukawa, A.; Futamura, J.; Ueda, K.; Sawama, Y.; Hamamoto, H.; Fujioka, H. J. Org. Chem. 
2001, 66, 8779. 
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diethyl ether (6.0 mL) and subsequent treatment with water (6.0 mL) and acetic acid (85 µL, 
1.4863 mmol, 2.5 eq) for 0.75 hours at 0 °C provides 72.3 mg of 1-methyl-3-vinylcyclopent-
2-enol as slightly colorless oil with 99% yield (purification by column chromatography was 
not necessary, see spectra). (Attention: Dienol 12 should be stored below 0°C.) 
1
H-NMR (400MHz, CDCl3): 6.53 (dd, J=17.5 Hz, J=10.6 Hz, 1H), 5.67-5.64 (m, 1H), 5.21 
(dd, J=17.5 Hz, J=0.9 Hz, 1H), 5.16 (dd, J=10.6 Hz, J=1.3 Hz, 1H), 2.66-2.57 (m, 1H), 2.47-
2.37 (m, 1H), 2.13-1.95 (m, 2H), 1.55-1.48 (bs, 1H), 1.40 (s, 3H). 
13
C-NMR (100MHz, CDCl3, ppm): 143.8, 136.5, 133.4, 116.5, 83.3, 40.0, 29.3, 27.6. 
IR (film, cm
-1
): 3338, 2965, 2929, 2852, 1593, 1450, 1367, 1287, 1236, 1178, 1107, 1081, 
986, 904, 852. 
HRMS (EI, m/z): [M-CH3]
+
 calc.: 109.0653; found: 109.0651. 
 
 
3-Isopropenyl-1-methylcyclopent-2-enol (13) 
 
 
 
According to “method B” reaction of 3-methyl-2-cyclopentenone (0.57 mL, 5.585 mmol,  
1.0 eq) with 2-propenyl lithium, prepared from 2-bromopropene (1.0 mL, 11.24 mmol, 2.0 eq) 
and tert-butyllithium (1.9 M, 11.5 mL, 21.85 mmol, 3.9 eq), in anhydrous diethyl ether  
(56 mL) and subsequent treatment with water (56 mL) and acetic acid (0.8 mL, 13.99 mmol, 
2.5 eq) for 1 hour at 0 °C provides 599.5 mg of 3-isopropenyl-1-methylcyclopent-2-enol as 
slightly yellow oil with 78% yield (column chromatography H/EE = 5/1). (Attention: Dienol 8 
should be stored below 0°C.) 
1
H-NMR (400MHz, CDCl3): 5.68 (s, 1H), 5.02-4.97 (m, 2H), 2.71-2.61 (m, 1H), 2.51-2.41 
(m, 1H), 2.12-1.95 (m, 2H), 1.92 (s, 3H), 1.56-1.52 (bs, 1H), 1.41 (s, 3H). 
13
C-NMR (100MHz, CDCl3, ppm): 145.4, 139.9, 133.4, 114.5, 83.7, 40.2, 30.8, 27.7, 20.6. 
IR (film, cm
-1
): 3354, 2967, 2928, 2855, 2346, 1600, 1452, 1368, 1304, 1180, 1133, 1084, 
889, 851. 
HRMS (EI, m/z): [M]
+
 calc.: 138.1045; found: 138.1045. 
 
 
3-Phenylcyclohex-2-enol (15)
7
 
 
 
 
According to “method A” reaction of 2-cyclohexenone (95%, 50 µL, 0.4892 mmol, 1.0 eq) 
with 1.0 M phenylmagnesium bromide (0.98 mL, 0.98 mmol, 2.0 eq) in anhydrous diethyl 
ether (4.9 mL) and subsequent treatment with water (4.9 mL) and trifluoroacetic acid (95 µL, 
                                                          
7 In agreement with: Reich, H. J.; Wollowitz, S. J. Am. Chem. Soc. 1982, 104, 7051. 
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1.2331 mmol, 2.5 eq) for 48 hours at ambient temperature provides 80.5 mg of  
3-phenylcyclohex-2-enol as colorless oil with 94% yield (column chromatography  
H/EE = 3/1). 
1
H-NMR (400MHz, CDCl3): 7.44-7.39 (m, 2H), 7.36-7.30 (m, 2 H), 7.29-7.23 (m, 1H), 6.17-
6.09 (m, 1H), 4.45-4.34 (bs, 1H), 2.53-2.43 (m, 1H), 2.43-2.32 (m, 1H), 2.01-1.86 (m, 2H), 
1.82-1.63 (m, 2H), 1.55 (d, J=5.2 Hz, 1H). 
13
C-NMR (100MHz, CDCl3, ppm): 141.5, 140.4, 128.5, 127.6, 126.7, 125.5, 66.5, 31.9, 27.7, 
19.6. 
IR (film, cm
-1
): 3336, 2934, 2862, 2358, 1494, 1446, 1344, 1276, 1053, 973, 907, 757, 695. 
HRMS (ESI, m/z): [M+Na]
+
 calc.: 197.0937; found: 197.0938. 
 
 
trans 4-Methyl-3-vinylcyclohex-2-enol (18) 
 
 
 
According to “method A” reaction of 6-methylcyclohex-2-enone (48.0 mg, 0.4358 mmol, 1.0 
eq) with 1.0 M vinylmagnesium bromide (0.87 mL, 0.87 mmol, 2.0 eq) in anhydrous diethyl 
ether (4.4 mL) and subsequent treatment with water (4.4 mL) and trifluoroacetic acid (84 µL, 
1.0903 mmol, 2.5 eq) for 2 hours at 0 °C and additional 2 hours at ambient temperature 
provides 50.1 mg of 4-methyl-3-vinylcyclohex-2-enol as colorless oil with a trans/cis ratio of 
2.3 to 1 and an combined yield of 83% yield (column chromatography  
H/EE = 5/1). Diastereomers were separated by means of HPLC. 
Analytical data for the trans-isomer 18a: 
1
H-NMR (400MHz, CDCl3): 6.23 (dd, J=17.7 Hz, J=10.9 Hz, 1H), 5.74 (d, J=4.3 Hz, 1H), 
5.27 (dd, J=17.7 Hz, J=0.3 Hz, 1H), 5.10 (dd, J=10.8 Hz, J=0.4 Hz, 1H), 4.24-4.16 (bs, 1H), 
2.61-2.51 (m, 1H), 1.96-1.86 (m, 2H), 1.72-1.64 (m, 1H), 1.47-1.39 (m, 2H), 1.06 (d,  
J=7.1 Hz, 3H). 
13
C-NMR (100MHz, CDCl3, ppm): 144.4, 138.5, 128.6, 113.9, 64.7, 27.9, 27.4, 25.2, 18.9. 
IR (film, cm
-1
): 3337, 2933, 2872, 1602, 1451, 1276, 1188, 1085, 1042, 1017, 998, 902, 876. 
HRMS (APCI, m/z): [M-H2O+H]
+
 calc.: 121.1012; found: 121.1007. 
Analytical data for the cis-isomer 18b: 
1
H-NMR (400MHz, CDCl3): 6.22 (dd, J=17.7 Hz, J=10.9 Hz, 1H), 5.66-5.60 (m, 1H), 5.23 (d, 
J=17.6 Hz, 1H), 5.07 (d, J=10.9 Hz, 1H), 4.38-4.26 (m, 1H), 2.60-2.48 (m, 1H), 1.99-1.89  
(m, 1H), 1.84-1.73 (m, 1H), 1.68-1.59 (m, 2H), 1.50-1.41 (bs, 1H), 1.15 (d, J=7.0 Hz, 3H). 
13
C-NMR (100MHz, CDCl3, ppm): 143.4, 138.3, 130.9, 113.4, 68.3, 28.6, 28.3, 27.6, 19.7. 
IR (film, cm
-1
): 3383, 2926, 2855, 1666, 1461, 1276, 1262, 1070, 1052, 1020, 994, 765, 757. 
HRMS (ESI, m/z): [M+Na]
+
 calc.: 161.0937; found: 161.0937. 
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trans 5-Methyl-3-vinylcyclohex-2-enol (21) 
 
 
 
According to “method A” reaction of 5-methylcyclohex-2-enone (49.7 mg, 0.4512 mmol, 1.0 
eq) with 1.0 M vinylmagnesium bromide (0.90 mL, 0.90 mmol, 2.0 eq) in anhydrous diethyl 
ether (4.5 mL) and subsequent treatment with water (4.5 mL) and trifluoroacetic acid (87 µL, 
1.1293 mmol, 2.5 eq) for 5 hours at ambient temperature provides 51.0 mg of  
5-methyl-3-vinylcyclohex-2-enol as colorless oil with a trans/cis ratio of 7 to 1 and a 
combined yield of 82% yield (column chromatography H/EE = 5/1). Diastereomers were 
separated by means of HPLC. 
Analytical data for the trans-isomer 21a: 
1
H-NMR (400MHz, CDCl3): 6.36 (dd, J=17.5 Hz, J=10.8 Hz, 1H), 5.81 (d, J=4.1 Hz, 1H), 
5.26 (d, J=17.5 Hz, 1H), 5.06 (d, J=10.8 Hz, 1H), 4.35-4.26 (m, 1H), 2.35 (dd, J=17.1 Hz, 
J=4.8 Hz, 1H), 2.02-1.86 (m, 1H), 1.82 (d, J=13.7 Hz, 1H), 1.64 (dd, J=17.2 Hz, J=10.5 Hz, 
1H), 1.53-1.35 (m, 2H), 1.04 (d, J=6.6 Hz, 3H). 
13
C-NMR (100MHz, CDCl3, ppm): 139.5, 139.3, 128.8, 113.5, 65.3, 39.8, 32.7, 23.6, 21.7. 
IR (film, cm
-1
): 3344, 2951, 2924, 2870, 1607, 1456, 1439, 1418, 1377, 1181, 1061, 999, 952, 
900, 872. 
HRMS (ESI, m/z): [M+Na]
+
 calc.: 161.0937; found: 161.0935. 
Analytical data for the cis-isomer 21b:
8
 
1
H-NMR (400MHz, CDCl3): 6.36 (dd, J=17.5 Hz, J=10.7 Hz, 1H), 5.70-5.66 (s, 1H), 5.19 (d, 
J=17.5 Hz, 1H), 5.04 (d, J=10.8 Hz, 1H), 4.44-4.33 (bs, 1H), 2.31-2.22 (m, 1H), 2.12-2.05 (m, 
1H), 1.81-1.63 (m, 2H), 1.46-1.38 (bs, 1H), 1.17-1.07 (m, 1H), 1.06 (d, J=6.4 Hz, 3H). 
13
C-NMR (100MHz, CDCl3, ppm): 139.0, 137.7, 132.1, 113.0, 68.7, 41.7, 32.6, 28.0, 22.2. 
IR (film, cm
-1
): 3321, 2951, 2926, 2871, 2360, 2341, 1606, 1456, 1375, 1358, 1302, 1190, 
1158, 1074, 1031, 1009, 989, 971, 898. 
HRMS (EI, m/z): [M]
+
 calc.: 138.1045; found: 138.1043. 
 
 
(1R,5S)-5-Isopropenyl-2-methyl-3-vinylcyclohex-2-enol (24) 
 
 
 
According to “method A” reaction of (R)-carvone (98%, 65 µL, 0.4067 mmol, 1.0 eq) with 
1.0 M vinylmagnesium bromide (0.81 mL, 0.81 mmol, 2.0 eq) in anhydrous diethyl ether  
(4.0 mL) and subsequent treatment with water (4.0 mL) and trifluoroacetic acid (157 µL, 
2.0379 mmol, 5.0 eq) for 7 days at ambient temperature provides 57.2 mg of  
(1R,5S)-5-Isopropenyl-2-methyl-3-vinylcyclohex-2-enol as colorless oil with a trans/cis ratio 
                                                          
8 In agreement with: Shimizu, N.; Akita, H.; Kawamata, T. Chem. Pharm. Bull. 1996, 44, 665. 
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of 6 to 1 and an combined yield of 79% yield (column chromatography H/EE = 10/1). 
Diastereomers were separated by means of HPLC. 
Analytical data for the trans-isomer 24a: 
1
H-NMR (400MHz, CDCl3): 6.78 (dd, J=17.5 Hz, J=11.0 Hz, 1H), 5.27 (dd, J=17.4 Hz,  
J=1.1 Hz, 1H), 5.11 (dd, J=11.1 Hz, J=0.9 Hz, 1H), 4.81-4.75 (m, 2H), 4.15-4.08 (m, 1H), 
2.47-2.36 (m, 2H), 1.99-1.87 (m, 5H), 1.79 (s, 3H), 1.66-1.55 (m, 2H). 
13
C-NMR (100MHz, CDCl3, ppm): 149.3, 134.9, 132.5, 131.4, 113.7, 109.5, 70.7, 36.6, 35.6, 
30.8, 21.0, 16.9. 
IR (film, cm
-1
): 3332, 3087, 2967, 2917, 1644, 1441, 1421, 1375, 1169, 1051, 1010, 987, 949, 
890. 
HRMS (APCI, m/z): [M-H2O+H]
+
 calc.: 161.1325; found: 161.1321. 
Analytical data for the cis-isomer 24b: 
1
H-NMR (400MHz, CDCl3): 6.79 (dd, J=17.5 Hz, J= 11.0 Hz, 1H), 5.22 (d, J=17.4 Hz, 1H), 
5.10 (d, J=11.2 Hz, 1H), 4.81-4.74 (m, 2H), 4.28-4.19 (m, 1H), 2.40-2.14 (m, 3H), 2.12-2.01 
(m, 1H), 1.89 (s, 3H), 1.79 (s, 3H), 1.54-1.46 (m, 2H). 
13
C-NMR (100MHz, CDCl3, ppm): 149.2, 135.0, 134.6, 130.3, 113.4, 109.6, 72.5, 39.4, 37.9, 
30.9, 20.8, 14.3. 
IR (film, cm
-1
): 3361, 2925, 2857, 1645, 1449, 1376, 1277, 1260, 1073, 1049, 1025, 1008, 
990, 891. 
HRMS (APCI, m/z): [M-H2O+H]
+
 calc.: 161.1325; found: 161.1318. 
 
 
3-(2’-Methyl-1’-propenyl)cyclohex-2-enol (25) 
 
 
 
According to “method A” reaction of 2-cyclohexenone (95%, 50 µL, 0.4892 mmol, 1.0 eq) 
with 0.5 M 2-methyl-1-propenylmagnesium bromide (1.95 mL, 0.975 mmol, 2.0 eq) in 
anhydrous diethyl ether (4.9 mL) and subsequent treatment with water (4.9 mL) and 
trifluoroacetic acid (95 µL, 1.2331 mmol, 2.5 eq) for 1 hour at 0 °C provides 36.5 mg of  
3-(2’-Methyl-1’-propenyl)cyclohex-2-enol as colorless oil with 49% yield and 35.0 mg of an 
inseparable cis/trans mixture of 1-(cyclohex-2-enylidene)-2-methyl-2-propanol with 47% 
yield (column chromatography H/EE = 10/1 to 5/1). 
Analytical data for 25: 
1
H-NMR (400MHz, CDCl3): 5.59-5.34 (m, 2H), 4.34-4.23 (m, 1H), 2.15-1.93 (m, 2H), 1.89-
1.67 (m, 8H), 1.66-1.58 (m, 2H), 1.45-1.35 (bs, 1H). 
13
C-NMR (100MHz, CDCl3, ppm): 139.2, 134.6, 127.3, 126.8, 66.2, 31.9, 29.6, 27.1, 19.8, 
19.4. 
IR (film, cm
-1
): 3369, 2933, 2863, 2359, 1447, 1377, 1276, 1261, 1190, 1158, 1056, 1018, 
975, 914, 891, 764, 750. 
HRMS (ESI, m/z): [M+Na]
+
 calc.: 175.1093; found: 175.1086. 
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Analytical data for 26 (E/Z = 3/1): 
1
H-NMR (400MHz, CDCl3): 6.97-6.91 (m, 0.25H), 6.00-5.92 (m, 0.75H), 5.90-5.73 (m, 1H), 
5.41-5.22 (2 s, 1H), 2.69-2.59 (m, 1.5H), 2.27-2.20 (m, 0.5H), 2.16-2.04 (m, 2H), 1.76-1.65 
(m, 2H), 1.54-1.42 (2 bs, 1H), 1.39 (s, 6H). 
13
C-NMR (100MHz, CDCl3, ppm): 136.7 (E), 134.8 (Z), 134.1 (E), 131.9 (Z), 131.7 (E), 
131.0 (Z), 129.4 (E), 125.3 (Z), 71.4 (Z), 71.3 (E), 33.1 (Z), 31.9 (Z), 31.3 (E), 26.1 (Z),  
26.1 (E), 25.4 (E), 23.4 (Z), 22.6 (E). 
IR (film, cm
-1
): 3387, 2974, 2936, 2867, 1685, 1451, 1377, 1276, 1260, 1159, 1059, 956, 917, 
764, 750. 
HRMS (ESI, m/z): [M+Na]
+
 calc.: 175.1093; found: 175.1089. 
 
 
(1S)-3-Isopropenylcyclopent-2-enol (28)
5
 
 
 
 
To a solution of racemic dienol 8 (520.5 mg, 4.191 mmol, 1.0 eq) and anhydrous MTBE  
(14.5 mL) were added Amano lipase PS (111.0 mg) and vinyl acetate (0.4 mL,  
4.340 mmol, 1.0 eq). The resulting mixture was stirred at ambient temperature for 24 hours. 
After a small NMR-sample indicated conversion > 50% solids were removed by filtration and 
the resulting filtrate concentrated in vacuo. Purification of the residue by chromatography 
(H/EE = 10/1 to 1/1) using Merck aluminium oxide 90 (0.063-0.200 mm70-230 mesh) 
provided 321.0 mg of ester 27 with 46% yield and 234.8 mg of optically enriched alcohol 28 
with 45% yield and an enantiomeric excess > 95% (Attention: Ester 27 is acid labile and 
should be stored below 0°C.). Analytical data for compound 28 is consistent with racemic 
alcohol 8, see above. [α]D
20
 = - 124.9 (c = 1.175 g/100 ml, DCM). 
Analytical data for ester 27: 
1
H-NMR (400MHz, CDCl3): 5.81-5.71 (m, 2H), 5.05 (s, 2H), 2.74-2.65 (m, 1H), 2.52-2.33 
(m, 2H), 2.04 (s, 3H), 1.95 (s, 3H), 1.93-1.85 (m, 1H). 
13
C-NMR (100MHz, CDCl3, ppm): 171.2, 150.0, 139.5, 124.9, 115.6, 81.0, 30.7, 30.3, 21.5, 
20.6. 
IR (film, cm
-1
): 2947, 2857, 1732, 1600, 1454, 1372, 1238, 1165, 1100, 1027, 962, 888. 
HRMS (ESI, m/z): [M]
+
 calc.: 166.0994; found: 166.0995. 
[α]D
20
 = + 213.7 (c = 1.110 g/100 ml, DCM). 
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Racemization of ester 27: 
 
 
 
To solution of acetate 27 (251.4 mg, 1.512 mmol, 1.0 eq) and THF (8 mL) cooled to 0°C was 
added water (8 mL) and Merck silica gel (0.04-0.063 mm, 240-400 mesh) (256.5 mg). The 
resulting mixture was vigorously stirred for 36 hours at ambient temperature before solids 
were removed by filtration. The filtrate was treated with saturated aqueous NaHCO3 and 
extracted with dichloromethane (4x). The combined organic extracts were washed with brine, 
dried (Na2SO4) and concentrated in vacuo. Purification of the residue by chromatography 
(H/EE = 4/1) provided 178.1 mg of 3-isopropenylcyclopent-2-enol (8) with 95% yield. For 
analytical data, see above. [α]D
20
 = 0.000 (c =1.05 g/100 ml, DCM). 
 
Lactone 29
5
 
 
 
 
Anhydrous MgBr2•Et2O (977 mg, 3.783 mmol, 2.0 eq) was suspended in anhydrous 
dichloromethane (4.5 mL), treated with diisopropylethylamine (1.3 mL, 7.644 mmol, 4.0 eq) 
and stirred for 15 minutes until the suspension turns magenta. Then compound 28 (234.8 mg, 
1.891 mmol, 1.0 eq) dissolved in dichloromethane (14.5 mL) was added slowly via canula. 
After stirring for 1 hour methyl acrylate (0.34 mL, 3.776 mmol, 2.0 eq) was added dropwise. 
The resulting mixture was stirred for 6 hours before it was quenched with saturated aqueous 
NH4Cl. For a better phase separation potassium sodium tartrate was added and the solution 
extracted with diethyl ether (2x) and dichloromethane (3x). The combined extracts were dried 
(Na2SO4) and concentrated in vacuo. Purification by chromatography (H/EE = 6/1) furnished 
273.7 mg of compound 29 as white solid with 81% yield. 
1
H-NMR (400 MHz CDCl3, ppm): 4.84 (dt, J=5.5Hz, J=1.0Hz, 1H), 3.02 (ddd, J=6.5Hz, 
J=6.0Hz, J=3.2Hz, 1H), 2.88-2.80 (m, 1H), 2.63-2.51 (m, 1H), 2.32-2.18 (m, 1H), 2.15-1.87 
(m, 6H), 1.65 (s, 3H). 
13
C-NMR (100MHz, CDCl3, ppm): 178.7, 130.4, 129.3, 83.4, 43.8, 39.7, 29.1, 27.5, 27.2, 
20.2, 19.9. 
IR (film, cm
-1
): 2925, 1763, 1449, 1335, 1142, 1020, 985, 932, 877. 
HRMS (EI, m/z): [M]
+
 calc.: 178.0994; found: 178.0997. 
[α]D
20
 = -94.4 (c = 0.710 g/100mL, DCM). 
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2. NMR Spectra 
 
3-Vinylcyclopent-2-enol (3a) 
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3-Vinylcyclohex-2-enol (5) 
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3-Vinylcyclohept-2-enol (7) 
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3-Isopropenylcyclopent-2-enol (8) 
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2-Methyl-3-vinylcyclopent-2-enol (10) 
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1-Methyl-3-vinylcyclopent-2-enol (12) 
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3-Isopropenyl-1-methylcyclopent-2-enol (13) 
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3-Phenylcyclohex-2-enol (15) 
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trans 4-Methyl-3-vinylcyclohex-2-enol (18a) 
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cis 4-Methyl-3-vinylcyclohex-2-enol (18b) 
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trans 5-Methyl-3-vinylcyclohex-2-enol (21a) 
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cis 5-Methyl-3-vinylcyclohex-2-enol (21b) 
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(1R,5S)-5-Isopropenyl-2-methyl-3-vinylcyclohex-2-enol (24a) 
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(1S,5S)-5-Isopropenyl-2-methyl-3-vinylcyclohex-2-enol (24b) 
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3-(2’-Methyl-1’-propenyl)cyclohex-2-enol (25) 
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1-(Cyclohex-2-enylidene)-2-methyl-2-propanol (26) 
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Ester 27 
 
 
 
146 
 
Lactone 29 
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5.3 Total Synthesis of Lycoflexine, SI 
 
Experimental procedures and analytical data of all compounds discussed in chapter 4.4.2 (Synthesis 
of the Lycopodium Alkaloid (+)-Lycoflexine) are summarized in the following supporting information. 
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1. Procedures 
 
1.1 General: 
 
All reactions were carried out in oven-dried glassware under an argon atmosphere unless 
stated otherwise. Anhydrous dichloromethane and 1,2-dichloroethane were destilled under 
Argon from P2O5, pyridine from CaH2, anhydrous tetrahydrofuran (99.9%), 
dimethylformamide (99.8%) and ethyl acetate (99.5%) were purchased from Aldrich, ethanol 
(99.9%) from Merck. All other solvents were HPLC grade. Commercially available reagents 
were used without further purification besides stated otherwise. tert-Butyloxycarbonyl 
protected allylamine and (R)-5-Methylcyclohex-2-enone were prepared according to literature 
known procedures.
9,10
 Reactions were magnetically stirred and monitored by thin layer 
chromatography with E. Merck silica gel 60 F254 plates. Flash column chromatography was 
performed with Merck silica gel (0.04-0.063 mm, 240-400 mesh) under pressure besides 
stated otherwise. Yields refer to chromatographically and spectroscopically pure compounds 
unless stated otherwise. 
1
H NMR (400 MHz or 600 MHz) and 
13
C NMR (100 MHz or 150 
MHz) spectra were either recorded on Bruker Avance 400, DRX 400, or DRX 600 
spectrometers at 400.13 MHz (100.61 MHz) or 600.13 MHz (150.90 MHz). All NMR spectra 
were measured in CDCl3 or CD2Cl2 solutions. The chemical shifts δ are reported relative to 
the residual solvent peaks (
1H, δCDCl3 = 7.26 ppm, δCD2Cl2 = 5.32 ppm; 
13C, δCDCl3 = 77.16 
ppm, δCD2Cl2 = 53.80 ppm). All 
1
H and 
13
C shifts are given in ppm (s = singulet; d = doublet; t 
= triplet; q = quadruplet; m = multiplet; b = broad signal). If possible, assignments of proton 
resonances were confirmed by correlated spectroscopy. Optical rotations were measured at 
20°C on a P 341 Perkin-Elmer polarimeter at 589 nm. IR spectra were recorded of samples 
prepared as films on silicium plates on a Perkin-Elmer Spectrum 2000 Series FTIR 
spectrometer. High resolution mass spectra (HRMS) were measured on a Finnigan MAT 8230 
apparatus with a resolution of 10000. The CD spectrum of (+)-lycoflexine was measured on a 
Applied Photophysics π*-180 spectrometer. 
                                                          
9  For preparation of Boc-protected allylamine see: Dhami, A.; Mahon, M. F.; Llyod, M. D., Threadgill, M. D. Tetrahedron 
2009, 65, 4751 
10 For preparation of (R)-5-Methylcyclohex-2-enone see: Caine, D.; Procter, K.; Cassell, R. A. J. Org. Chem. 1984, 49, 2647 
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1.2 Experimetal procedures: 
 
Allylcrotylcarbamate 
 
 
A solution of allylcarbamate (3.40 g, 21.63 mmol, 1.0 eq) dissolved in DMF (43 mL) was 
slowly added to a suspension of sodium hydride (60%, 1.47 g, 36.75 mmol, 1.7 eq) and DMF 
(43 mL) while cooling to 0°C. After stirring for 30 minutes the resulting mixture was treated 
with crotyl bromide (85%, predominantly trans, 4.75 mL, 39.24 mmol, 1.8 eq). After 5 
minutes the icebath was removed and the reaction mixture stirred for 16 hours. Saturated 
aqueous NH4Cl was added after recooling to 0°C, followed by water and diethyl ether. The 
aqueous layer was extracted with diethyl ether (4x), the combined organic phases were 
washed with brine, dried (Na2SO4) and concentrated in vacuo. Purification of the residue by 
chromatography (hexane/EtOAc 50/1) provided 4.43 g allylcrotylcarbamate as clear 
colourless oil with a cis:trans-ratio of 1:3.3 and 97% yield. 
1
H-NMR (400MHz, CDCl3): 5.84-5.69 (m, 1H), 5.66-5.49 (m, 1H), 5.45-5.34 (m, 1H), 5.16-
5.03 (m, 2H), 3.93-3.63 (m, 4H), 1.69 (dd, J=6.34 Hz, J=1.30 Hz, 2.3H), 1.64 (dd, J=6.94Hz, 
J=1.34Hz, 0.70H), 1.47 (s, 2.09H), 1.44 (s, 6.91H) 
13
C-NMR (100MHz, CDCl3, ppm): 155.6, 134.41, 134.35, 128.2, 126.9, 126.8, 116.4, 79.64, 
79.56, 48.8, 48.5, 48.1, 28.6, 17.8, 13.0 
IR (film, cm
-1
): 2977, 2923, 1692, 1456, 1406, 1365, 1243, 1172, 1146, 968, 918, 875 
HRMS (ESI, m/z): [M]
+
 calc.: 212.1651; found: 212.1654 
 
Iodocarbamate 8 
 
 
Cyclohexene (4.25 mL, 41.91 mmol, 2.0 eq) was added dropwise to a cooled (0°C) 1.0 M 
borane solution in THF (25.0 mL, 25 mmol, 1.2 eq). After 2.5 hours the resulting white 
suspension was treated with allylcrotylcarbamate (4.39 g, 20.78 mmol, 1.0 eq) dissolved in 
THF (35 mL). The icebath was removed and the solution stirred for 1 hour at room 
temperature and 3 hours at 50°C. After recooling to room temperature a 1.0 M sodium acetate 
solution in methanol (50 mL, 50 mmol, 2.4 eq) and iodine monochloride (1.25 mL, 24.94 
mmol, 1.2 eq) dissolved in methanol (24 mL) were added sequentially and stirred for another 
30 minutes. The reaction was quenched with diluted aqueous NaHCO3, diethyl ether was 
added and the excess iodine monochloride destroyed by careful addition of saturated aqueous 
Na2S2O3 until the solution decolorates. The aqueous layer was extracted with ether (3x), the 
combined extracts were washed with brine, dried (Na2SO4) and concentrated in vacuo. 
Purification by chromatography (hexane/EtOAc 50/1) furnished 3.84 g of compound 8 as 
clear yellow oil with 54% yield. (Caution: Iodocarbamate 8 is of moderate stability and 
should be stored at -25°C.) 
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1
H-NMR (400 MHz CD2Cl2): 5.66-5.53 (m, 1H), 5.47-5.36 (m, 1H), 3.91-3.66 (m, 2H), 3.26-
3.12 (m, 4H), 2.10-1.98 (m, 2H), 1.74-1.66 (m, 3H), 1.50-1.40 (s, 9H) 
13
C-NMR (100MHz, CD2Cl2): 155.6, 134.8, 128.5, 127.3, 127.2, 79.6, 79.0, 48.3, 47.7, 47.3, 
32.9, 28.6, 17.8, 13.1, 3.7 
IR (film, cm
-1
): 2974, 2930, 1691, 1463, 1412, 1366, 1237, 1154, 953 
HRMS (ESI, m/z): [M]
+
 calc.: 339.0695; found: 339.0688 
 
Alcohol 10 
 
 
 
(R)-5-Methylcyclohex-2-enone (803 mg, 7.290 mmol, 1.0 eq) was dissolved in 
dichloromethane (15 mL), cooled to -78°C and TiCl4 (0.82 mL, 7.514 mmol, 1.03 eq) was 
added dropwise. The resulting dark red solution was stirred for 5 minutes before 
allyltrimethylsilane (0.87 mL, 5.451 mmol, 1.25 eq) was added within 5 minutes. After 1.5 
hours TLC indicated the complete consumption of the enone the in situ formed enolate was 
treated with acetaldehyde (0.37 mL, 6.544 mmol, 1.5 eq) and stirred for additional 1.5 hours. 
Then water and diethyl ether were added and the solution was warmed to room temperature. 
The aqueous layer was extracted with ether (4x), the combined organic phases were washed 
with saturated aqueous NaHCO3 and brine, dried (Na2SO4) and concentrated in vacuo. 
Purification of the residue by chromatography (hexane/EtOAc 4/1 to 3/1) provided 610.4 mg 
of an inseparable mixture of two diastereomeric alcohols as clear colourless oil with 70% 
yield. 
1
H-NMR (400 MHz CDCl3): 5.80-5.66 (m, 1H), 5.11-5.00 (m, 2H), 4.10-4.00 (m, 1H), 2.48-
1.96 (m, 8H), 1.72-1.60 (m, 2H), 1.30 (d, J=6.28Hz, 1.3H), 1.21 (d, J=6.28Hz, 1.7H), 0.99 (d, 
J=6.76Hz, 3H) 
13
C-NMR (100MHz, CDCl3): 214.4, 214.1, 135.83, 135.82, 117.42, 117.37, 67.4, 66.7, 61.44, 
61.39, 48.9, 48.7, 38.1, 37.8, 37.3, 35.6, 34.9, 34.5, 29.8, 29.3, 22.9, 21.5, 21.3, 20.9 
IR (film, cm
-1
): 3425, 2957, 2925, 1702, 1642, 1457, 1378, 1277, 1092, 914 
HRMS (ESI, m/z): [M-CH3]
+
 calc.: 181.1229; found: 181.1233 
 
Diketone 11 
 
 
 
 
 
Alcohol 10 (1.27 g, 6.470 mmol, 1.0 eq) was dissolved in anhydrous ethyl acetate (65 mL) 
and IBX (5.46 g, 19.50 mmol, 3.0 eq) was added. After refluxing for 3 hours the suspension 
was cooled to 0°C and hexane (65 mL) was added. The white precipitate was removed by 
filtration and washed with hexane/ethyl acetate (1/1) twice. The filtrate was concentrated in 
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vacuo to yield a clear, colourless oil, which was used in the next step without further 
purification. A solution of the crude diketo compound in DMF (21 mL) was treated with 
Cesium carbonate (4.09 g, 12.55, 2.0 eq). After 10 minutes the mixture was cooled to -15°C 
and iodocarbamate 8 (3.17 g, 9.345 mmol, 1.5 eq) dissolved in DMF (10 mL) was added. 
After stirring 15 hours the solution was slowly warmed to 0°C during additional 6 hours. The 
reaction was quenched with diluted aqueous ammonium chloride and diethyl ether was added. 
The aqueous layer was extracted with ether (4x), the combined extracts were washed with 
brine, dried (Na2SO4) and concentrated in vacuo. Purification by chromatography 
(hexane/EtOAc 20/1 to 10/1) furnished 1.79 g of compound 11 as clear slightly yellow oil 
with 68% yield over 2 steps. 
1
H-NMR (400 MHz CDCl3): 5.73-5.61 (m, 1H), 5.61-5.47 (m, 1H), 5.45-5.31 (m, 1H), 5.08-
4.95 (m, 2H), 3.93-3.63 (m, 2H), 3.14 (b, 2H), 2.50-2.39 (m, 1H), 2.31-1.85 (m, 10H), 1.74-
1.55 (m, 5H), 1.44 (s, 9H), 1.40-1.23 (m, 2H), 0.96 (d, J=6.53Hz, 3H) 
13
C-NMR (100MHz, CDCl3): 210.0, 208.0, 155.7, 155.6, 137.0, 128.2, 127.1, 126.95, 126.90, 
116.6, 79.6, 79.5, 69.5, 48.9, 47.3, 46.4, 43.4, 39.3, 34.5, 31.9, 30.3, 29.9, 28.6, 28.5, 23.4, 
21.1, 17.8, 13.0 
IR (film, cm
-1
): 2957, 2929, 1691, 1456, 1414, 1365, 1236, 1171, 1140 
HRMS (ESI, m/z): [M]
+
 calc.: 406.2957; found: 406.2955 
[α]D
20
 = -46.7 (c = 1.62 g/100mL, DCM) 
 
Triflate 12 
 
 
 
 
 
Diketone 11 (470 mg, 1.159 mmol, 1.0 eq) was dissolved in THF (18 mL) and treated with 
Comins reagent
11
 (937 mg, 2.386 mmol, 2.0 eq). The resulting solution was cooled to -78°C 
and a solution of 0.7 M KHMDS in toluene (1.8 mL, 1.26 mmol, 1.1 eq) and THF (6 mL) was 
added slowly within 1½ hours. After stirring for 30 minutes again 0.7 M KHMDS in toluene 
(0.9 mL, 0.63 mmol, 0.55 eq) was added within 45 minutes. 30 minutes later additional 0.7 M 
KHMDS in toluene (0.45, 0.315 mmol, 0.25 eq) was added within 20 minutes and the 
resulting solution stirred until complete conversion of the starting material was observed (30 
minutes). Diluted aqueous NaHCO3 and diethyl ether were added. The aqueous layer was 
extracted with ether (3x), the combined extracts were washed with brine, dried (Na2SO4) and 
concentrated in vacuo. Purification by chromatography (hexane/EtOAc 30/1 to 10/1) provided 
531 mg of compound 12 as clear colourless oil with 85% yield. 
                                                          
11 Comins, D. L.; Dehghani, A. Tetrahedron Lett. 1992, 33, 6299 
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1
H-NMR (400 MHz CDCl3): 6.14 (d, J=4.27Hz, 1H), 5.70-5.46 (m, 3H), 5.44-5.30 (m,1H), 
5.07-4.94 (m, 2H), 3.88-3.56 (m, 2H), 3.37-2.95 (m, 2H), 2.39-2.03 (m, 6H), 1.86-1.74 (m, 
2H), 1.74-1.61 (m, 5H), 1.57-1.40 (m, 10H), 1.21-1.08 (m, 1H), 1.00 (d, J=6.27Hz, 3H) 
13
C-NMR (100MHz, CDCl3): 208.2,.155.6, 153.2, 136.0, 128.4, 126.9, 126.7, 123.1, 120.0, 
117.1, 116.8, 113.6, 109.5, 79.6, 79.5, 59.7, 49.0, 47.3, 45.9, 45.6, 43.3, 42.4, 33.9, 31.9, 30.5, 
28.6, 23.2, 22.2, 17.7, 12.9 
IR (film, cm
-1
): 2959, 2932, 1694, 1409, 1366, 1209, 1174, 1141, 910, 770, 731, 609 
HRMS (ESI, m/z): [M]
+
 calc.: 537.2372; found: 537.2370 
[α]D
20
 = +31.6 (c = 1.46 g/100mL, DCM) 
 
Dienyne 6 
 
 
 
 
 
A solution of triflate 12 (527 mg, 0.980 mmol, 1.0 eq) and anhydrous pyridine (10 mL) was 
heated to 60°C. After 15 hours the resulting solution was cooled to room temperature and 
treated with 5% aqueous citric acid and diethylether. The aqueous layer was extracted with 
diethylether (3x), washed with saturated aqueous NaHCO3 and brine, dried (Na2SO4) and 
concentrated in vacuo. Purification by chromatography (hexane/EtOAc 10/1) furnished 374.4 
mg of compound 6 as clear colourless oil with 99% yield. 
1
H-NMR (400 MHz CDCl3): 5.75-5.61 (m, 1H), 5.61-5.48 (m, 1H), 5.44-5.32 (m, 1H), 5.06-
4.96 (m, 2H), 3.90-3.62 (m, 2H), 3.16 (b, 2H), 2.85 (b, 1H), 2.61-2.46 (m,1H), 2.38 (s, 1H), 
2.23 (b, 1H), 2.12-1.60 (m, 11H), 1.54-1.38 (m, 10H), 0.91 (d, J=7.03, 3H) 
13
C-NMR (100MHz, CDCl3): 207.9, 155.74, 155.67, 136.7, 128.0, 127.1, 127.0, 116.6, 83.3, 
79.4, 79.3, 75.3, 54.9, 48.7, 46.3, 45.1, 43.1, 42.5, 35.0, 32.2, 29.5, 28.6, 23.9, 20.4, 17.7, 13.0 
IR (film, cm
-1
): 3308, 2962, 2929, 1719, 1688, 1456, 1414, 1365, 1234, 1172 
HRMS (ESI, m/z): [M]
+
 calc.: 388.2852; found: 388.2865 
[α]D
20
 = -29.6 (c = 1.32 g/100mL, DCM) 
 
Tricyclic carbamate 5 
 
 
 
Dienyne 6 (56.4 mg, 0.1455 mmol, 1.0 eq) was dissolved in freshly distilled and degassed 
1,2-dichloroethane (40 mL). Grubbs II catalyst (24.1 mg, 0.0284 mmol, 0.2 eq) dissolved in 
1,2-dichloroethane (8 mL) was added and the resulting solution stirred for 30 minutes at room 
temperature. After refluxing for 24 hours the solution was cooled to room temperature and 
then transferred into an autoclave via cannula. The autoclave is pressurized with dihydrogen 
(10 atm) and heated to 70°C for 16 hours. The solvent is evaporated and the residue purified 
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by chromatography (hexane/EtOAc 10/1 to 5/1) to furnish 26.1 mg of compound 5 as clear 
colorless oil with 52% yield. 
1
H-NMR (400 MHz CDCl3, some peaks are doubled and/or broadened due to conformational 
isomers)
12
: 5.72-5.63 (m, 1H), 3.52-3.30 (m, 1H), 3.26-2.87 (m, 3H), 2.73-2.51 (m, 1H), 2.50-
2.28 (m, 2H), 2.25-1.80 (m, 7H), 1.74-1.50 (m, 5H), 1.44 and 1.43 (s, 9H), 1.40-1.28 (m, 1H), 
0.93 and 0.91 (d, J=6.78Hz, 3H) 
13
C-NMR (100MHz, CDCl3, some peaks are doubled and/or broadened due to conformational 
isomers)
4
: 215.9, 215.6, 156.5, 156.0, 144.4, 143.9, 129.7, 129.2, 79.2, 79.1, 66.0, 65.8, 50.6, 
49.9, 47.8, 47.0, 46.9, 43.7, 42.8, 39.2, 38.1, 37.7, 36.6, 32.1, 30.0, 28.7, 27.4, 26.6, 26.3, 
26.0, 25.8, 24.6, 22.53, 22.48, 22.1, 21.3 
IR (film, cm
-1
): 2954, 2924, 1694, 1480, 1456, 1413, 1365, 1247, 1167 
HRMS (ESI, m/z): [M]
+
 calc.: 347.2460; found: 347.2458 
[α]D
20
 = -137.4 (c = 1.02 g/100mL, DCM) 
 
(+)-Lycoflexine (1) 
 
 
 
 
A solution of tricyclic carbamate 5 (18.3 mg, 0.05266 mmol, 1.0 eq) dissolved in THF (0.53 
mL) was cooled to 0°C and treated with 1.0 M borane THF complex (0.53 mL, 0.53 mmol, 10 
eq) before it was heated to 50°. After 8 hours the resulting solution was cooled to 0°C and 
methanol (0.22 mL, 5.424 mmol, ~100 eq) was added. The icebath was removed and the 
colourless solution stirred for an additional hour. Then the solvent is evaporated and the 
residue redissolved in ethyl acetate (2.1 mL). IBX (148.8 mg, 0.5314, 10 eq) is added and 
refluxed for 24 hours. The suspension was cooled to 0°C and ethyl acetate (2.1 mL) and 
hexane (2.1 mL) were added. The white precipitate was removed by filtration through a short 
pad of silica gel and washed with hexane/ethyl acetate (1/2). The filtrate was concentrated in 
vacuo to yield a clear, slightly yellow oil, which was used in the next step without further 
purification. The crude diketo compound was dissolved in Ethanol (3.2 mL) cooled to 0°C 
and treated with 0.5 M HCl (0.32 mL, 0.16 mmol, 3.0 eq). Then aqueous formaldehyde (37%, 
86 µL, 1.060 mmol, 20.0 eq) was added and the resulting clear and colourless solution 
refluxed for 48 hours. The reaction was quenched with diluted aqueous NaHCO3 and 
dichloromethane was added. The aqueous layer was extracted with dichloromethane (4x), 
dried (Na2SO4) and concentrated in vacuo. Purification by chromatography (DCM/ethyl 
acetate 200/1 to 50/1) affords 9.3 mg of compound 1 as white solid with 64% yield over 2 
steps. 
                                                          
12 consistent with: Linghu, X.; Kennedy-Smith, J. J.; Toste, F. D. Angew. Chem. Int. Ed. 2007, 46, 7671. 
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1
H-NMR (400 MHz CDCl3)
13
: 3.22-3.07 (m, 2H), 3.02-2.91 (m, 1H), 2.90-2.75 (m, 2H), 
2.70-2.59 (m, 2H), 2.42-1.72 (m, 13H), 1.63-1.53 (m, 1H), 1.36-1.28 (m, 1H), 1.03 (d, J=6.02, 
3H) 
13
C-NMR (100MHz, CDCl3)
5
: 218.5, 214.0, 60.8, 58.6, 56.8, 53.7, 53.4, 46.8, 40.4, 40.2, 
36.4, 31.4, 29.4, 28.1, 26.2, 22.5, 19.5 
IR (film, cm
-1
): 2924, 2854, 1727, 1699, 1456, 1414, 1377, 1353, 1208, 1175, 1130, 1063, 
1000 
HRMS (ESI, m/z): [M-H2O]
+
 calc.: 275.1885; found: 275.1882 
[α]D
20
 = +9.0 (c = 1.04 g/100mL, DCM) 
m.p.: 129-130 °C 
 
 
                                                          
13
 In exact agreement with: Takayama, H.; Katakawa, K.; Kitajima, M.; Yamaguchi, K.; Aimi, N. Tetrahedron 
Lett. 2002, 43, 8307. A comparison of the NMR spectra provided by Professor Takayama can be found in 
section 2 of the supporting information. 
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2. NMR Spectra 
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Tricyclic carbamate 5 
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(+)-Lycoflexine (1) (comparison of synthetic (+)-lycoflexine with an authentic sample) 
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(+)-Lycoflexine (1) (comparison of synthetic (+)-lycoflexine with an authentic sample) 
 
range: 3.3-0.9 ppm 
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(+)-Lycoflexine (1) (comparison of synthetic (+)-lycoflexine with an authentic sample) 
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3. CD Spectra 
 
(+)-Lycoflexine (1) (comparison of synthetic (+)-lycoflexine with an authentic sample) 
 
 
         authentic sample measured by Takayama 
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6 Abbreviations 
 
Ac acetyl 
aq aqueous 
BBN borabicyclo[3.3.1]nonane 
Bn benzyl 
Boc tert-butoxycarbonyl 
n-Bu n-butyl 
tert-Bu (tBu) tert-butyl 
cat. catalyst (or catalytic) 
CoASH coenzyme A 
mCPBA meta-chloroperoxybenzoic acid 
DBU diazabicyclo[5.4.0]undec-7-en 
DCC N,N’-dicyclohexylcarbodiimide 
DCM dichloromethane 
DIBAH diisobutylaluminium hydride 
DMAPP γ,γ-dimethylallylpyrophosphate 
DMP Dess-Martin periodinane 
DMSO dimethyl sulfoxide 
Et ethyl 
GABA γ-aminobutyric acid 
HDDA hydroxy-directed Diels-Alder 
IMDA intramolecular Diels-Alder 
IPP isopentenylpyrophosphate 
Me methyl 
MW microwave 
NMO N-methylmorpholine N-oxide 
Np naphthyl 
Nu nucleophile 
OP phosphate 
OPP pyrophosphate 
[Ox] oxidation 
PDC pyridinium dichromate 
Ph phenyl 
PPTS pyridinium p-toluenesulfonate 
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iPr isopropenyl 
py pyridine 
[Red] reduction 
SAR structure-activity relationship 
SI supporting information 
TBAF tetrabutylammonium fluoride 
TBAI tetrabutylammonium iodide 
TBS tert-butyldimethylsilyl 
TFA trifluoroacetic acid 
TMS trimethylsilyl 
TPAP tetrapropylammonium perruthenate 
Ts tosyl 
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Title: “Skeletal rearrangements by noble transition metals” 
Supervisor: Prof. Dr. Alois Fürstner 
17.07.2007   Diploma examination with distinction 
Examiner: Prof. Dr. Herfried Griengl 
2007 - to date   PhD work at the University of Vienna (Austria) 
Title: “Total Synthesis of Valerenic Acid and Lycoflexine” 
    Supervisor: Prof. Dr. Johann Mulzer 
 
Civil Service 
1998 - 1999   12 months civilian service at the Red Cross Deutschlandsberg 
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Fellowships 
01.05.2006 - 31.10.2006 “Scholarship for short time academic research and expert courses 
abroad” 
 
Scientific Communications 
Publications: 
 “From Planning to Optimization: Total Synthesis of Valerenic Acid and some Bioactive 
Derivatives” 
Ramharter, J.; Mulzer J. Eur. J. Org. Chem. submitted (21.12.2011) 
 “Efficient and Scalable One-Pot Synthesis of 2,4-Dienols from Cycloalkenones; Optimized Total 
Synthesis of Valerenic Acid” 
Ramharter, J.; Mulzer J. Org. Lett. 2011, 13, 5310 
 “Synthesis of the Lycopodium Alkaloid (+)-Lycoflexine” 
Ramharter, J.; Weinstabl, H.; Mulzer J. J. Am. Chem. Soc. 2010, 132, 14338 
(highlighted in Synfacts 2011, 2, 125) 
 “Valerenic acid derivatives as novel subunit-selective GABAA receptor ligands” 
Khom, S.; Strommer B.; Ramharter J.; Schwarz T.; Schwarzer C.; Erker T.; Ecker G. F.; Mulzer, J.; 
Hering S. British J. Pharm. 2010, 161, 65 
 “Total Synthesis of Valerenic Acid, a potent GABAA Receptor Modulator” 
Ramharter, J.; Mulzer J. Org. Lett. 2009, 11, 1151 
(highlighted in Synfacts 2009, 10, 1062) 
Patents: 
 “Methods for making Valerenic Acid derivatives and their use as GABAA receptor ligands” 
Mulzer J.; Ramharter J.; Khom S.; Hering, S. PCT Int. Appl. 2010 WO 2010/084182 
Oral presentations: 
 “Wie macht man eine Naturstoffsynthese effizient?“ 
Doktorandenworkshop Naturstoffchemie 2011 (Bayreuth, Germany) 
 “Hydroxy-dirigierte Totalsynthese von Valerensäure, Von der Planung zur Optimierung“ 
Doktorandenworkshop Naturstoffchemie 2010 (Jena, Germany) 
 “First Total Synthesis of Valerenic Acid” 
Organic Chemistry Symposium 2009 (Paris, France) 
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Poster presentations: 
 “Synthesis of Natural Products applicable against CNS Dysfunctions” 
Balticum Organicum Syntheticum 2010 (Riga, Latvia) 
 “First Total Synthesis of (-)-Valerenic Acid” 
Münchner Naturstofftage 2009 (Munich, Germany) 
 
Languages 
 German as mother tongue 
 English fluently 
 Italian moderate 
 Russian moderate 
 
Social/Teamwork Interests 
 Sports: Soccer, Tennis, Volleyball, alpine and cross-country skiing 
 Other: Reading, Music 
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